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 Scope of this thesis 
Dendritic cells (DCs) are the most potent 
professional antigen-presenting cells of our 
immune system. The DC family is 
heterogeneous comprising various 
functionally different subsets, such as the 
plasmacytoid DCs (pDCs). Plasmacytoid DCs 
differ from other DC subsets in one specific 
feature, the secretion of large amounts of 
type I interferons (IFNs) in response to 
bacterial or viral derived stimuli. Via type I 
IFNs they are able to cross-talk with other 
immune cells and link the innate with the 
adaptive arm of the immune system. The 
scope of this thesis is to gain understanding of 
the ability of human pDCs to take up and 
handle antigens and their ability to stimulate 
T cells. This knowledge expands our insight in 
antigen presentation mechanisms exploited 
by pDCs and their applicability for DC-based 
vaccination strategies. Furthermore, we 
applied this rare blood DC subset as a 
treatment modality for metastatic melanoma 
patients. 
Part I This part of the thesis introduces 
and elaborates on pDC biology. Chapter 1 
introduces the different DC subsets circulating 
in the blood as well as monocyte-derived DCs. 
Furthermore, it provides an overview on the 
Toll like receptor (TLR) expression profiles and 
the ability of the different DC subsets to cross-
talk with each other. Chapter 2 zooms in on 
the ability of human pDCs to take up antigens 
by various mechanisms and subsequently on 
their ability to process and (cross-) present 
antigens to T cells.  
Part II The role of pDCs in the generation 
of antigen specific immune responses, is 
controversial. This part describes the ability of 
pDCs to take up and present exogenous 
antigens that are specifically delivered to 
antigen uptake receptors. Chapter 3 describes 
that human and monkey pDCs express the Fc 
receptor CD32a which can be harnessed to 
facilitate the targeted delivery of TLR agonists. 
We show that targeted delivery of CpG ODN 
to pDCs via CD32 augments the secretion of 
IFNα. These new findings open up new 
treatment principles for allergic patients, 
wherein IFNα can revert allergic Th2 
responses in unbiased or mixed Th0/Th1 
responses. Chapter 4 describes that human 
pDCs express the C-type lectin receptor DEC-
205. Furthermore, our data show that 
triggering DEC-205 impairs TLR-induced IFNα 
secretion by human pDCs, and that targeting 
antigen toward DEC-205 on steady state and 
activated pDCs induces antigen specific T cell 
proliferation. Chapter 5 reports on the ability 
of human pDCs to phagocytose 
microparticles. Our data demonstrate that 
particulate TLR agonists induce full pDC 
maturation and that human pDCs can 
phagocytose, process and present 
encapsulated antigens to T cells. These 
findings might contribute to new innovative 
strategies to manipulate immune responses 
by directly targeting pDCs in vivo. 
Part III Plasmacytoid DCs, as main 
producers of type I IFN, are considered to be 
very important in linking the innate and 
adaptive arm of our immune system. By this 
virtue we proposed that pDCs might be a 
promising cell type for DC-based 
immunotherapy. This part of the thesis deals 
with both the preclinical and clinical 
implication of pDCs in cancer and cancer 
therapy. A prerequisite for the application of 
pDCs in DC-based immunotherapy is that they 
should be properly activated. The limited 
availability of clinical grade synthetic TLR 
agonists hampered the development of pDC-
based immunotherapy. In Chapter 6 we 
describe that preventive vaccines commonly 
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 used in every day practice have the ability to 
activate human pDCs in terms of IFNα 
secretion and phenotypical maturation. 
Furthermore, we found that certain vaccines 
behaved remarkably similar to different forms 
of CpG ODNs. Chapter 7 describes that human 
pDCs activated with the Früh-Sommer-
Meningo-Encephalitis (FSME) vaccine attain a 
mature phenotype, display migratory 
capacities, secrete IFNα and activate antigen 
specific CD4+ and CD8+ T cells. In addition, our 
data show that FSME-activated pDCs express 
CD56 and are endowed with tumoricidal 
activity. This potent maturation stimulus 
enabled us to generate clinically applicable 
activated pDCs and paved the way to 
introduce this relatively rare subset in a 
clinical trial. Vaccination with activated and 
tumor peptide-loaded pDCs results in an 
increase in antigen specific CD8+ T cells and an 
increase in overall survival of metastatic 
melanoma patients. The results of this trial 
are described in Chapter 8. Recent advances 
in treatment modalities for cancer suggest 
that therapies should be combined rather 
than administered separately as mono-
therapy. Chapter 9 explores this possibility by 
studying the effect of platinum-based 
chemotherapeutics on the function of pDCs 
and blood myeloid DCs. Our data suggest, that 
oxaliplatin decreases the T cell stimulatory 
potential of TLR-activated human pDCs by 
increased expression of the programmed cell 
death 1 ligand 1 and decreased expression of 
the co-stimulatory molecules CD80 and CD86. 
Part IV Discusses and summarizes the 
results that are described in this thesis. 
Chapter 10  provides an overview on cross-
presentation by DC subsets and discusses 
which DC subset should be considered as the 
best antigen cross presenting subset. We 
conclude, that once antigen uptake occurs, 
virtually all DC subsets have the capacity to 
cross-present exogenous antigens. Based on 
this conclusion, Chapter 11 elaborates on 
which receptor we should aim for when 
considering strategies that target pDCs 
directly in vivo. Furthermore, it is discussed 
how we should move forward in designing 
new treatment modalities using human pDCs 
as mono-therapy and more importantly as 
part of a combined treatment modality.  
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Introduction 
 
 
 
 
 
 
 
 
 
 
Success is not the key to happiness, happiness is the key to success 
If you love what you are doing you will be successful 
Albert Schweitzer 
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Abstract 
Dendritic cells (DCs) are central players of the 
immune response. To date, DC-based 
immunotherapy is explored worldwide in 
clinical vaccination trials with cancer patients, 
predominantly with ex vivo-cultured 
monocyte-derived DCs (moDCs). However, 
the extensive culture period and compounds 
required to differentiate them into DCs may 
negatively affect their immunological 
potential. Therefore, it is attractive to 
consider alternative DC sources, such as blood 
DCs. Two major types of naturally occurring 
DCs circulate in peripheral blood, myeloid DCs 
(mDCs) and plasmacytoid (pDCs). These DC 
subsets express different surface molecules 
and are suggested to have distinct functions. 
Besides scavenging pathogens and presenting 
antigens, DCs secrete cytokines, all of which is 
vital for both the acquired and the innate 
immune system. These immunological 
functions relate to Toll-like receptors (TLRs) 
expressed by DCs. TLRs recognize pathogen-
derived products and subsequently provoke 
DC maturation, antigen presentation and 
cytokine secretion. However, not every TLR is 
expressed on each DC subset nor causes the 
same effects when activated. Considering the 
large amount of clinical trials using DC-based 
immunotherapy for cancer patients and the 
decisive role of TLRs in DC maturation, this 
review summarizes TLR expression in different 
DC subsets in relation to their function. 
Emphasis will be given to the therapeutic 
potential of TLR-matured DC subsets for DC-
based immunotherapy. 
 
Keywords  
Dendritic cell vaccination, myeloid dendritic 
cells, plasmacytoid dendritic cells, Toll-like 
receptors 
 
Introduction 
To date, dendritic cell (DC)-based 
immunotherapy is explored worldwide in 
clinical vaccination trials, predominantly in 
cancer patients (reviewed in1). The therapy 
consists of autologous ex vivo-cultured, 
antigen-loaded monocyte-derived DCs 
(moDCs) or CD34+ progenitor-derived DCs that 
are administered to patients with the 
intention of inducing antigen-specific T-and B-
cell responses. The generation of anti-tumor 
immune responses involves the induction of 
Th1-type CD4+ T cells and CD8+ cytotoxic T 
lymphocytes. Although DC-based 
immunotherapy potently induces 
immunological responses, thus far, only a 
limited number of clinical responses have 
been observed2. It is unclear whether DCs 
differentiated ex vivo from precursor cells are 
the most optimal source of DCs for the 
induction of potent immune responses. The 
extensive culture period (8-9 days) and 
compounds required to differentiate them 
into DCs may negatively affect DC function, 
especially migration3,4. Therefore, it is 
attractive to consider alternative DC sources, 
such as blood DCs. Two major types of DCs 
circulate in the blood, which can be 
distinguished by the presence of different 
surface markers: myeloid dendritic cells 
Introduction
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 (mDCs) and plasmacytoid dendritic cells 
(pDCs).  
In melanoma patients we demonstrated that 
moDC maturation is a prerequisite for the 
generation of tumor-specific T cell responses5. 
While blood DCs may not require extensive 
culture, also for these cells activation is 
essential prior to reinfusion, as immature DCs 
may cause tolerance rather than immunity. To 
date, most clinical studies use TNFα, IL-1β, IL-
6 and prostaglandin E2 for moDCs maturation. 
However, it has been suggested that the 
current protocols used to generate mature 
moDCs may not result in optimal Th1 
responses. Murine studies have shown that 
activation of DCs by solely pro-inflammatory 
cytokines yields DCs that support CD4+ T cell 
clonal expansion, but fail to efficiently direct 
helper T cell differentiation. In contrast, 
exposure of DCs to pathogen associated 
molecular patterns (PAMPs) induces DCs that 
produce high levels of the Th1 skewing 
cytokine IL-12p70 and promote efficient T cell 
help. PAMPs are recognized by pattern 
recognition receptors (PRRs). MoDCs, mDCs 
and pDCs express different repertoires of 
PRRs and respond dissimilar to extracellular 
stimuli, suggesting that the DC subsets have 
specialized and complementary functions6. In 
this review we summarize the expression of 
the most well known PRRs, Toll-like receptors 
(TLRs) on different DC subtypes in relation to 
their function. 
 
Dendritic cell subsets 
DCs are the most potent professional antigen 
presenting cells (APC) of the immune system. 
Upon infection or inflammation, immature 
DCs are activated and differentiate into 
mature DCs that instruct and activate B and T 
lymphocytes, the mediators of adaptive 
immunity7. DCs take up and process 
pathogens and present pathogen-derived 
peptides to T cells via major histocompatibility 
complex (MHC) molecules. The recognition of 
the peptide-MHC complex (signal 1) and 
stimulation via costimulatory molecules 
(signal 2) and cytokines (signal 3) leads to the 
activation of T-cells. The immunological 
outcome strongly depends on the activation 
state of DCs. Resting DCs or DCs receiving 
inhibitory signals like IL-10 or corticosteroids 
induce immune tolerance via T cell deletion or 
induction of regulatory T cells, whereas 
mature DCs induce immunity.  
The classical view of DCs is that of immature 
DCs, waiting for pathogens to be recognized, 
residing mainly in parts of the body that are in 
close contact with the outside world, such as 
skin and mucosal tissue. These immature DCs 
are able to quickly sense and take up 
pathogens that could harm the host. After 
recognition of a pathogen the DCs mature and 
migrate to lymphoid tissues to present the 
pathogenic peptides to T cells7. DC maturation 
is comprised of a tightly controlled series of 
events, including downmodulation of 
endocytic and phagocytic receptors, 
upregulation of costimulatory molecules, such 
as CD40, CD58, CD80 and CD86, changes in 
morphology and reorganization of the DC 
lysosomal and MHC class II compartment. DC 
maturation is highly complex and should be 
regarded as a flexible process of which the 
outcome depends on the type of signals a DC 
receives in the periphery.  
The DC population is a heterogeneous 
population. The DC subtypes differ in 
function, localization and phenotype. In 
human peripheral blood two main 
populations of DCs can be distinguished, 
CD11c expressing myeloid DCs (mDCs) and 
CD11c negative plasmacytoid DCs (pDCs)8. 
These DCs express distinct PRRs and respond 
to different pathogenic stimuli, suggesting 
that each subset has a specialized function in 
directing immune responses. However, both 
mDCs and pDCs have the capacity to initiate 
suitable T cell responses, depending on the 
pathogens they encounter. 
 
Plasmacytoid dendritic cells 
Human pDCs are a rare subpopulation of cells; 
they constitute only 0.1% of all blood 
mononuclear cells. PDCs are devoid of lineage 
markers and myeloid antigens and do not 
express CD11c. PDCs express BDCA2 and 
BDCA49. In steady state they are round, non-
dendritic and relatively long-lived cells. After 
receiving inflammatory stimuli, pDCs develop 
dendritic cell morphology and function. Most 
notably pDCs produce large amounts of type I 
1 
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 Interferons in response to viruses and are 
therefore crucial in antiviral immunity10. 
Initially, pDCs were thought to be of lymphoid 
origin11. However, several human and mouse 
studies pointed out that the cytokine Flt3L is 
of importance for pDC development and that 
pDCs can develop out of myeloid precursors 
under the influence of Flt3L10,12,13. PDCs reside 
in blood as well as in several lymphoid organs 
and some recent studies suggest functional 
differentiation between different tissue-
residing pDCs14. Whether these are actual pDC 
subsets or whether environmental factors 
influence pDC function is not clear yet.  
 
Myeloid dendritic cells 
Myeloid DCs found in peripheral blood are 
defined by the expression of myeloid markers, 
such as CD13 and CD33. They lack lineage 
specific markers (CD3, CD14, CD19 and CD56), 
but express MHC class II and CD11c. The mDC 
population can be further subdivided based 
on differential surface expression of CD1c 
(BDCA1), CD16 and BDCA3. In addition, 
another small subset of CD16-expressing DC 
termed M-DC8 DCs or SlanDCs has been 
described15. CD16-mDCs comprise the largest 
population of mDCs (65-75% of total mDC 
population), followed by CD1c-mDCs (10-20%) 
and BDCA3-mDCs (3-5%)16,17. Although CD16-
mDCs have the highest frequency in human 
peripheral blood, CD1c-mDCs have been 
studied most extensively. The mDC subsets 
differ in their expression of cell surface 
markers and potency to stimulate T cells16-18. 
For instance, the recently identified C-type 
lectin receptor CLEC9a is expressed only by 
BDCA3-mDCs19. According to MacDonald et al, 
CD1c-mDCs are the most potent T cell 
stimulators of the three mDC sub-
populations16.  
 
Monocyte-derived dendritic cells 
Since the frequency of circulating mDCs in 
human blood is very low, many studies exploit 
in vitro-generated “monocyte-derived 
dendritic cells” (moDCs)20. Monocytes are pre-
DCs that originate from myeloid progenitor 
cells. In vivo, monocytes are capable of 
transforming into DCs after sensing 
inflammatory signals and are important for 
the replenishment of dendritic cells in the 
host. In vitro, a cocktail of 
granulocyte/macrophage colony-stimulating 
factor (GM-CSF) and interleukin-4 (IL-4) 
differentiates monocytes into moDCs20. 
MoDCs are the major DC type used in clinical 
DC-vaccination studies2,21. Whether these 
moDCs reflect immature “steady state” in vivo 
mDCs remains to be seen as most of these 
moDCs show a dramatically higher expression 
of MHC molecules and costimulatory 
molecules compared to freshly isolated 
immature mDCs22. In addition, moDCs and 
mDCs respond differently to physiologic 
stimuli and they differ in their ability to 
stimulate T cells23,24. Therefore, although in 
vitro-generated moDCs share many 
phenotypic and functional characteristics with 
circulating mDCs, it is yet unclear to what 
extend they resemble blood DCs.  
In addition to monocytes, CD34+ precursors in 
blood are also used to generate DCs for 
vaccination of cancer patients. They consist of 
two populations: one with Langerhans cell-
like properties and one called 
interstitial/dermal DCs with properties 
resembling moDCs. Immunological and clinical 
responses have been observed in cancer 
patients vaccinated with CD34+-derived DCs25. 
However, to date most clinical studies use 
monocytes to generate DCs.  
 
Pathogen recognition by Toll-like receptors 
In evolution, the immune system has acquired 
various receptor families that recognize 
several crucial molecular components of 
pathogens. This set of PAMPs recognized by 
the immune system is limited and constituted 
mostly of general molecular patterns that are 
absent on cells of the host and are essential 
for survival of the microbe. On DC 
membranes, two main PRR families are 
present: C-type lectins and Toll-like receptors 
(TLRs), of which the TLR family is best 
characterized and recognizes the most diverse 
group of PAMPs. Nowadays 15 mammalian 
Toll-like receptors are found (TLR1-15), of 
which 10 in humans26,27. The binding partners 
of the recently discovered TLR10, TLR12, 
TLR13 and TLR15 are unknown. TLR11 is only 
expressed in mice and recent studies suggest 
Introduction
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 that TLR11 associates with molecules 
originating from uropathogenic bacteria and 
Toxoplasma Gondii28,29. The better-described 
TLR1-9 can be divided in two main groups: 
extracellular TLRs that are found on the cell 
surface (TLR1, TLR2, TLR4, TLR5, and TLR6) 
and the intracellular TLRs that are located in 
endosomal compartments (TLR3, TLR7, TLR8 
and TLR9). In general, intracellular TLRs 
recognize nucleotide-containing structures, 
for example RNA molecules (TLR3, TLR7 and 
TLR8) and unmethylated CpG DNA (TLR9), 
originating from viruses and bacteria. 
Extracellular TLRs recognize exterior 
components of bacteria and fungi, e.g. cell 
wall components. Examples of ligands include 
lipopolysaccharide (LPS) for TLR4, flagellin for 
TLR5 and peptidoglycan for TLR2. TLR2 forms 
heterodimers with either TLR1 or TLR6. The 
TLR1/2 heterodimer recognizes bacterial 
triacyl lipopeptides and TLR2/6 recognizes 
bacterial diacyl lipopeptides. Besides PAMPs 
derived from pathogens, TLRs have been 
proposed to recognize endogenous ligands 
such as heat shock proteins or necrotic 
cells30,31. The signaling pathways associated 
with ligation of the different TLRs are not 
identical and therefore distinct biological 
responses are initiated. Ligand binding of TLRs 
recruits one or more adaptor molecules. The 
difference in signaling outcome (e.g. variation 
in cytokine production) can be explained in 
part by the use of different adaptor molecules 
by the Toll-like receptors. All TLRs, except 
TLR3, rely on MyD88 for signal transduction. 
TLR3 uses TRIF as adaptor molecule, whereas 
TLR4 is able to recruit both MyD88 and TRIF32. 
 
TLR expression and functionality in DC 
subpopulations 
DCs show different expression levels of TLRs 
and respond dissimilar to TLR ligands. The 
expression of TLRs varies with species, DC 
subtype and maturation stage. In this review 
we focus on TLR expression and function in 
human DC subsets. We have divided the 
human DC population in three groups: in 
vitro-generated moDCs and circulating mDCs 
and pDCs. Expression of TLRs and the effects 
of TLR activation in the three DC subtypes are 
summarized in table 1. 
TLR expression and activation: moDCs and 
mDCs compared 
DCs derived in vitro from monocytes (moDCs) 
have provided immunologists important 
insights into the biology of DCs. Because of 
the large amounts of clinical trials using 
moDCs as alternative for naturally occurring 
blood- mDCs, we here compare the TLR 
expression profile in human moDCs and their 
blood-isolated mDC counterparts. Of the 
three blood mDC subpopulations, CD1c-mDCs 
have been studied most extensively. Only a 
study by Piccioli and colleagues compared the 
expression and function of TLRs in the three 
circulating mDC subtypes, CD16-mDCs, CD1c-
mDCs and BDCA3-mDCs. They detected 
expression of TLR1-10 at the RNA level in all 
three mDC subsets, with the exception of 
TLR3, which was not expressed by CD16-
mDCs. In addition, both CD16-mDCs and 
CD1c-mDCs strongly responded to all TLR 
agonists, except the TLR9 agonist CpG. 
Interestingly, CD16-mDCs were responsive to 
the TLR3 ligand poly(I:C), while TLR3-mRNA 
was not detected in these cells. The authors 
suggest that poly(I:C) may activate CD16-
mDCs through TLR3-independent 
mechanisms17, such as cytosolic RNA sensors 
like RIG-like helicases33. Another possibility 
may be that minor contaminations of for 
instance endotoxin in poly(I:C) have activated 
other TLRs. Due to the low frequency of 
BDCA3-mDC in peripheral blood, no functional 
studies were performed on this mDC subset.  
Since other studies on TLR expression and 
function in mDC subtypes are lacking, we 
focused on CD1c-mDCs when comparing 
moDCs with blood mDCs. Human moDCs and 
mDCs show very similar TLR expression 
profiles (table 1). Both DC subsets express the 
extracellular TLRs TLR1, TLR2, TLR4, TLR5, and 
TLR6, and the endosomal TLRs TLR3 and TLR8 
(table 1). In addition, both moDCs and mDCs 
respond to specific ligands of these TLRs, 
leading to a mature phenotype and 
production of proinflammatory cytokines34-42. 
However, some significant differences 
between moDCs and CD1c-mDCs in TLR 
expression and ligand reactivity were found.  
Most notably, moDCs showed negligible 
TLR10 expression, whereas blood mDCs did 
1 
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 express TLR10. An extensive qPCR expression 
profiling by Means et al. revealed that mDCs 
have 20-fold higher expression levels of TLR10 
mRNA compared to moDCs39. MRNA 
expression of TLR10 in mDCs was even 
comparable to that of TLR5. Unfortunately, 
the ligands and functionality of TLR10 are still 
unknown, so this difference between moDCs
 
Table 1. TLR expression and functionality on DC subtypes 
DC 
subtype 
TLR Expression Effects of activation References 
moDC 1  + - See TLR2 35;39-41;44;71 
 2  ++ - Increased IL-6, IL-8, IL-10, IL-12, TNFα 
- Low IFNβ response and no IFNα response 
35;38-41;44;71 
 3  + - Specific IFNβ mRNA upregulation (not IFNα) 35;38-41;44;71 
 4  ++ - Upregulation of CD80, CD86, CD83, CCR7 
- Secretion of IFNβ, IFNγ, IL-1β, IL-12p70, IL-13, IP-10 
- Decreased endocytic capacity 
35;38-41;44;71 
 5  + - Upregulation of CD80, CD86, CD83, CCR7 
- Secretion of IFNγ, IL-1β, TNF, IL-8, IL-12p40 (not IL-12p70), 
IL-13 
- Decreased endocytic capacity 
35;39-41;44;71 
 6  +/- - See TLR2 35;38;39;41;71 
 7  +/- - 35;39;41;41;71 
 8  + - Increased TNFα, IL-8, IL-12p40, MCP-1, CCL2, CCL3, CCL4, 
CCL5 
35;39;41;71 
 9  -  35;39;41;71 
 10  -  39;41 
mDC 1  + - See TLR2 35-37;39;51 
 2  ++ - Upregulation of CCR7, IL-6, IL-10, IL-12p70,TNFα, no INFα 35-39;51 
 3  ++ - IFNα (intermediate), IL-12p70 (high)  
- No TNFα or IL-6 
35-39;51 
 4  + - Upregulation of CD80, CD86, CD83, CD40, CCR7 
- Secretion or upregulation of CCR7, IL-6, IL-8, IL-10, IL-
12p70 
- No IFNα response 
34-39;51 
 5  + - Upregulation of CD80, CD86, CD83, CCR7  
- Secretion of TNF and IL-8  
- upregulation of CCR7,  
35-37;39 
 6  + - See TLR2 35-37;39;51 
 7  + - Upregulation of CD40, CD80 and CD86 
- Secretion of IL-12p70 
- No IFNα response 
34-37;39;51 
 8  +/- - See TLR7 35-37;39;51 
 9  -  34-37;39;51 
 10  + - No ligand known 36;39;51 
pDC 1  +/-  35-37;50;51 
 2  -  35-38;50;51 
 3  -  35-38;50;51 
 4  -  34-38;50;51 
 5  -  35-37;50 
 6  -  35-37;50;51 
 7 ++ - Upregulation of CD40, CD80, CD86, CCR7  
- Very high IFNα response 
- No IL-12p70 response 
34-37;50;51 
 8  -  35-37;50;51 
 9  +++ - Upregulation of CD40, CD80, CD86, CD83, HLA-DR, CCR7 
- Upregulation of IFNα (very high), IFNβ (lower), IL-6, TNFα 
(low), IL-8, IP-10 
- No IL-10 secretion 
34-37;50;51 
 10  + - No ligand known 36;50-52 
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  and mDCs could not be explained. However, 
since TLR10 is also expressed by regulatory T 
cells43, TLR10 activation on DCs may induce 
tolerogenic DCs. The fact that moDCs have a 
more mature phenotype22 may thus explain 
the absence of TLR10 in moDCs.  
Iwasaki and Medzhitov concluded that human 
mDCs totally lack TLR4 expression27. The 
authors mainly base their conclusion on a 
study performed by Visintin and colleagues44. 
However, their results were contradicted by 
Ito et al34 and Matsumoto et al38, in 2002 and 
2003 respectively, who show that freshly 
isolated human blood CD1c-mDCs do express 
TLR4. This was confirmed by experiments in 
the same study of Ito et al, which showed that 
stimulation of mDCs with LPS induced the 
production of IL-1234. According to Means and 
colleagues, moDCs secrete type I IFNs upon 
LPS administration, whereas this ligand did 
not provoke type I IFN secretion in mDCs39. 
While this was confirmed by Matsumoto and 
co-workers38, the function of type I IFN 
secretion after LPS challenge remains unclear, 
as type I IFNs have anti-viral rather than anti-
bacterial properties. The disparity in IFN 
secretion may also be caused by the 
difference in maturation stage between 
moDCs and CD1c-mDCs. Muzio et al showed 
that as differentiation of monocytes 
progresses towards moDCs, the expression of 
TLR 3, 4 and 5 increases. Eventually the 
expression of TLR4 in moDCs is higher than 
that in mDCs40. This higher number of TLR4 
molecules per cell may explain the difference 
in type I IFN secretion between moDCs and 
mDCs. A high number of TLR4 molecules 
might induce a broader immune response: a 
low number of TLR4 molecules is able to only 
activate the MyD88 pathway, resulting in an 
immune response without an IFN response, 
whereas a higher amount of TLR4 molecules 
might be able to activate both the MyD88 and 
TRIF pathway, leading to a broader immune 
response, including production of type IFNs45. 
This is in line with the finding that the TRIF 
adapter protein in non-plasmacytoid DCs is 
mainly responsible for the activation of 
transcription factors that induce type I 
interferons45.  
TLR1, 2 and 6 are expressed by both moDCs 
and mDCs (table 1)35-39,41. Through the 
formation of heterodimers with TLR1 or TLR6, 
TLR2 gains the capacity to bind a wide variety 
of bacterial and yeast-derived ligands. 
Consequently, this plays a central function in 
pathogen recognition by DCs. TLR1/2/6 
activation leads to DC maturation and 
secretion of several cytokines important in 
immune system activation, especially IL-6, IL-
8, IL-10, IL-12 and TNF-α. Differences in 
expression between moDCs and mDCs in 
TLR1, TLR2 and TLR6 expression and reactivity 
are negligible.  
TLR5 expression was evident in both moDCs 
and CD1c-mDCs as indicated in table 1. Means 
et al especially investigated the role of TLR5 
and its main ligand, bacterial flagellin, in 
moDCs and to a lesser extent in mDCs39. They 
found increased surface expression of 
maturation markers for both, without the 
induction of a type I IFN response, which is 
expected considering the bacterial origin of 
flagellin. 
Studies on TLR7 expression on moDCs or 
mDCs show conflicting results. This 
inconsistency was also noted in the review by 
Iwasaki and Medzhitov27. It was especially 
fuelled by the contradictory results from 
Jarossay et al and Krug et al35. Using three 
different primer sets for RT-PCR on TLR7, Ito 
et al concluded that human CD1c-mDCs do 
express TLR734. For TLR7 expression in moDCs, 
there is still disagreement between studies, 
however the most recent findings suggest 
that moDCs indeed express TLR739. For moDCs 
a thorough study of TLR7 mRNA/protein 
expression, as was performed for mDCs by Ito 
et al, is lacking. Confirmation of TLR7 protein 
expression is difficult due to low expression 
and a lack of good antibodies. Therefore, TLR7 
expression in moDCs is still unclear, as 
indicated by the “+/-” in table 1. TLR8, the 
“near cousin” of TLR7, was found to be 
consistently expressed in lower amounts in 
both moDCs and mDCs. As TLR7 and TLR8 
share the same ligands, it was impossible to 
attribute TLR8 as the binding receptor 
responsible for the secretion of cytokines or 
DC maturation after, for example, R848 
challenge34. 
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 Human moDCs and mDCs do not express TLR9 
and do not respond to TLR9 ligands34,37. TLR9 
is only expressed by pDCs in the human 
setting and is responsible for a very high type I 
IFN response46. 
In summary, data suggest that both moDCs 
and mDCs express TLR1-8 and not TLR9 and 
only mDCs express TLR10. The mRNA 
expression of these receptors was confirmed 
by DC reactivity studies using TLR ligands, 
summarized in table 1. 
 
TLR expression by human pDCs 
Evidence suggests that pDCs are specialized in 
the recognition of viral antigens, as they 
largely lack expression of extracellular TLRs 
and only express TLRs that recognize and 
respond to viral antigens. PDCs abundantly 
express TLR7 and TLR9 in their endosomal 
compartments. In addition, triggering of TLR7 
and TLR9 on pDCs leads to high type I IFN 
secretion and a typical mature DC phenotype, 
i.e. upregulation of expression of major 
histocompatibility molecules and the co-
stimulatory molecules CD80 and CD86.  
Interestingly, it has been suggested that in 
human pDCs TLR9 displays a unique feature 
that is not shared by the other described TLRs. 
Depending on the stimulus, activation of TLR9 
on human pDCs can have different outcome. 
The dual function of TLR9 is attributed to the 
distinct intracellular locations where TLR9 can 
be triggered. Upon encountering nucleic acids 
TLR9 will traffic from the endoplasmatic 
reticulum through the Golgi to the early 
endosomes47,48. There TLR9 triggering may 
induce the recruitment and phosphorylation 
of IRF7, which in turn induces IFN  secretion, 
thus activating an innate immune response. In 
contrast, in the late endosomes TLR9 
triggering preferentially activates NF- B, 
which results in phenotypical maturation of 
DCs and secretion of IL-6 and TNF , hence 
activating an adaptive immune response49.  
Especially IFNα is produced after TLR7 or TLR9 
triggering34-37,50. IL-12, a cytokine commonly 
produced by mDCs and moDCs after TLR 
stimulation, is not secreted by pDCs as found 
in the majority of the studies. Only Jarrossay 
and colleagues mentioned a weak IL-12 
response by pDCs, which was possibly due to 
a polluting mDC subset in the samples 
tested35.  
Some reports showed a minimal expression of 
TLR1 on pDCs36,37,51. However, the possible 
function of TLR1 on pDCs remains ambiguous, 
especially since its heterodimeric partner 
TLR2 is not expressed by pDCs and pDCs do 
not respond to TLR1/TLR2 ligands35-38.  
Interestingly, pDCs do not express TLR3 and 
TLR8. Since both TLR3 and TLR8 bind viral 
ligands and pDCs are specialized in 
recognition of viral pathogens, it would not be 
unlikely for pDCs to express these receptors. 
Possibly, TLR8 lost its function during 
evolution as TLR7 binds the same ligands and 
shares the same signaling pathway, leading to 
similar effects. However, why pDCs lack TLR3 
expression is still unknown.  
Surprisingly, pDCs also express TLR10, both at 
mRNA and protein level37,51,52, but the 
function and binding partner of TLR10 have 
yet to be identified. Overall, human pDCs only 
express TLR7, 9 and 10 and react upon TLR7 
and TLR9 activation by secreting type I IFNs, 
especially IFNα. 
 
Practical limitations 
When comparing data obtained by different 
groups, we noticed inconsistencies between 
studies, which may be caused by technical 
limitations. For instance, several different 
techniques to isolate fresh mDCs and pDCs 
from blood were used by different groups, 
including cell sorting by FACS and magnetic 
beads. Even small impurities in the isolated 
cell population can interfere with the results, 
as was demonstrated by the IL-12 secretion 
by a small contaminating mDC subpopulation, 
which was first contributed to the pDC 
population34,37,50. In addition, most expression 
profiling of TLRs on DCs is performed by RT-
PCR, because of a lack of antibodies directed 
against TLR molecules. But when antibodies 
were used, several of them proved to be 
unreliable as demonstrated by Matsumoto et 
al, who showed that a TLR3-specific antibody 
also bound to a centrosomal protein that 
shared an epitope with TLR3 and incorrectly 
suggested TLR3 protein expression in pDCs, 
although TLR3 mRNA expression was absent38. 
Even small impurities in the isolated cells (~1-
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 5%) can cause problems. Furthermore, mRNA 
expression level interpretation is highly 
subjective and does not always correlate with 
the expression level of the encoded protein. 
In addition, mRNA levels do not reveal the 
localization of the protein. Perhaps TLR 
proteins residing in intracellular 
compartments and showing high mRNA 
expression are only effective when 
transported to another compartment or to 
the extracellular membrane after stimulation. 
For instance, it has been demonstrated that 
the ectodomain of TLR9 is cleaved in the 
endolysosome before TLR9 is transported to 
endosomal compartments and that only the 
cleaved form of TLR9 is functional after ligand 
binding53. In addition, post-translational 
modification like ubiquitination may affect 
TLR expression and functionality54. Therefore, 
next to TLR expression profiling, functional 
studies using TLR ligands are important in 
establishing whether the TLR expressed in a 
given DC subtype is functional. However, 
cytokine responses and DC maturation may 
also be caused by non-TLR receptors, such as 
C-type lectins, or undiscovered TLRs that 
recognize the same pathogenic ligands. In 
addition, it is very important to use highly 
purified TLR ligands, since minor 
contaminations of for instance endotoxin may 
obscure the results. 
 
Implications for immunotherapy of cancer 
The above summarized data suggest that 
mDCs mainly recognize and respond to 
bacterial and fungal antigens, whereas pDCs 
are specialized for viral recognition. However, 
although pDC and mDC subsets have different 
functional specialization, as they express a 
different repertoire of TLRs and respond 
dissimilar to microbial stimuli, both pDCs and 
mDCs may be of importance for the induction 
of anti-tumor responses in DC vaccination 
therapy. MDCs as well as pDCs can induce Th1 
responses after TLR stimulation34 and anti-
tumor responses induced by pDCs have been 
reported in animal models55,56.  
 
Reactivation of tumor-infiltrating DCs 
Several studies suggest that human pDCs have 
the ability to infiltrate solid tumors since they 
are found in a wide variety of human cancers 
including breast cancer57, head and neck 
cancer58 and ovarian cancer59. Soluble factors 
secreted by the tumor create a suppressive 
environment, thus preventing differentiation 
and maturation of infiltrating DCs60-62. Despite 
their ability to infiltrate solid tumors, pDCs on 
site are unable to sense DNA via TLRs and 
become activated. These findings have been 
correlated with poor prognosis57 and are 
linked to the induction of regulatory T cells63. 
Although pDCs at the tumor site have a pre-
pDC phenotype and maintain the 
immunosuppressive environment, several 
studies have now demonstrated that topical 
TLR7-agonist (Imiquimod) treatment led to 
enhanced pDC recruitment and type I IFN 
production by resident pDCs at the tumor site, 
which on its turn generated a inflammatory 
environment resulting in tumor re-
gression64,65. Furthermore, activation of 
resident-tumor pDCs can also be achieved by 
intratumoral injection of CpG motifs inducing 
TLR9 triggering. This strategy has therapeutic 
potential in patients with basal cell carcinoma 
and melanoma skin metastases66. Since TLR9 
is believed to be expressed only on pDCs, CpG 
injection will not directly activate mDCs. 
Therefore, intratumoral injection of other TLR 
ligands, such as the TLR7/8 ligand R848 that 
activates both mDCs and pDCs will be even 
more potent in reactivating DCs at the tumor 
site and might favor the induction of anti-
tumor immune responses.  
 
DC vaccination with pDCs and mDCs 
Recent studies suggest that pDCs and mDCs 
cooperate and act synergistically (figure1). In 
mice, pDCs do not only directly induce tumor 
antigen-specific CD8+ T cell immune 
responses, but they can also enhance the 
ability of mDCs to present tumor antigens to T 
cells67. Moreover, human mDCs and pDCs 
activate each other after specific stimulation 
of only one of the DC subsets with 
appropriate TLR ligands in vitro68. These 
studies suggest that also in a clinical setting, 
such as DC vaccination in cancer patients, 
vaccination with both pDCs and mDCs may 
generate stronger anti-tumor responses than 
vaccination with moDCs alone.  
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 We recently completed a clinical trial with 
tumor antigen-loaded, TLR ligand-matured 
pDCs in stage IV melanoma patients, which 
appeared feasible and safe (manuscript in 
preparation). In the majority of patients 
vaccinated with pDCs we found responses 
against the monitoring protein, 
demonstrating that even small numbers of 
naturally occurring DCs can induce 
immunological responses. When mDCs and 
pDCs would be used in combination, both DC 
subsets will need stimulation with carefully 
selected TLR ligands, due the fact that they 
express a different repertoire of TLRs (Table 1, 
Figure 1). Since TLRs act in synergy69, the 
combination of different TLR ligands may even 
be more potent (Figure 1). It is of importance 
to find TLR ligands that either induce optimal 
maturation of both mDCs and pDCs, or at 
least do not interfere with maturation of 
either DC subtype. Future studies will address 
whether mDC-pDC cross-talk can improve 
anti-tumor responses in cancer patients. 
 
Concluding remarks 
To date, most clinical studies apply moDCs for 
DC vaccination of cancer patients. As 
described above, culturing procedures 
required to obtain moDCs may affect their 
ability to induce anti-tumor immunity. We 
hypothesize that TLR-matured blood DCs may 
be a potent alternative, since these cells do 
not require extensive culturing and can be 
isolated in a closed system in accordance to 
GMP standards. Despite their low frequencies, 
human naturally occurring DCs may have 
superior migratory and antigen-presenting 
capacities compared to in vitro-generated 
moDCs, especially when combining different 
DC subsets. Alternatively, the potency of in 
vitro-generated moDCs could be improved by 
electroporation with mRNA encoding proteins 
Fig. 1 TLR-activation of human DC subsets can enhance anti-tumor responses in vivo.DC subsets express a wide 
repertoire of TLRs, which upon triggering induce the activation of the DC. Where pDCs predominantly express TLRs in 
endosomal compartments, mDCs have a broader TLR expression pattern, both at endosomal and extracellular 
membranes. By cross-talk between mDCs and pDCs, either by cell-cell contact or soluble factors such as type I IFNs, TLR-
induced activation of one subset can lead to the activation of the other subset. Type I IFNs appear to yield more potent 
mDCs in terms of IL-12 secretion, induction of tumor-specific cytotoxic T cells and Th1 repsones in vitro. Upon direct TLR 
activation mDCs gain the ability to secrete large quantities of IL-12, which is beneficial for the polarization of a Th1 
response. Both mDCs and pDCs have the capacity to evoke T helper cell responses. Moreover pDCs can promote the 
ability of mDCs to cross-prime CD8+ T cells. Consequently, TLR activation of mDCs and pDCs and the cross-talk between 
those two subsets can strongly enhance anti-tumor responses in vivo. 
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 involved in DC maturation, migration, and T 
cell activation, as was suggested by Bonehill 
and colleagues70. Future studies will need to 
prove the feasibility and potency of TLR-
matured DC subsets for DC-based 
immunotherapy. 
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Abstract 
The plasmacytoid dendritic cell (pDC) 
constitutes a unique DC subset that links the 
innate and adaptive arm of the immune 
system. Whereas the unique capability of 
pDCs to produce large amounts of type I IFNs 
in response to pathogen recognition is 
generally accepted, their antigen presenting 
function is often neglected since most studies 
on antigen presentation are aimed at other 
DC subsets. Recently, pDCs were 
demonstrated capable to present antigen 
leading to protective tumor immunity. In this 
review we discuss how pDCs could be 
exploited in the fight against cancer by 
analyzing their capacity to capture, process 
and (cross)present antigen.  
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Introduction 
 
The human immune system constitutes of a 
wide variety of cell types to maintain immune 
homeostasis. In this system, professional 
antigen presenting cells (APCs) control the 
tight balance between tolerance and 
immunity. All professional APCs exploit an 
efficient antigen uptake machinery and long-
lived MHC class II-peptide complexes on the 
cell surface. Dendritic cells (DCs) represent a 
family of professional APCs that are derived  
from hematopoietic precursors, and have the 
capacity to induce antigen specific T-cell 
responses. Efficient priming is dependent on 
full maturation of DCs, which is evoked by the 
recognition of specific pathogen associated 
molecular patterns by their distinct pathogen 
recognition receptors (PPRs). Some of the 
best characterized PPRs expressed by DCs are 
the toll like receptors (TLRs) which are able to 
bind different pathogen structures like LPS, 
lipoprotein structures, DNA or single and 
double stranded RNA motifs, thereby 
initiating a signaling cascade leading to up-
regulated expression of MHC and co-
stimulatory molecules on the DC surface, 
presentation of antigens and enhanced 
cytokine production1,2. After infection or 
inflammation, this maturation process 
enables DCs to migrate to the lymph nodes 
and present encountered antigens to naïve T-
cells.  
The DC family is very heterogeneous and 
consists of different DC subsets each with 
specific functional characteristics. In general, 
two different DC subtypes can be 
distinguished, e.g. myeloid DCs (mDCs) and 
plasmacytoid DCs (pDCs). These distinct 
subsets express various surface receptors and 
PPRs, which determine their specialized 
functions (Table 1)3. The mDC subset can be 
identified and subdivided in three different 
subtypes by the expression of CD11c in 
combination with their unique surface 
molecules CD1c (BDCA1), CD141 (BDCA3) and 
CD164. Classically, mDCs reside in peripheral 
tissues in an immature state and migrate to 
lymph nodes after their maturation where 
they produce IL-12 and activate T cells5,6. PDCs 
are an extraordinary subset that differ from 
the other DC subsets by a specific feature: the 
capacity to produce large amounts of type I 
IFNs in response to viral or bacterial stimuli. 
PDCs employ TLR7 and TLR9, located in 
intracellular endosomes and lysosomes, to 
recognize single stranded viral RNA or 
Introduction
26
 unmethylated CpG DNA motifs,  
respectively7,8. Through the secretion of high 
levels of type I IFNs, pDCs communicate with 
other immune cells, e.g. they stimulate mDCs 
to enhance T-cell activation and activate 
natural killer cells and B cells. In this way pDCs 
link the innate and adaptive arm of the 
immune response2,9. In contrast to mDCs, 
pDCs are hardly found in peripheral tissues 
under steady state conditions. Instead, pDCs 
circulate through the body after entering the 
bloodstream and reach secondary lymphoid 
organs via high endothelial venules, while 
most other DC subsets enter secondary 
lymphoid organs via the lymph vessels. 
Following inflammation, pDCs leave the 
bloodstream and accumulate in the infectious 
site to take up antigens, followed by migration 
to lymph nodes to present the encountered 
antigens10. The unique capability of pDCs to 
produce large amounts of type I IFNs in 
response to pathogen recognition is well 
accepted. However, the position of pDCs as 
professional APCs has long been dictated by 
the view that pDCs are inferior to mDCs as it 
comes to antigen presentation. In this review 
we discuss how pDCs could be exploited in the 
fight against cancer by analyzing their capacity 
to capture, process and (cross)present 
antigen.  
 
pDC induce anti-tumor immune responses 
leading to protective immunity 
Most DC-based immunotherapy has been 
performed with monocyte derived DCs that 
were generated ex vivo 11-13. Although, clinical 
outcomes were observed in a fraction of 
patients treated with DCs 12-17, it has been 
postulated that moDCs might be less effective 
than naturally occuring DC subsets. PDCs 
comprise one of these natural DC subsets 
circulating in the blood and are potential 
candidates for DC based anti-tumor 
immunotherapy as detailed below. 
The observation that human pDCs were able 
to induce T cell responses in vitro confirmed 
results observed in mice where CpG or 
influenza virus matured pDCs induced 
ovalbumin (OVA) specific CD4+ and CD8+ T cell 
responses 18-22. While CpG matured pDCs 
induced CD8+ T cell responses against 
endogenous antigens no T cell responses were 
observed against exogenous OVA antigen23. 
This discrepancy could in part be attributed to 
the fact, that in some studies pDCs were 
pulsed with the entire OVA protein, while 
others used OVA fragments. In other studies 
with exogenous antigens like influenza A or 
HSV, pDCs also induced CD4+ and CD8+ T cell 
responses, again indicating their capacity to 
present antigens and stimulate T cells24-26. 
Notwithstanding these results, pDCs were less 
effective in CD4+ priming when compared to 
mDCs when both are stimulated with TLR 
agonists, like LPS19. This might be explained by 
the fact that mDCs express high levels of TLR4 
where pDCs do not. Salio et al. proposed that 
high numbers of peptide pulsed pDCs are 
equally efficient as peptide pulsed mDCs in 
priming of CD8+ T cells23. This notion is 
supported by the finding that murine pDCs 
exposed to influenza virus induced the 
generation of memory CD8+ T cells as well as 
effector CD8+ T cells upon rechallenge with 
the virus, leading to protective immunity20. 
Further evidence that pDCs can induce 
protective immunity comes from studies 
where mice were vaccinated with CpG 
matured tumor peptide pulsed pDCs or pulsed 
by a Leishmania major (L. major) lysate. Mice 
vaccinated with tumor peptide loaded pDCs 
gained anti-tumor immunity and were 
protected upon tumor challenge, whereas 
non vaccinated animals showed unhampered 
tumor growth23. This indicates that mature 
pDCs can effectively generate protective 
immunity27. Together, these data emphasize 
the potential of pDCs as type I IFN secreting 
professional APCs.  
 
Antigen cross-presentation by pDCs 
 
A potent immune response requires both 
CD4+ T cell and effector CD8+ responses. To 
this end the capacity of DCs to cross-present 
antigen is absolutely essential. In contrast to 
the well defined capacity of human CD141+ 
mDCs and mouse CD8α+ mDCs to 
crosspresent antigens28-31, controversy exists 
about ability of pDCs to cross-present.
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 Table 1 Phenotypical and functional characteristics of blood DC subsets3,6,45,62,82-84 
  pDCs   mDCs  
    BDCA-1 BDCA-3 CD16 
  Steady 
state 
Activated  Steady 
state 
Activated Steady 
state 
Activated Steady 
state 
Activated 
Phenotype CD4 
CD11c 
CD40 
CD80 
CD83 
CD86 
HLA-DR 
HLA-ABC 
CCR7 
++ 
- 
+/- 
- 
- 
+ 
++ 
+/- 
- 
++ 
- 
+++ 
++ 
+ 
+++ 
+++ 
++ 
++ 
 + 
+++ 
+/- 
- 
- 
+ 
++ 
+ 
- 
++ 
+++ 
+++ 
++ 
+ 
+++ 
+++ 
++ 
++ 
+ 
++ 
+/- 
- 
- 
+ 
++ 
+ 
- 
++ 
+++ 
+++ 
++ 
+ 
+++ 
+++ 
++ 
++ 
+ 
+++ 
+/- 
- 
- 
++ 
++ 
+ 
- 
++ 
+++ 
+++ 
++ 
+ 
+++ 
+++ 
++ 
++ 
       
Toll like 
receptors 
TLR-1 
TLR-2 
TLR-3 
TLR-4 
TLR-5 
TLR-6 
TLR-7 
TLR-8 
TLR-9 
TLR-10 
+ 
- 
- 
- 
- 
+/- 
++ 
- 
+++ 
+ 
 + 
++ 
++ 
+ 
+ 
+ 
+/- 
+ 
- 
+ 
+ 
++ 
++ 
+ 
+/- 
+ 
+/- 
+ 
- 
+ 
+ 
++ 
- 
+ 
+ 
+ 
+/- 
+ 
- 
+ 
       
C-type lectin 
receptors 
DEC-205 
DCIR 
BDCA-2 
CLEC9a 
++ 
+ 
++ 
- 
 ++ 
+ 
- 
- 
+++ 
- 
- 
+ 
+ 
+ 
- 
- 
       
Fc receptors FcαR 
FcεRI 
Fc RI 
Fc RIIa 
Fc RIIb 
Fc RIII 
+/- 
+ 
- 
+ 
- 
- 
 - 
+ 
- 
+ 
+ 
+ 
- 
- 
- 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
+/- 
       
Upon activation       
Cytokine 
secretion  
IFNα 
IFNβ 
IFNω 
IFN  
IL-1β 
IL-6 
IL-8 
IL-12 
TNFα 
+++ 
+++ 
++ 
+ 
+ 
++ 
+++ 
- 
+++ 
 - 
 + 
- 
+ 
+ 
++ 
+++ 
+ 
+++ 
- 
+ 
- 
+ 
+ 
++ 
+++ 
 + 
+++ 
- 
+ 
- 
+ 
+ 
+++ 
+++ 
+ 
+++ 
       
Migration  +  + + + 
       
Ag (cross)-
presentation 
CD4 
Th1* 
CD8 
+ 
+ 
+ 
 + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+/- 
* After activation, pDC-derived type I IFNs and mDC-derived IL-12 are involved in the differentiation of Th1 cells. 
Although in some studies murine pDCs fail to 
induce functional CD8+ T cells18,32, human 
pDCs appear to be competent in processing 
exogenous antigens to be presented in MHC 
class I molecules33-35 (Figure 1). Exogenous 
antigens captured by pDCs might end up in 
MHC class I through distinct routes; via an 
endosome-to-cytosol pathway or via a cytosol 
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 independent pathway 36-38. Di Pucchio et al. 
showed that a functional proteasome is not 
necessary for pDCs to present captured viral 
antigens in MHC class I molecules, indicating 
that pDCs have the capacity to process and 
load captured antigens directly onto MHC 
class I molecules in endosomal compart-
ments35. This is in contrast with findings 
showing that exogenous antigens need to be 
transported from endosomal vesicles into the 
cytosol, become processed by the 
proteasome and subsequently loaded on MHC 
class I molecules, similar to endogenous 
antigens39,40. Other studies showed that pDCs 
can cross-present antigens directly after 
stimulation with viral pathogens with 
comparable efficacy as mDC subsets. It has 
been reported that pDCs have larger amounts 
of MHC class I molecules stored in endosomes 
when compared to other DC subsets, and can 
therefore rapidly transport these MHC class I 
molecules to the plasma membrane35. Taken 
together, studies performed with human 
pDCs suggest that an effective cross-
presentation machinery is present. Human 
pDCs can be regarded as professional APCs 
and should therefore be considered for 
immunotherapy.  
 
Antigen Uptake by pDC  
 
Two main strategies are exploited in DC-based 
cancer immunotherapy; 1) isolation and ex 
vivo stimulation of autologous DCs and 2) via 
direct targeting of DCs in vivo. Until now, 
clinical trials have primarily focused on the 
generation, stimulation and manipulation of 
DCs ex vivo. To compose a potent vaccine, the 
antigenic cargo needs to be efficiently and 
specifically delivered, avoiding inappropriate 
release of vaccine content. Furthermore, to 
explore the most potent mechanism to 
stimulate immature pDCs with antigens in 
vivo, it is important to dissect the antigen 
uptake and stimulation mechanisms of pDCs. 
Immature DCs are able to take up various 
types of exogenous antigens through 
macropinocytosis, phagocytosis or receptor-
mediated endocytosis41. Macropinocytosis 
refers to a process that mediates nonspecific 
capture of soluble antigens, without the 
involvement of receptors. While, phagocytosis 
comprises receptor mediated engulfment of 
larger antigenic particles or pathogens, 
receptor-mediated endocytosis is considered 
the most specific and efficient mechanism to 
capture antigens41. 
Phagocytosis & pinocytosis 
Like reported for immature mDCs, immature 
pDCs can phagocytose viral pathogens such as 
cytomegalovirus, HIV-I and influenza A 
resulting in priming naïve CD8+ T-cells42,43. In 
contrast to their ability to engulf viruses, 
there has been some controversy whether or 
not pDCs are involved in the uptake of 
bacteria. Some studies demonstrate that pDCs 
were able to take up and get activated by  
bacteria like S. pyogenes and S. aureus43,44, 
while Piccioli et al. showed that pDCs were 
not able to phagocytose nor get activated by 
S. aureus45. Other studies demonstrated that 
pDCs hardly take up apoptotic cells compared 
with mDCs46,47, while Hoeffel et al. showed 
that pDCs are capable of taking up apoptotic 
cell fragments39. These opposing results 
suggest that pDCs are endowed with specific 
PRRs that are involved in the specific 
recognition of particular bacteria43. Other 
studies have focused on the mechanisms for 
taking up soluble antigens including KLH and 
OVA. Immature pDCs are likely capable of 
taking up soluble antigens, but less efficient 
than mDCs18,21,48. This difference in 
effectiveness could be caused by the lower 
macropinocytosis activity of pDCs compared 
with mDCs49. Although pDCs are considered to 
be ineffective in engulfing particulate antigens 
like bacteria and apoptotic cells, we 
previously demonstrated that human pDCs 
induced immune responses after internalizing 
particulate matter50. Stimulating pDCs with 
polylactic-co-glycolic acid (PLGA) micro-
particles packed with antigens and TLR 
agonists  resulted in the activation of antigen 
specific CD4+ T cells50. Thus, although pDCs 
are less efficient than mDCs, they can 
phagocytose and process particles, which 
simultaneously release TLR agonists and 
antigens. Interestingly, although human pDCs 
were found to be less efficient 
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  when compared to mDCs in taking up 
particulate compounds, both cell types were 
fully matured. These findings suggest that 
pDCs might even be more competent in 
handling engulfed materials than mDCs. 
 
Receptor mediated endocytosis  
Next to the ability to take up encountered 
pathogens and antigens by phagocytosis, 
pDCs are also known to express a broad 
repertoire of antigen uptake receptors on 
their cell surface (Table 1 and Figure 1). This 
large repertoire facilitates the uptake of 
encountered pathogens and antigens via 
receptor-mediated endocytosis, resulting in 
more efficient antigen uptake than via 
phagocytosis. 
Fc receptors 
One of the best defined receptor families 
relevant for the uptake of microbial 
pathogens is the Fc receptor family. They 
mediate endocytosis and presentation of 
antigens by capturing immune complexes. Fc 
receptors do not mediate uptake of soluble 
antigens, but antigens forming immune 
complexes with antibodies51,52. The human 
Fc R family consists of the activating 
receptors Fc RI (CD64), Fc RIIa/c (CD32a/c) 
and Fc RIIIa/b(CD16), and the inhibitory 
receptor Fc RIIb  (CD32b)53. PDCs express 
Fc RIIa54,55, FcαR (unpublished observation) 
and FcєRI56, but not Fc RI and  Fc RIIIa/b 
(Table 1). Fc RIIa mediated internalization 
stimulates the redistribution of MHC class II 
molecules from lysosomal vesicles to the 
plasma membrane, facilitating presentation of 
antigen-IgG complexes captured by Fc RIIa in 
both MHC class I and MHC class II 
molecules54,57. The Fc RIIa surface expression 
levels are similar for immature and mature 
pDCs. However, triggering of TLRs results in 
decreased endocytosis via Fc RIIa, indicating 
impaired internalization after pDC maturation. 
This might prevent the uptake of antigens, 
that are not associated with TLR activation, to 
be captured after maturation55. Whether FcαR 
and FcєRI expressed by human pDCs are 
Fig. 1 Plasmacytoid dendritic 
cells (pDCs) express a wide 
variety of pattern recognition 
receptors involved in pDC 
function. These receptors can 
be harnessed to facilitate the 
targeted delivery of antigen 
to pDCs, leading to antigen 
(cross-) presentation and 
activation of both CD4+ and 
CD8+ T cells. Furthermore, 
receptors that are involved in 
the recognition of pathogen-
associated molecular 
patterns induce the 
activation of human pDCs 
leading to phenotypical 
maturation as well as the 
secretion of cytokines and 
chemokines. Those soluble 
factors on their turn can 
attract and induce the 
activation of other immune 
cells, thereby enhancing the 
immune response. The 
combination of ‘‘vaccine 
targets’’ for antigen delivery 
and stimulation largely 
affects the ‘‘immunological 
output’’ generated by pDCs. 
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 involved in antigen uptake and presentation 
remains to be established. Triggering FcєRI or 
Fc RIIa does not affect the expression of 
surface receptors involved in providing co-
stimulatory signals during T cell activation54. 
However, these receptors differ in their ability 
to modulate the secretion of type I IFN by 
pDCs in response to TLR ligation. Although 
both receptors employ an ITAM for 
downstream signaling, FcєRI triggering 
strongly impairs TLR9-induced IFNα 
secretion56 while Fc RIIa triggering leaves 
TLR9-induced IFNα secretion unaffected55.  
C-type Lectin Receptors on pDCs 
Another endocytic receptor family expressed 
on the of immature pDCs are the C-type lectin 
receptors (CLRs) (Figure 1). CLRs recognize 
carbohydrate moieties leading to 
internalization, the “C” indicating Ca2+ 
dependence of carbohydrate binding58. BDCA-
2 is a type II CLR exclusively expressed by 
immature pDCs and used as a marker to 
distinguish immature pDCs from mDCs and 
other immune cells59. BDCA-2 is shown to 
capture antigens decorated with 
carbohydrates, leading to presentation of the 
captured antigen on MHC class II molecules. 
However, triggering BDCA-2 impairs TLR9 
mediated type I IFN secretion by pDCs, 
thereby attenuating the induction of innate 
immune responses60. Furthermore, BDCA-2 
expression is reduced by TLR7 and TLR9 
signaling, indicating that the endocytic 
function of BDCA-2 is primarily important in 
immature pDCs61. In addition to BDCA-2, pDCs 
also express the more broadly expressed CLRs 
DEC-205 and DCIR62,63. Triggering DEC-205 or 
DCIR both inhibit TLR9 mediated type I IFN 
secretion by pDCs, but to a lesser extent than 
triggering through BDCA-2. Moreover, neither 
DEC-205 nor DCIR affect the expression of co-
stimulatory molecules on the plasma 
membrane62,64. While the expression and/or 
scavenging function of most endocytic 
receptors on pDCs, such as DCIR, is down-
regulated upon TLR-induced activation, DEC-
205 expression is enhanced and still able to 
capture and internalize antigens62. Like 
antigen capture by other CLRs, uptake of 
antigens by DEC-205 and DCIR leads to 
antigen processing and presentation in MHC 
class II molecules, followed by the induction 
of CD4+ T cell responses62,63. Interestingly, 
under same conditions targeting of DEC-205 
on pDCs induced highly similar T cell 
responses compared to responses induced by 
CD1c+ mDCs and moDCs62. These findings 
reveal that pDCs, although generally 
considered inferior, are as efficient and 
professional as other mDCs, generally 
accepted as professional APC. Whether BDCA-
2, DEC-205 and/or DCIR are involved in 
antigen cross-presentation by human pDCs 
remains to be elucidated. Initial observations 
that mDCs can cross-present antigens 
captured by DEC-205 and DCIR suggest that 
both receptors might be able to perform a 
similar role in pDCs as well63,65-67. 
 
Conclusion 
Human pDCs seem well equipped for 
therapeutic strategies aimed at eliciting 
specific immune response and tumor 
eradication. Although there is still some 
controversy on the cross-presenting ability of 
pDCs, several studies demonstrate that they 
can cross-present antigens and effectively 
induce antigen specific CD8+ T cell responses 
leading to protective tumor immunity in both 
mice and man. Therefore, it might be 
interesting to directly target pDCs in vivo to 
simultaneously deliver TLR agonists and 
antigens. Based on existing literature, DCIR 
seems a potent target, since triggering of this 
receptor leads to antigen presentation by 
pDCs as well as other DC subsets without 
totally blocking the TLR-induced cytokine 
secretion. Furthermore, combined stimulation 
of pDCs and mDCs seems to induce a more 
potent and powerful immune response and 
therefore deserves more elaborate study. This 
knowledge will certainly help to map the way 
for DC-based targeting strategies that can be 
exploited in autoimmune and infectious 
diseases as well as in cancer. 
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Abstract  
Atopic diseases are characterized by the 
presence of Th2 cells. Recent studies, in mice 
and man, demonstrated that allergen-specific 
Th2 responses can be shifted to Th0/Th1 
responses. Plasmacytoid dendritic cells (pDCs) 
produce large amounts of type I interferons 
(IFNs) after stimulation of Toll Like Receptor 9 
(TLR9) and are likely to play an important role 
in the reorientation of these Th2 cells. The 
expression of CD32a on the cell surface of 
pDCs makes this cell type attractive for 
targeted delivery of antigen and TLR agonists 
to revert Th2 responses. Therefore we sought 
to determine the efficacy of targeted delivery 
of CpG-C ODN to CD32a on the ability of 
human and monkey pDCs to secrete 
inflammatory cytokines. Here we 
demonstrate that targeted delivery of 3’-
biotinylated CpG-C to CD32a on pDC induced 
phenotypical maturation as determined by 
CD80, CD83 and CD86 expression. 
Furthermore, targeting both monkey and 
human pDCs strongly augmented the 
secretion of IFNα  compared to the delivery of 
CpG-C in an untargeted fashion (p<0.001). 
TLR9 induced activation hampers the ability of 
human pDCs to internalize CD32a. Therefore 
we opted for targeted delivery of CpG-ODNs 
to CD32a, which reduces the risk of undesired 
side effects of systemic TLR treatment and in 
addition delivers a superior signal for the 
activation of pDCs. This approach opens new 
treatment principles for allergic patients. 
Key words: allergy, CD32a, CpG ODN, 
plasmacytoid dendritic cell, targeting 
 
Introduction 
Dendritic cells (DCs) constitute a family of 
antigen presenting cells defined by their 
morphology, phenotype and their unique 
capacity to attract and interact with naïve T 
cells1. Tissue DCs are generally found as 
immature cells, which undergo a complex 
maturation process, and migrate to lymph 
nodes where they present antigens to T cells, 
following infection or inflammation. Recent 
progress in understanding DC activity to 
produce cytokines has revealed that myeloid 
DCs (mDCs) and plasmacytoid DCs (pDCs) 
show different susceptibilities to products 
derived from pathogens, depending on their 
toll-like-receptor (TLR) expression profiles2-5. 
PDCs are one of two major subsets of human 
DCs that circulate in the peripheral blood, and 
are characterized as CD4+CD45RA+IL-3R + 
(CD123) ILT3+ILT1- CD11c- lineage- cells6. PDCs 
can be further characterized by BDCA-2 and 
BDCA-4 that in humans are exclusively 
expressed by pDCs in peripheral blood and 
bone marrow7. Upon viral stimulation and 
subsequent TLR-mediated signaling, human 
pDCs produce large amounts of type I IFNs 
(IFN-α/β) that stimulate T cell function of the 
Th1 type and stimulate NK cell cytolytic 
activity8. Type I IFNs also promote 
differentiation, maturation, and immune-
stimulatory functions of myeloid DCs9. 
Moreover, type I IFNs are important for 
antiviral immunity, but several studies show 
that they also play a role in bacterial 
infections, allergy and anti-cancer immunity10-
12. Because of their high IFN production pDCs 
are considered to have an important role in 
controlling both innate and adaptive immune 
responses. In a resting state pDCs might 
induce unbiased Th, Th2 or regulatory 
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 responses whereas their activated equivalents 
have stimulatory capacities and trigger Th1 
responses13-15.  
Atopic diseases are characterized by the 
presence of Th2 cells that secrete interleukin 
(IL)-4, IL-5 and/or IL-13 but no or only limited 
amounts of the Th1 cytokine IFN 16-18. 
However, recent studies demonstrated that 
allergen-specific Th2 responses can be shifted, 
in vitro in man and in vivo in mice, towards 
Th0 or even Th1 responses19-23. PDCs, as 
potential producers of large quantities of type 
I IFNs, thereby instigating Th1 responses, 
represent therefore an attractive target for 
antigen specific treatment of allergic diseases. 
The potency of activated human pDCs to 
revert allergy induced Th2 responses into Th1 
responses has already been exploited in 
experimental animal models24. Previously 
performed studies have provided pivotal 
information on how TLR agonists can be used 
for redirecting Th2 responses. However, these 
TLR agonists have been delivered to pDCs in a 
non-targeted fashion. In addition, several 
recent studies highlight the importance of co-
delivery of antigen and TLR agonists for the 
induction of superior immune responses over 
the separate delivery of the components25. It 
is known since the early nineties that antigen 
uptake by DCs can be boosted tremendously 
by targeting the antigens to FcRs26. It is 
tempting to speculate that also receptor-
mediated uptake of TLR agonists and antigens 
is superior to non-targeted uptake in 
stimulating pDCs27. However, not all receptors 
may have the desired effect. Like in antigen 
uptake through IgE may lead to deterioration 
of the disease28-30, whereas IgG specific for an 
allergen may be able to counteract this 
effect31.  
There is now ample evidence that pDCs 
express several receptors that may mediate 
antigen uptake, e.g. DEC-205, BDCA-2 and 
DCIR, which can be targeted to facilitate 
antigen delivery, but at the same time hamper 
the ability of pDCs to secrete type I IFNs32-34. 
Also other surface receptors expressed by 
human pDCs are described that negatively 
influence TLR-induced IFNα  secretion upon 
receptor cross-linking by various 
mechanisms35,36. We recently reported that 
pDCs can internalize soluble exogenous 
antigen bound to antigen-specific antibodies 
via CD32a, resulting in CD4+ T cell activation 
without hampering the TLR-induced IFNα  
secretion37,38. Here we describe the potency 
of targeting CpG ODNs to the Fc receptor 
CD32a on human and monkey pDCs. 
 
Material & methods 
 
Monoclonal antibodies. 
The following mAb were used; CD20V450 
(clone L27), CD3FITC (clone SP34), CD16FITC 
(clone 3G8), CD80PE (clone L307.4), CD86PE 
(clone IT2.2), anti-IL-12p40/70PE (clone 
C11.5), anti-TNFαPE (clone Mab11), 
CD123PerCP-Cy5, CD11cAPC (clone S-HCL3), 
CD4PE-Cy7 (clone SK3), anti-TNFαPE-Cy7 
(clone Mab11), HLA-DRAPC-CY7 (clone L243) 
all from Becton & Dickinson, CD8FITC (clone 
DK25, DAKO), CD14PE-TxRed (clone RM052, 
Beckman Coulter), CD83PE (clone HB15a, 
Beckman Coulter), CD32biot (clone AT-10, 
AbD Serotec), CD32FITC (clone IV.3, Stemcell 
technologies), mIgG1-PE, mIgG1-APC, anti-
CD83-PE, anti-CD80-PE and anti-CD86-APC (all 
BD Bioscience Pharmingen, San Diego, CA, 
USA), CD16 and CD64 (both DAKO). For IFNα  
detection the mAb MMHA2 was used (In 
Vitrogen). Mean fluorescence intensity and 
percentage of positive human cells are based 
upon inclusion of cells in a live cell gate and 
determined on a FACSCalibur (BD Biosciences, 
San Jose, CA, USA). 
 
Monkey whole blood stimulation assay 
Heparinized blood was obtained from captive-
bred, mature (4- to 5 year old) out-bred 
Indian origin rhesus macaques 
(Macacamulatta). This study was critically 
reviewed and approved and undertaken by 
the institute’s animal ethical committee and 
performed in accordance with Dutch law and 
international guidelines for the use of animals 
in research (BPRC IACUC ID 610). Collected 
heparin blood was used within 3 hours of 
collection. The assay was performed in 5 ml 
polypropylene tubes (Becton & Dickinson), to 
which 200 μl of whole blood was added. 
Subsequently, a part of the tubes were 
incubated for 20 min at 4°C with 5 or 10 μl of 
3 
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 biotinylated anti CD32 mAb (clone AT-10, 100 
μg/ml) and thereafter washed twice with 1 ml 
ice-cold PBS. The tubes were then incubated 
with 100 l PE-Cy7 labeled streptavidin (1:500 
in PBS, Becton & Dickinson) for 20 min. at 4°C. 
After two washes with PBS, a part of the tubes 
were incubated with either CpG (M362) or 
biotinylated CpG (M362) (both from Girundus, 
USA) for 20 min. at 4°C. Subsequently, a part 
of the tubes were washed twice with PBS. The 
stimulation assay was performed by adding to 
all tubes 800 l RPMI1640medium (GIBCO), 
15 U/ml heparin, 0.1% FCS (GIBCO), β 
mercapto-ethanol (50 μM, GIBCO), penicillin 
(50 U/ml) and streptomycin (50 mg/ml), 10 
ng/ml recombinant human IL-3 (Peprotech). 
The tubes were incubated either without 
further stimulus or in the presence of CpG 
(M362) at 37°C for different time intervals as 
described in the results section. Golgiplug 
(1:1000, Becton & Dickinson) was added 
either directly or after 1 or 2 hours of 
incubation, to prevent protein trafficking.  
 
Monkey FACS analysis 
After incubation the tubes were centrifuged 
for 10 minutes at 500g and supernatant was 
harvested from the tubes in which no 
Golgiplug had been added. Subsequently, the 
cells were washed with cold PBS. After 
discarding the supernatant the cells were 
incubated for 20 min. at 4°C with a mixture of 
mAb for surface staining, consisting of: 
CD20V450, CD3FITC, CD8FITC, CD16FITC, 
CD14PE-TxRed, CD123PerCP-Cy5, CD11cAPC, 
HLA-DRAPC-CY7, supplemented with CD83PE 
or in some experiments with CD80PE or 
CD86PE. Subsequently, cells were washed 
once with 1 ml cold PBS and then 2 ml lysing 
solution (Becton Dickinson) was added to all 
tubes followed by incubation at room 
temperature for 10 minutes, then 
centrifugation for 10 minutes at 500g. The 
supernatant was aspirated and the cells were 
either re-suspended in 1 ml PBS with 2% para-
formaldehyde or incubated with an anti-IFNα  
PE labeled complex or 5 l anti-IL-12PE or 4 l 
anti-TNFαPE diluted in Becton & Dickinson 
perm/wash solution for 30 minutes at 4°C in 
the dark. After washing with 1ml of 
perm/wash solution, 1 ml PBS with 2% 
paraformaldehyde was added and all samples 
were stored overnight at 4°C. For detection of 
IFNα  in rhesus macaques only an unlabelled 
mAb (MMHA2) was available. The mAb was 
labeled with PE in house using the Zenon 
labeling technology (Zenon mouse IgG1 kit, 
Molecular Probes). With this method the 
unlabelled mAb is first incubated with PE 
labeled Fab fragments of an antibody directed 
against mouse IgG1 Fc (reagent A) and then 
incubated with non-specific IgG, which 
complexes unbound Fab fragments (reagent 
B). The anti-IFNα  complex was prepared by 
diluting 1 mg of mAb MMHA2 (stock 0.5 
mg/ml) in 20 l PBS and adding 5 l of 
compound A. After 5 min. incubation at room 
temperature, 5 l of compound B was added 
and the mixture was incubated for another 5 
min. Then the volume was adjusted to 50 l 
with PBS and diluted in 1 ml of perm/wash 
solution. For staining of IFNα  100 ml of this 
mixture was added per tube. Flow cytometry 
was performed on a LSRII or FACSaria 
machine using Diva software (Becton 
Dickinson).  
 
Monkey ELISA 
For determination of IFNα  a Verikine 
Cynomolgus/rhesus IFNα  serum ELISA kit 
(Pestka Biomedical Laboratories, inc., 
Piscataway, NJ, USA). Assays were performed 
according to the manufacturer’s instructions. 
Purification of human pDCs 
Buffy coats were obtained from healthy 
volunteers after informed consent and 
according to institutional guidelines and pDCs 
were purified by positive isolation using anti–
BDCA-4–conjugated magnetic microbeads 
(Miltenyi Biotec) and cultured in X-VIVO-15 
medium (Cambrex) supplemented with 2% 
human serum (Sanquin, Nijmegen The 
Netherlands). PDC purity was routinely up to 
95%, as assessed by double staining BDCA-
2/CD123 (Miltenyi Biotec) (Figure 1A) 
performed on a FACSCalibur using CellQuest 
Pro software (Becton Disckinson). 
 
Stimulation of human PBMCs and purified 
pDCs: 
Freshly isolated human pDCs were cultured as 
indicated with 10 ng/ml rhIL-3 (Cellgenix, 
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 Freiburg, Germany) or activated in the 
presence of ODN-CpG-C (M362, Axxora), 
ODN-CpG-C-3’-biotin or ODN-CpG-C-5’-biotin 
(both M362, Biosearch Technologies). 
PBMCs and freshly isolated pDCs were 
incubated with biotinylated anti-CD32 (10 
μg/ml, clone AT-10, AbD Serotec,) in PBA (PBS 
containing 5% BSA) on ice for 30 minutes and 
washed twice with PBA, followed by an 
incubation with 10 μg/ml streptavidin-
Alexa647 in PBA on ice for 30 minutes and 
two times washing with PBA. Subsequently, 
pDCs were incubated on ice for 15 minutes 
with either PBA, 5 μg/ml CpG-C or 5 μg/ml 
CpG-C-3’-biotin. Unbound CpG was washed 
away three times with PBA and pDCs were 
cultured overnight in X-VIVO-15 medium, 
supplemented with 2% human serum. After 
overnight stimulation phenotypical 
maturation was analyzed by flow cytometry 
and supernatants were collected from PBMC 
and pDC cultures, and IFNα  production was 
analyzed with murine monoclonal capture and 
HRP-conjugated anti-IFNα  antibodies and IL-
6, IL-8 and TNF  was analyzed with a human 
Multiplex kit (all BenderMed System) 
according to the manufacturer’s instructions.  
 
Statistics 
All results are shown as the mean ± SEM. 
Statistical differences as determined by 
(paired) student t-test or by One-way ANOVA 
followed by Tukey’s multiple comparison test 
as indicated. 
 
Results 
 
Fc receptor expression and regulation on 
human pDCs 
To investigate the expression of antigen 
uptake receptors, pDCs were isolated from 
blood of healthy donors using anti-BDCA-4 
coated beads and magnetic separation (Figure 
1A).In accordance with the literature 32, 
freshly isolated human pDCs expressed the 
pDC-specific CLR BDCA-2 and low levels of 
CD32, and expressed only minimal levels of 
CD16 and CD64 (Figure 1B). Given that 
endocytic receptors are differentially 
regulated during pDC activation, we 
investigated CD32a expression after 
activation. In accordance with previous 
findings we could demonstrate that BDCA-2 
expression is decreased after CpG-C induced 
activation (Figure 1C) while CD32a expression 
remains unaffected.  
 
Functionality of CpG-C after 3’-biotinylation 
remains unaffected 
Next we determined whether biotinylation of 
CpG-C was feasible without hampering its 
stimulatory function. For the generation of 
targeting constructs we used 3’ and 5’ 
biotinylated CpG-C ODNs. As a positive control 
we used unbiotinylated CpG-C. Both the 3’- 
and 5’-biotinylated CpG-C were capable to 
Figure 1 Fc receptor expression on human pDCs (A) 
Forward scatter (FSC)-Sideward scatter (SSC) plot of 
cell population following MACS isolation and staining 
of pDCs with CD123-FITC and BDCA-2-PE. MACS 
isolation yields a population of >95% pure pDCs. (B) 
Freshly isolated pDCs express CD32a and BDCA-2 but 
minimally CD16 and CD64 (grey filled histograms) 
compared to isotype controls (black lined histograms). 
(C) IL-3 cultured or CpG C activated pDCs 
downregulate BDCA-2 receptor expression whilst 
CD32a expression remains unaffected (grey filled 
histograms) compared to isotype controls (black lined 
histograms). Data shown are from 1 representative 
experiment out of at three performed. 
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 induce a full phenotypical maturation based 
on the surface expression of CD80, CD83 and 
CD86 (Figure 2A). Unexpectedly, biotinylation 
of CpG-C on the 5’ end hampered the ability 
of this ODN to induce IFNα  secretion by pDCs 
(Figure 2B), whilst 3’ biotinylation of CpG-C 
left the integrity unaltered resulting in high 
secretion of IFNα  after stimulation (Figure 
2B). In a dose finding experiment we could 
demonstrate that 5 μg/ml 3’-biotin-CpG-C was 
most effective for the generation of fully 
mature pDCs (Figure 2A,B). 
 
TLR9 induced activation hampers CD32a 
receptor internalization on human pDCs 
The dogma that mature DCs are incapable to 
endocytose and present encountered 
antigens was recently challenged by several 
groups34,39,40. Therefore, we studied the 
capacity of freshly isolated and CpG activated 
and matured pDCs to internalize their CD32a 
receptor. Upon triggering surface receptor 
molecules, freshly isolated pDCs internalized 
BDCA-2 (data not shown) and CD32a as 
determined by analyzing surface expression 
levels (Figure 3A,B,C). Although pDCs still 
expressed CD32a after CpG C induced 
activation they were incapable to internalize 
CD32a upon receptor triggering (Figure 
3A,B,C).  
 
Targeted delivery of CpG-C to CD32a on 
human pDCs enhances secretion of 
inflammatory cytokines 
In agreement with previous studies using 
human pDCs, it was observed that without 
stimulation there was a loss of pDCs after 
overnight culture (data not shown). 
Subsequent experiments showed that the 
addition of IL-3 could preserve these cells, 
with minimal induction of activation markers 
(Figure 4A, first bar in graph). The maturation 
status of pDCs was studied by determining 
CD83 expression levels. Furthermore, 
expression of CD80 and CD86 was analyzed to 
determine the potential capacity to provide 
co-stimulation along with antigen 
presentation. To study the efficacy of CpG-C 
delivery we incubated pDCs with biotinylated 
αCD32 monoclonal antibody and streptavidin 
followed by a short incubation with either 
biotinylated (targeted) or unbiotinylated (non-
targeted) CpG-C at 4oC. This strategy ensured 
that solely bound CpG-C internalized upon 
subsequent incubation at 37oC. Interestingly, 
we could demonstrate that both targeted and 
Figure 2 Functionality of CpG-C remains 
unaffected after 3’-biotinylation Freshly 
isolated pDCs were cultured or activated 
overnight with either IL-3, CpG-C, 3’-biotin-
CpG-C or 5’-biotin-CpG-C. (A) CpG-C induced 
activation resulted in upregulation of surface 
receptor expression of CD80, CD83 and CD86 
compared to IL-3 cultured pDCs. The graphs 
show the receptor expression (MFI) relative 
to IL-3 cultured pDCs. (B) Supernatants of 
pDC cultures following incubation were 
analyzed for the presence IFNα . The graphs 
show the mean ± SEM of three independent 
experiments performed with different 
donors. 
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 non-targeted delivery of CpG-C was able to 
induce a mature phenotype as demonstrated 
by upregulated expression of CD80, CD83 and 
CD86 compared to IL-3 treated pDCs (Figure 
4A). These data reveal that CpG-C despite 
rigorous washing, binds or sticks to the 
plasma membrane of human pDCs in 
sufficient amounts to induce activation (data 
not shown). Moreover, short incubation with 
targeted and non-targeted delivery of CpG C 
was able to induce the same phenotypical 
maturation as pDCs activated overnight at 
37oC with 3’-biotin-CpG-C (Figure 4A). The 
receptor for the binding of CpG-C to the cell 
surface is not identified although candidates 
have been suggested in the literature41,42.  
Thereafter, we determined the effect of 
targeting CpG-C to CD32a on the ability to 
secrete inflammatory cytokines. As expected, 
untargeted pDCs cultured in IL-3 did not 
secret any IFNα  (Figure 4B,C) nor IL-6, IL-8 
and TNFα (Figure 4C). However, when CpG-C 
was targeted to CD32a we observed a 4 fold 
increase in the IFNα  secretion as compared to 
pDCs that were stimulated with CpG-C in an 
untargeted fashion (Figure 4B,C). 
Unexpectedly, we also demonstrated that 
targeted delivery of CpG-C was superior in 
inducing IFNα  secretion as compared to pDCs 
that were activated with the optimal 
concentration of 3’-biotin-CpG-C overnight 
(Figure 4B). Furthermore, targeted delivery of 
CpG-C also resulted in significantly enhanced 
secretion of IL-6, IL-8 and TNFα by human 
pDCs (Figure 4C). Since human pDCs do not 
uniquely express CD32a and TLR9, we 
investigated whether targeting pDCs in whole 
PBMC cultures also enhanced inflammatory 
cytokine secretion. In accordance with the 
findings in purified pDCs, targeted delivery of 
CpG-C to CD32a in PBMCs also significantly 
enhanced the secretion of IFNα  (Figure 4D) 
and slightly enhanced IL-8 and TNFα secretion 
(Figure 4D). In contrast to purified pDCs, IL-6 
production could not be enhanced by 
targeted delivery of CpG-C (Figure 4D).  
 
Targeted delivery of CpG-C to CD32a on 
monkey pDCs enhances secretion of 
inflammatory cytokines 
The goal of the monkey study was to develop 
conditions to test our targeting modality in a 
non human primate animal model and to 
compare the result to those obtained from 
similar experiments with human cells. 
Figure 3 Freshly isolated but not TLR-activated human 
pDCs internalize CD32a upon triggering with specific 
antibodies (A) CD32a surface expression levels at 4 
degrees (grey filled histograms) and after internalization 
at 37 degrees (black lined histograms) compared to 
isotype control (dotted lined histograms) on freshly 
isolated and CpG-C activated pDCs. Results shown are 
representative data of one experiment out of 3 
performed. (B) CD32a receptor expression (black bars) 
depicted as surface expression levels (%) following 
internalization at 37 degrees for 30 min relative to 
surface expression following incubation at 4 degrees 
(white bars). (C) CD32a receptor expression (black bars) 
depicted as surface expression levels (MFI) following 
internalization at 37 degrees for 30 min relative to 
surface expression following incubation at 4 degrees 
(white bars). The graphs show the mean ± SEM of three 
independent experiments performed with different 
donors. Significant differences as determined by paired 
student t-test (* p<0,05). 
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 Because of the low number of pDCs in 
peripheral blood of rhesus macaques, 2.71 ± 
1.57 pDCs/μl blood, and the small volume of 
blood that can be ethically drawn from these 
animals, experiments on purified pDCs were 
not possible. Instead, a whole blood assay was 
developed to determine cytoplasmatic 
cytokine production in monkey pDCs (Figure 
5A) and the results obtained were confirmed 
using whole blood cytokine production 
measured by ELISA. After incubation, cells 
were first stained for several surface markers 
that allowed discrimination of different 
antigen presenting cell subsets including B-
cells, monocytes, pDCs and mDCs. As shown 
in figure 5A, a Mhc-DR positive, Lineage (CD3, 
CD8, CD16) negative subset could be 
discriminated, which contained CD20+ B-cells, 
CD14+ monocytes and a subset of CD20, CD14 
double negative cells. The latter contained a 
CD123+/CD11c- pDC subset and a CD123- 
/CD11c+ mDC subset. After surface staining, 
the cells were permeabilized and 
subsequently stained for the presence of 
intracellular IFNα  and TNFα. As expected, 
targeted delivery of CpG-C did not induce 
IFNα  or TNFα production by mDCs, B-cells or 
monocytes (data not shown). This confirms 
the close similarity between the immune 
system of monkeys and humans. However, 
targeted delivery of CpG-C significantly 
enhanced IFNα production, whereas the 
production of TNFα showed only a trend as 
determined by intracellular FACS (Figure 5B). 
Like with human cells, targeted delivery of 
CpG-C to PBMC also induced a significant 
Figure 5 Targeted delivery of CpG-C to CD32a on monkey pDCs enhances secretion of inflammatory cytokines A whole 
blood assay was setup to test the ability of our targeting modality to specifically target pDCs in a non-human primate model 
(A) Gating strategy for detection of intracellular cytokine production in monkey pDCs. (B) Graphs show the  effect of the 
different targeting strategies on the relative production of IFNα  and TNFα after overnight culture. (C) After overnight 
incubation of the differently targeted monkey pDC supernatant was harvested and tested for the presence of IFNα . The 
graphs show the mean ± SEM of at least five independent experiments performed with different animals. Significant 
differences as determined by paired student t-test (** p<0.01; *** p<0.001). 
 
Figure 4 Targeted delivery of CpG-C to CD32a on human pDCs enhances secretion of inflammatory 
cytokines Freshly isolated pDCs (A,B,C) or total PBMCs (D) were incubated with 1) biotinylated αCD32 
followed by streptavidin-Alexa647 and subsequently with 3’-biotin-CpG-C, 2) biotinylated αCD32 
followed by streptavidin-Alexa647 and subsequently with CpG-C at 4 degrees. After short incubation 
unbound CpG-C was washed away and cells were cultured overnight at 37 degrees.  3) PDC were 
incubated with biotinylated αCD32 and subsequently activated overnight with 3’biotin-CpG-C without 
washing. (A) Phenotypical maturation of differently activated pDCs determined by the expression of 
CD80, CD83 and CD86. The graphs show the receptor expression (MFI) relative to IL-3 cultured pDCs 
incubated with αCD32. (B) Graphs show the secretion of IFNα  after overnight culture. (A,B) ; 0.5 
or 5 µg/ml of ither CpG-C or 3’-biotin-CpG-C as indicated. The graphs show the cytokine secretion 
relative to IL-3 cultured pDCs incubated with biotinylated αCD32 (C) and PBMCs (D) under different 
targeting conditions. The graphs show the mean ± SEM of at least three independent experiments 
performed with different donors. Significant differences as determined by One-way ANOVA followed 
by Tukey’s multiple comp rison test (* p<0.05; *** p<0.0 1). 
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 increase in IFNα  as measured by ELISA 
(p<0.001) (Figure 5C).  
 
Discussion  
Atopic diseases are characterized by the 
presence of activated Th2 cells16-18. However, 
recent studies demonstrated that allergen-
specific Th2 responses can be skewed, in vitro 
in man and in vivo in mice, to Th0 or even Th1 
responses19-22. PDCs, as potential producers of 
large quantities of type I IFNs thereby 
instigating Th1 responses, represent therefore 
a potential target for specific treatment of 
allergic diseases. The potency of activated 
pDCs to revert allergy induced Th2 responses 
into Th1 responses has already been exploited 
in experimental animal models 24. Until now, 
studies were performed wherein CpG and 
allergen were applied separately and at 
random to the immune system. Some 
investigators have explored, in mice, the 
potential of linking the allergen directly to 
danger signals that activate DC via TLR. In a 
clinical trial this same concept was exploited 
to reduce the symptoms of ragweed allergic 
individuals. Unfortunately, a multicentre 
placebo-controlled trial (DARTT) involving 
over 700 patients with ragweed allergy was 
discontinued because only minimal ragweed-
specific disease was observed in the overall 
study population and no significant efficacy 
could be assessed. On the other hand the 
ragweed allergen has been conjugated to 5` 
end of the CpG, which leads to a decreased 
stimulation potential of the CpG (43 and our 
figure 2). However, to date neither in 
preclinical animal models nor in the 
multicentre trial, pDCs were specifically 
harnessed for massive amounts of type I IFN 
secretion. In the current study we 
demonstrate that targeted delivery of CpG-C 
to CD32a on both human and monkey pDCs 
augments the secretion of IFNα . Anticipating 
future targeting modalities that facilitate the 
Figure 5 Targeted delivery of CpG-C to CD32a on monkey pDCs enhances secretion of inflammatory cytokines A whole blood 
assay was setup to test the ability of our targeting modality to specifically target pDCs in a non-human primate model (A) Gating 
strategy for detection of intracellular cytokine production in monkey pDCs. (B) Graphs show the effect of the different targeting 
strategies on the relative production of IFNα and TNFα after overnight culture. (C) After overnight incubation of the differently 
targeted monkey pDC supernatant was harvested and tested for the presence of IFNα . The graphs show the mean ± SEM of at least 
five independent experiments performed with different animals. Significant differences as determined by paired student t-test (** 
p<0.01; *** p<0.001). 
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 targeted delivery of CpG-C and antigen 
simultaneously through CD32, we showed 
that rhesus macaques have a strong 
immunological homology with humans and 
can therefore be used as a preclinical animal 
model for this strategy. 
Unmethylated CpG ODNs that target TLR9 
were demonstrated to prevent and reverse 
airway allergy in experimental animal 
models24. Although in mice TLR9 is expressed 
by many cell types, including B cells and 
several subsets of DCs and 
monocytes/macrophages, under normal 
conditions TLR9 expression in man is 
restricted to B cells, granulocytes and pDCs44. 
PDCs constitutively express the interferon 
regulatory factor-7 (IRF-7), but this is not the 
mere reason that only pDCs, and not other 
TLR9 expressing cells, efficiently produce type 
I IFNs. Moreover, the levels of IRF-7 are often 
even higher in other cells than the expression 
of IRF-7 in pDCs45. Notwithstanding, the 
contribution of other immune cells in type I 
IFN secretion in response to TLR9 agonists is 
marginal. Honda et al. demonstrated that the 
capacity of pDCs to induce IRF-7 activation 
differed from other TLR9 expressing cells 46. In 
pDCs, the TLR9-associated MyD88–IRF-7 
complex was retained for a longer period of 
time in the endosomal compartment after 
treatment with CpG ODNs, whereas in other 
cell types, the complex rapidly translocated to 
lysosomes46. Taken together, pDCs are the 
main cell to produce large amounts of type I 
IFN after TLR9 ligation. 
Both Farkas et al. and Schroeder et al. 
demonstrated the dichotomy of pDCs in 
controlling immune responses by the 
expression of TLR9 and the IgE receptor19,47. 
Their studies unambiguously showed that 
TLR9-induced activation resulted in complete 
downregulation of the IgE receptor which 
correlated with a selective suppression of 
allergen-induced CD4+ T cell proliferation 19,47. 
These findings illustrate that properly 
activated pDCs have the potential to revert 
allergic Th2 responses.  
Although advantageous immune responses 
were observed after TLR agonist 
administration in mice and man, often 
systemic or high dose administration of TLR 
agonist also resulted in multiple undesired 
side effects and toxicity at the same time. 
These reports emphasize that both the 
specific induction of the immune response as 
well as the reduction of undesired side effects 
would greatly benefit from targeted delivery 
of TLR-ligands48. There are already reports 
demonstrating an improved and safe strategy 
by covalently linking CpG-ODN to the allergen 
Amb a 1 in order to revert the allergen-
specific Th2 response in a non-targeted 
fashion49,50. Various studies have 
demonstrated that endocytic receptors, apart 
from DEC-205, are downregulated after pDC 
activation34. Furthermore, triggering of these 
endocytic receptors on pDCs in a steady state 
impairs the ability of pDCs to secrete type I 
IFNs32-34. Here we describe that although 
CD32a receptor expression remains unaltered 
upon activation, receptor internalization is 
hampered. Therefore, we propose that 
targeted delivery of antigens and TLR agonists 
should be contemporaneous for the 
generation of a superior immune response.  
The finding that conjugation of moieties to 
the 5’-end of CpG motifs abrogates their 
immunostimulatory potential was previously 
demonstrated by 2 different groups43,51. 
Interestingly, we observed that although the 
IFNα  secretion was hampered, conjugation of 
biotin at the 5’-end left the ability of CpG-C to 
induce phenotypical maturation unaffected. 
However, since the induction of IFNα  is a key 
target for manipulation of immune responses, 
targeting modalities exploiting this feature 
should be designed by conjugation of moieties 
at the 3’-end of CpG ODNs. In the previously 
discontinued multicentre trial TOLAMBATM 
(Dynavax) was used, which consisted of an 
immunostimulatory CpG sequence linked at 
the 5’-end with the ragweed allergen Amb-1. 
The impaired IFNα  production might partially 
explain the low success rate of previous 
studies. 
 
Concluding remark 
Administration of TLR agonists benefits the 
reversion of allergen-specific Th2 responses in 
unbiased Th0/Th1 responses. Our results 
envision that specific targeting of pDCs, as 
main producers of type I IFN, is an attractive 
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 approach that can be exploited to revert the 
Th2 responses. Moreover, these findings pave 
the way to improve the efficacy of currently 
used strategies by using targeting modalities 
wherein antigen and TLR agonist are delivered 
simultaneously. 
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Abstract 
DEC-205 is a type I C-type lectin receptor 
(CLR) that is expressed on various APC subsets 
and has been suggested to bind necrotic and 
apoptotic cells. Here we study DEC-205 
characteristics in pDCs obtained from healthy 
individuals and assess its ability to mediate  
antigen presentation by isolating sufficient 
numbers of pDCs from apheresis material 
obtained from stage III/IV melanoma patients. 
The results demonstrate that DEC-205 is 
expressed on human plasmacytoid DCs 
(pDCs). Internalization of DEC-205 after 
antibody ligation is clathrin- and dynamin-
dependent as it is blocked by hypertonic 
shock or by inhibition of dynamin activity. 
Antibody targeting to DEC-205 does not affect 
TLR-induced expression levels of co-
stimulatory and MHC molecules, but clearly 
impairs TLR-induced IFN  secretion by 40%. 
We observed that TLR mediated signaling 
increases DEC-205 expression levels without 
affecting receptor internalization. Moreover, 
human pDCs, retained the capacity to present 
antigens via DEC-205 following TLR activation.  
 
Key words: human pDCs, DEC-205, TLR 
modulation, targeting, antigen presentation 
 
Introduction 
Plasmacytoid dendritic cells (pDCs) are one of 
two major subsets of human DCs that 
circulate in the peripheral blood, and are 
characterized as CD4+CD45RA+IL-3R +ILT3+ 
ILT1- CD11c- lineage- cells1. PDCs can be 
further characterized by BDCA-2 and BDCA-4 
that are exclusively expressed by human pDCs 
in peripheral blood and bone marrow2. Upon 
stimulation by viruses or bacteria, pDCs 
become activated and produce large amounts 
of type I interferon (IFN- / )3. 
Because of their high IFN production pDCs are 
considered to have an important role in 
controlling both innate and adaptive immune 
responses. In a resting stage pDCs might 
induce regulatory responses whereas their 
activated equivalents have stimulatory 
capacities4. In the tumor micro-environment 
of patients with ovarian carcinoma, pDCs with 
this resting phenotype have been 
demonstrated to maintain the tumor 
immunosuppressive environment5. Activated 
pDCs on the other hand induce the expansion 
of antigen-specific CD8+ T cells against the 
tumor-associated epitope MART-1/melan A26-
35
6 and Th1 CD4+ T cell populations specific for 
endogenous antigens7 and influenza virus8,9. 
During influenza virus infection, pDCs are able 
to prime virus-specific primary and secondary 
CD4+ and CD8+ T cell immune responses in 
vitro and in vivo10. Fonteneau et al described 
that only pDCs exposed to replicative virus 
and not to nonreplicating, boiled or ultraviolet 
irradiated virus can induce these responses8, 
suggesting that intracellular virus protein 
expression is crucial for antigen presentation. 
In contrast, Di Pucchio et al. have shown that 
pDCs can induce the expansion of virus 
specific CD8+  T cells after uptake of 
inactivated virus11.  
C-type lectin receptors (CLRs) recognize 
defined carbohydrate moieties in a Ca2+-
dependent manner. Ligand binding to CLRs 
can be of exogenous or endogenous nature12. 
In APCs, CLRs and TLRs together play an 
important role as pattern-recognition 
receptors that recognize pathogen-associated 
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 molecular patterns13. Human pDCs express 
several potential antigen uptake receptors 
including DCIR14,15, BDCA-22,16,17 and BDCA-
42,16, but many of the CLRs that are 
abundantly expressed in other subpopulations 
of DCs18, such as mannose receptor (CD206), 
Dectin-1 and DC-SIGN14 are not expressed. As 
most CLRs are rapidly internalized following 
ligand binding, CLRs are increasingly 
employed in vaccination strategies involving 
targeted delivery of antigens to various DC 
subsets19. The selection of the appropriate 
receptor for targeted delivery is crucial to 
improve antigen processing and (cross-) 
presentation for the induction of antigen 
specific T cells. The CLR DEC-205 belongs to 
the macrophage mannose receptor family of 
C-type lectin endocytic receptors and was first 
identified in mice20. DEC-205 has been 
extensively employed for targeted delivery of 
antigens to antigen presenting cells in murine 
studies, resulting in presentation of antigenic 
peptides in MHC classes I and II21-24. Recent 
findings have revealed that DEC-205 
recognizes dying murine thymocytes, 
displaying a role for DEC-205 as a potential 
sensor for apoptotic and necrotic cells25. The 
ligand recognized by DEC-205 on dead cells is 
not known and the role of DEC-205 in antigen 
cross-presentation associated with dead cells 
remains to be elucidated.  
Blood DCs, including pDCs, Langerhans cells 
and in vitro cultured immature monocyte-
derived DCs express low levels of DEC-205, 
but expression levels strongly increase upon 
DC activation, indicating that DEC-205 might 
be an activation-associated molecule12,26-29. In 
mice DEC-205 expression is restricted to DCs, 
whereas in humans DEC-205 is much more 
broadly expressed on multiple cell types29. 
The cytoplasmatic domain of the DEC-205 
receptor contains protein motifs for 
endocytosis and late endosome/MHC class II 
compartment-targeting. These motifs 
facilitate efficient antigen-loading to MHC 
class II molecules for antigen presentation to 
T cells24. The DEC-205 endocytic pathway does 
not lead to activation of myeloid DCs. It has 
been exploited in vitro in man and in vivo, in 
mice, to deliver specific antigens to DCs, and 
induces specific CD8+ and CD4+ T-cell 
responses22,23.  
It is still unclear whether mature DCs take up 
and present antigens. There are reports 
showing that Fc receptors on pDCs are 
incapable of internalization following pDC 
maturation, and DEC-205 was reported not to 
internalize on mature moDCs30,31. Recent 
findings in mice have demonstrated that 
mature DCs can still endocytose and present 
antigens32,33. In contrast, Young et al. have 
shown that cDC matured in vivo can take up 
OVA in vitro, but do not present it to T cells 
because MHC class II synthesis has stopped. 
However, pDCs continue to produce MHC 
class II after maturation and this allows them 
to present antigens encountered in an 
activated state34. 
Here, we describe that DEC-205 is expressed 
by human pDCs and becomes upregulated 
upon maturation. In contrast to activated 
monocyte-derived DCs31, activated pDCs 
internalize DEC-205 upon receptor ligation. 
We show that targeting DEC-205 on fresh as 
well as on activated human pDCs induces 
antigen presentation and proliferative recall 
responses. In addition, ligation of DEC-205 by 
antibodies impaired TLR-induced IFN  
production by human pDCs. 
 
Material and Methods 
Cells 
Buffy coats and patient material were 
obtained from volunteers after informed 
consent and according to institutional 
guidelines. CD1c+ mDCs and pDCs were 
purified by positive isolation using anti-CD1c- 
and anti–BDCA-4–conjugated magnetic 
microbeads (Miltenyi Biotec, Bergisch-
Gladbach, Germany) and adjusted to 106 
cells/ml in X-VIVO-15 (Lonza, Verviers, 
Belgium) supplemented with 2% of human 
serum. mDC and pDC purity was routinely up 
to 95%, as assessed by double staining BDCA-
2+/CD123+ for pDCs (Supp Figure 2A) and 
CD11c+/CD1c+ for mDCs (Miltenyi Biotec). 
PDCs were cultured overnight with 10 ng/ml 
rhIL-3 or activated overnight in the presence 
of 4 μg/ml R848 (Axxora, Breda, Netherlands) 
or 5 μg/ml ODN-CpG-C (M362, Axxora). 
Monocyte-dervied DCs were generated from 
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 adherent PBMCs, and subsequently by 
culturing in the presence of IL-4 (500 U/ml) 
and GM-CSF (800 U/ml) (both Cellgenix, 
Freiburg, Germany). Cells were cultured in X-
VIVO 15 medium supplemented with 2% of 
human serum and harvested on day 6 as 
immature DC. 
 
Phenotype 
The phenotype of pDCs was determined by 
flow cytometry. The following primary 
monoclonal antibodies (mAbs) and the 
appropriate isotype controls were used: anti-
HLA DR/DP (clone Q5/13; Becton Dickinson, 
Mountain View, CA, USA); anti-DEC-205 (clone 
MG38, eBioscience, Halle Zoersel, Belgium); 
anti-BDCA-2 (AC144, Miltenyi Biotec) and 
anti-CD32 (clone AT-10; ABD Serotec, 
Dusseldorf, Germany) followed by goat-anti-
mouse PE (BD, Breda, Netherlands); mIgG1-
PE, mIgG1-APC, anti-HLA-ABC-PE (W6/32), 
anti-HLA-DR/DP-FITC (Q5/13), anti-CD80-PE, 
anti-CD86-APC (all BD Bioscience Pharmingen, 
San Diego, CA, USA); anti-CD40 (Beckman 
Coulter, Mijdrecht, the Netherlands). Mean 
fluorescence intensity and percentage of 
positive cells are based upon inclusion of cells 
in a live cell gate (Supp Figure 2A, B, C, D) and 
determined on a FACSCalibur (BD Biosciences, 
San Jose, CA, USA). FACS gating strategies for 
the different experiments in this manuscript 
are shown in Supp Figure 2. 
 
DEC-205 internalization assays 
Purified or overnight activated pDCs were 
incubated with primary monoclonal anti-DEC-
205 (10 µg/ml, clone MG38, IgG2b 
ebioscience) and anti-BDCA-2 (10 µg/ml, 
clone AC144, IgG1, Miltenyi biotec) in PBS, for 
30 min on ice. Unbound antibodies were 
washed away and cells were incubated either 
for 30 min at 37oC to induce endocytosis or 
kept at 4oC. Subsequently, isotype-specific 
secondary antibodies were added (goat anti-
mouse Alexa 647, Invitrogen Life 
Technologies, Breda, Netherlands). To inhibit 
clathrin-mediated endocytosis, cells were 
incubated in hypertonic medium. Incubation 
in medium containing 450 mM sucrose 
(Boom, Meppel, Netherlands) results in 
disruption of clathrin-coated pits and induces 
formation of nonfunctional so-called clathrin 
microcages14. This process is fully reversible 
once cells are returned into isotonic media. 
Incubation in medium containing 80 μM 
Dynasore (Sigma Aldrich, Zwjindrecht, 
Netherlands), a reversible noncompetitive 
dynamin inhibitor, results in a loss in vesicle 
fissure. 
 
Confocal Microscopy 
For confocal imaging, pDCs were allowed to 
adhere to poly-L-lysine coated cover slips, 
fixed in 1% paraformaldehyde in PBS and 
permeabilized with 0.1 % triton-X100. PDCs 
were incubated for 30 minutes at 4 oC  with 
primary anti-DEC-205 and anti-BDCA-2 mAbs. 
Unbound antibodies were washed away and 
cells were incubated at 37 oC for 30 minutes. 
Then cells were stained with isotype-specific 
goat-anti-mouse Alexa-488 and Alexa-647 
secondary antibodies (Invitrogen). Cells were 
mounted with Mowiol (Brunschwig Chemie, 
Amsterdam, Netherlands) and  were imaged 
with a Bio-Rad MRC 1024 confocal system 
operating on a Nikon Optiphot microscope 
and a Nikon 60x planApo 1.4 oil immersion 
lens. Pictures were analyzed with Bio-Rad 
Lasersharp 2000 and Adobe Photoshop 7.0 
(Adobe Systems, Mountain View, CA) 
software. 
 
Cytokine detection 
PDCs were cultured overnight at a 
concentration of 1*105 pDCs/100 μl/ well in a 
96-wells roundbottom plate. Supernatants 
were collected from pDC cultures after 16 h of 
activation, and IFNα and IL-6 production was 
analyzed by murine monoclonal capture and 
HRP-conjugated anti-IFNα antibodies (Bender 
MedSystems, Vienna, Austria) or anti-IL-6 Abs 
(Sanquin, Amsterdam, The Netherlands) using 
standard ELISA procedures. TNFα production 
was measured using a human Multiplex kit 
(Bender MedSystems) according to 
manufacturer’s instructions. 
 
Specific KLH responses 
Cellular responses against the protein KLH 
were measured in a proliferation assay. 
PBMCs, pDCs, CD1c+ mDCs and immature 
monocyte-derived DCs were isolated from 
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 stage III and IV melanoma patients 
participating in ongoing vaccination trials with 
mature monocyte-derived DCs, which were 
pulsed with KLH to provide T cell help 35. 
These patients developed KLH specific T cell 
responses and therefore CD4+ T cells were 
isolated with a CD4+ T cell isolation kit 
(Miltenyi Biotec) according to the 
manufacturer’s instructions. Freshly isolated 
pDCs, CD1c+ mDCs, immature monocyte-
derived DCs and CpG C activated pDCs were 
incubated for 45 minutes at 4o C with 
biotinylated anti-DEC-205 (clone MG38, 
eBioscience), biotinylated anti-DCIR (Clone 
216110, R&D Systems) or with biotinylated 
mIgG (1 µg/ml). Finally, KLH coupled to an 
anti-biotin antibody (10 μg/ml) was added for 
30 minutes at 4o C. As a control purified T cells 
were stimulated with PHA (0.5 µg/ml). The 
purified T cells were plated in a 96-well tissue 
culture round-bottom microplate with 
autologous KLH loaded DCs in a ratio 20:1 
(1*105 T cells:5*103 pDCs). After 4 days of 
culture, 1 µCi/well of tritiated thymidine was 
added for 16 hr and incorporation was 
measured in a beta-counter. In experiments 
where both fresh and activated pDCs from the 
same donor were used, T cell proliferation 
data were normalized to account for intra-
experimental differences induced by the fact 
that experiments with fresh and activated 
cells were performed on consecutive days. 
Therefore, stimulation indices were calculated 
by dividing tritium counts of experimental 
samples by those of the control pDCs-mIgG-
KLH sample. 
 
Statistics 
All experiments were performed at least three 
times and results are shown as the mean ± 
SEM. Data sets were either tested by an One-
way ANOVA followed by Tukey’s multiple 
comparison test or by a Two-way ANOVA 
followed by Bonferroni. 
 
Table 1 Surface receptor expression on human pDCs 
Marker % positive cells 
MHC class II 
CD32 
BDCA-2 
DEC-205 
99.2 ± 0.5 
18.4 ± 4.8 
79.9 ± 8.2 
91.9 ± 5.5 
 
Results 
 
DEC-205 is expressed and internalized by 
purified human pDCs 
To investigate the expression of antigen 
uptake receptors, pDCs were isolated from 
blood of healthy donors using anti-BDCA-4 
coated beads and magnetic separation. In 
accordance with known literature, freshly 
isolated human pDCs expressed DEC-205 
(Table 1), CD32 and the pDC-specific CLR 
BDCA-2 (Table 1), but did not express other 
uptake receptors including DC-SIGN, Dectin-1 
or mannose receptor (data not shown). Since 
the natural ligands for DEC-205 are yet 
unknown, we mimicked ligand binding to DEC-
205 by mAb ligation. Upon triggering surface 
receptor molecules, pDCs internalized CD32, 
BDCA-2 and DEC-205 as determined by 
analyzing surface expression levels (Figure 1). 
Thus, human pDCs express a repertoire of 
antigen uptake receptors that are internalized 
upon receptor triggering, suggesting a role for 
pDCs in receptor-mediated antigen capture 
and presentation. 
 
Triggering DEC-205 affects TLR induced IFN  
secretion 
To establish whether DEC-205 triggering 
modulates human pDC activation and 
function, we studied the effect of DEC-205 
triggering on the viability, expression of 
maturation markers and secretion of 
cytokines by pDCs. DEC-205 triggering did not 
affect the viability of human pDCs (Supp. 
Figure 1A) nor CD40, CD80 and CD86 
expression (Figure 2A, B), nor the expression 
levels of MHC class I and class II molecules 
after overnight activation (Figure 2B). PDCs 
are known to secrete IFN  within the first 12 
hours subsequent to TLR induced activation. 
Therefore, we tested the ability of pDCs to 
secrete IFN , TNF  and IL-6 following DEC-
205 and BDCA-2 triggering and subsequent 
activation by the TLR ligands R848 or CpG C, 
that bind TLR7 and TLR9 respectively. In 
accordance with previous studies 2,36, 
triggering BDCA-2 impaired TLR induced IFN  
and TNF  secretion (IFN : mIgG2b-CpG C, 
15847 ± 5319 pg/ml; mIgG2b-R848, 3975 ± 
1372 pg/ml; BDCA-2-CpG C, 5409 ± 2103 
4 
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 pg/ml; BDCA-2-R848, 999 ± 402 pg/ml) (Figure 
2C) (TNF : mIgG2b-CpG C, 10976 ± 3552 
pg/ml; mIgG2b-R848, 9424 ± 5619 pg/ml; 
BDCA-2-CpG C, 8674 ± 5721 pg/ml; BDCA-2-
R848, 3978 ± 2205 pg/ml) (Figure 2D). 
Interestingly, pDCs triggered with αDEC-205 
antibody showed a ~40% decreased IFN  
secretion compared to pDCs that were 
treated with isotype control antibodies upon 
TLR induced activation (αDEC-205-CpG C, 
9573 ± 4547 pg/ml; αDEC-205-R848, 1412 ± 
393.6 pg/ml) (Figure 2C). This inhibitory effect 
of the αDEC-205 antibody on IFNα secretion 
was concentration dependent (Supp. Figure 
1B,C). In contrast to IFNα, secretion of IL-6 
and TNFα was not affected by DEC-205 
triggering (Figure 2D). 
These data demonstrate that following DEC-
205 triggering, pDCs remain sensitive for TLR 
mediated signals and develop a mature 
phenotype, but are impaired to secrete high 
amounts of IFN . 
 
Maturation of human pDCs induces 
upregulation of DEC-205  
Freshly isolated pDCs activated with CpG C or 
R848 displayed a fully activated phenotype as 
determined by upregulation of CD80, CD83, 
CD86 and MHC class I and II molecules (data 
not shown) and downregulation of the CLRs 
DCIR14 and BDCA-217 (Figure 3C). Interestingly, 
pDCs that were cultured with IL-3 or activated 
for 24 or 48 hours through TLR-9 or TLR-7 
showed a significant increase in the 
expression levels of DEC-205 (Figure 3A, B). 
Enhanced expression of the CLR DEC-205 on 
monocyte-derived DCs after activation has 
also been noted and hints towards the 
possibility that DEC-205 expressing DCs 
sample their environment and take up 
antigens even in an activated state. 
 
Activated pDCs internalize DEC-205 through 
a clathrin dependent mechanism 
Freshly isolated pDCs rapidly internalized DEC-
205 upon receptor triggering (Figure 4A). 
Surprisingly, upon TLR triggering with CpG C 
or R848 pDCs maintained the capacity to 
internalize DEC-205 and this even appeared to 
be enhanced when compared to freshly 
isolated pDCs (Figure 4B). Internalization was 
confirmed by confocal microscopy 
demonstrating that DEC-205 receptor really 
accumulates inside the cell after receptor 
triggering (Figure 4C). 
Subsequently, we sought to determine the 
mechanism underlying DEC-205 
internalization. A classical pathway for 
receptor-mediated endocytosis is clathrin-
dependent37. Clathrin-dependent endocytosis 
can be inhibited by incubation of cells in 
hypertonic media14. Disruption of clathrin-
coated pits in hyperosmolar medium 
abolished DEC-205 receptor internalization in 
CpG C activated pDCs completely (Figure 4D). 
Vesicle fission in clathrin-mediated 
endocytosis is dynamin dependent. Dynasore 
is a reversible noncompetitive dynamin 
inhibitor and is used to study dynamin 
involvement38. As expected, DEC-205 
internalization could also be inhibited by 
incubating CpG C activated pDCs with 
Dynasore (Figure 4D). These data indicate that 
the mechanism of DEC-205 internalization in 
Figure 1 Freshly isolated human pDCs express a 
variety of antigen uptake receptors PDCs were 
incubated with anti-CD32, anti-BDCA-2, anti-DEC-205 
and anti-MHC class II antibodies for 30 mins on ice, 
washed and then incubated for 30 mins at either 37oC 
or 4oC. Receptor surface expression was assessed by 
flow cytometry using goat-anti-mouse-PE. Results are 
representative of 3 independent experiments. 
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 activated human pDCs is clathrin- and 
dynamin- dependent. Furthermore, we here 
show that activated pDCs remain capable of 
internalizing DEC-205 upon receptor 
triggering.  
 
Targeting antigen towards DEC-205 on 
activated pDCs induces T cell proliferation 
Since pDCs rapidly internalize DEC-205 upon 
triggering, we next assessed whether DEC-205 
functions as an antigen uptake receptor on 
human pDCs by targeted delivery of the 
model antigen keyhole limpet hemocyanin 
(KLH). To this end pDCs and PBLs were 
isolated from peripheral blood of melanoma 
patients participating in ongoing vaccination 
trials that include the use of KLH as a helper 
antigen. To facilitate KLH targeting we made 
use of anti-biotin-KLH construct that provides 
us with a flexible tool to rapidly study various 
Figure 2 DEC-205 triggering modulates TLR induced pDC activation Freshly isolated pDCs were incubated with anti-DEC-
205 or mIgG2b control antibodies, washed and subsequently incubated overnight with either IL-3, R848 or CpG C. (A) 
Surface expression levels of CD40 and CD86 after mIgG2b or DEC-205 triggering and subsequent activation as determined 
by flow cytometry. Data are representative of at least 3 independent experiments. (B) Relative receptor expression levels 
of the pDC surface molecules CD40, CD80, CD86, HLA-ABC and HLA-DR of TLR-agonist activated pDCs relative to IL-3 
treated controls calculated from flow cytometry data by setting the receptor expression levels of IL-3 cultured pDCs at 1. 
(C, D) Supernatants of pDC cultures following incubation with isotype, anti-DEC-205 or anti-BDCA-2 antibodies and 
subsequent overnight TLR triggering with the indicated ligands were analyzed for (C) IFN  and (D) IL-6 (left graph) and 
TNF  (right graph) levels. (B-D) Data shown are mean ± SEM  of at least (B) three, (C) seven and (D) four independent 
experiments. Statistical significance difference as compared with isotype controls determined by two-way ANOVA 
followed by Bonferroni test; *p<0.05, ***p<0.001. 
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 receptors expressed by pDCs. Ultimately, 
fusion constructs for the generation of 
vaccines and clinical application should be 
made for the receptor of choice. 
Patient-derived purified pDCs were targeted 
via DEC-205, DCIR14 or control IgG using 
biotinylated antibodies. Subsequently, pDCs 
were incubated with anti-biotin-antibodies 
conjugated to KLH and cocultured with fresh 
patient-derived CD4+ T cells. Proliferation was 
measured after four days of co-culture. T cell 
stimulation with PHA, as a positive control, 
induced strong T cell proliferation (35372 
CPM ±1466 CPM). In concordance with 
previous results 39, pDCs did not present 
soluble exogenous antigen, as anti-biotin-KLH 
and mIgG-biotin-anti-biotin-KLH were not able 
to induce significant proliferative T cell 
responses (Figure 5A). Interestingly, targeting 
DEC-205 on freshly isolated human pDCs led 
to proliferative recall T cell responses, 
illustrating the capacity of this receptor to 
specifically deliver antigens in MHC class II 
loading compartments of pDCs (Figure 5A). 
Since DEC-205 is up-regulated and 
internalized by human pDCs following TLR-
induced activation, we investigated whether 
DEC-205 still mediates antigen presentation in 
fully activated pDCs. Antigen presentation via 
DEC-205 was compared to DCIR, which is 
down regulated upon TLR-induced activation. 
In accordance with the elevated expression 
levels and the capacity to internalize the 
receptor upon triggering, we observed that 
CpG C activated pDCs induced antigen-specific 
T cell responses via DEC-205 (Figure 5B). In 
contrast, DCIR could not mediate antigen 
presentation in activated pDCs (Figure 5B). 
Interestingly, we observed a significant 
increase in KLH-specific T cell proliferation 
when DEC-205 was targeted on activated 
pDCs compared to freshly isolated pDCs 
(Figure 5B). These data clearly demonstrate 
that activated pDCs not only display increased 
DEC-205 expression levels, but retain the 
capacity of receptor-mediated antigen 
uptake, processing and presentation to T cells. 
Next we sought to determine the difference in 
targeting DEC-205 on different DC subsets. 
Therefore, we isolated pDCs, CD1c+ mDCs and 
generated immature monocyte-derived DCs 
and loaded them with KLH via targeting DEC-
205. In Figure 5C, it can be appreciated that 
the three DC subsets were equally efficient in 
inducing KLH-specific recall T cell responses. 
Moreover, targeting DEC-205 on the different 
DC subsets with a construct lacking KLH or 
anti-biotin-KLH alone did not induce specific T 
cell activation (Figure 5C). Taken together, 
DEC-205 on human pDCs can be targeted to 
induce antigen specific proliferative T cell 
responses to a similar level as CD1c+ mDCs 
and monocyte-derived DCs. 
 
 
 
Figure 3 DEC-205 and BDCA-2 
surface expression on human 
pDCs after TLR-induced activation 
(A) Expression of DEC-205 on 
freshly isolated pDCs, 24 hr 
cultured pDCs and 48 hr cultured 
pDCs. Isotype controls (thin line, 
open histogram) for all different 
time points were identical. Results 
shown are representative data of 
one experiment out of 5 
performed. (B) DEC-205 and (C) 
BDCA-2 surface expression at 
different time points after 
activation depicted as mean 
fluorescent intensity (MFI). Data 
are mean ± SEM of 5 independent 
experiments. Statistical signi-
ficance determined by two-way 
ANOVA followed by Bonferroni 
test; *p<0.05; **p<0.01; 
***p<0.001.  
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 Discussion 
In this study we demonstrated that DEC-205 is 
expressed by freshly isolated human pDCs and 
mediates antigen uptake and presentation in 
a clathrin dependent manner. Endocytic 
receptors are generally down-regulated in 
DCs upon activation with maturation stimuli40. 
This could partially explain the fact that 
mature DCs have a decreased capacity to take 
up and present antigen. DEC-205 seems to be 
an exception to this rule, as it is upregulated 
in both human pDCs and monocyte-derived 
DCs upon maturation31. However, in contrast 
to activated moDCs31, activated human pDCs 
still internalized DEC-205 in a clathrin and 
dynamin dependent fashion. In mice, Platt et 
al. have recently shown that bone-marrow 
DCs also capture and present antigens in and 
activated state32. This suggests that DEC-205 
may perform distinct functions in the various 
DC subsets. Many CLRs, such as mannose 
receptor41, DCIR14 and DC-SIGN42 have the 
ability to rapidly internalize from the plasma 
membrane via clathrin coated vesicles. Our 
experiments showed that DEC-205 is 
connected to the clathrin-mediated receptor 
uptake machinery in human pDCs. Previously 
it was shown that DEC-205 delivers antigens 
Figure 4 Freshly isolated and TLR-activated human pDCs internalize DEC-205 upon triggering with specific antibodies 
(A) DEC-205 surface expression levels at 4 degrees and after internalization at 37 degrees on freshly isolated, CpG C and 
R848 activated pDCs. Results shown are representative data of one experiment out of 3 performed. (B) DEC-205 receptor 
surface expression following internalization for 30 min at 37oC relative to expression at 4oC. Data are mean ± SEM of 3 
independent experiments. Statistical significance determined by two-way ANOVA followed by Bonferroni test; *p<0.05 ; 
**p<0.01. (C) Confocal analysis of CpG C-pDCs showing expression of MHC class I (red) and CLR DEC-205 (green) after 
antibody-staining at 4oC and 37oC. Magnification x60. (D) pDCs were incubated with anti-DEC-205 or isotype controls for 
30 min at either 37oC or 4oC in isotonic or hypertonic (450 mM sucrose) medium or medium containing 80 μM Dynasore 
(an inhibitor of dynamin). DEC-205 receptor surface expression was assessed by flow cytometry. Data are representative 
of three independent experiments.  
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  to late endosomes or lysosomes, where they 
are degraded. The cytoplasmic domain of 
DEC-205 contains two functional regions24 a 
membrane-proximal region with a tyrosine-
based coated-pit sequence for uptake43 and a 
distal region with an EDE amino acid triad for 
targeting to proteolytic vacuoles. Our 
experiments showed that endocytosis of the 
exogenous antigen KLH via DEC-205 led to 
antigen presentation and induced 
proliferative recall CD4+ T cell responses. 
Since pDCs cannot take up soluble antigens in 
a receptor independent fashion1,44, receptor 
mediated uptake is essential for antigen 
presentation by pDCs. Previously, we 
demonstrated that both DCIR and CD32-
mediated antigen uptake leads to antigen 
presentation by freshly isolated human pDCs 
resulting in proliferative recall T cell 
responses14,39. However, upon pDC activation, 
DCIR expression levels dramatically drop and 
CD32-mediated antigen uptake and 
presentation is hampered30. These findings 
are in accordance with the notion that 
Figure 5 Targeting antigen uptake receptors leads to antigen presentation by human pDCs Freshly isolated pDCs were 
incubated with biotinylated antibodies directed against several uptake receptors and subsequently targeted with anti-
biotin-KLH. Autologous KLH-responsive PBLs from a patient previously vaccinated in  ongoing trials were added in a  1:20 
ratio (pDC:T-cells). After 4 days of culture and without addition of cytokines, proliferation was measured by 3H-
Thymidine incorporation assay. (A) Due to variability in counts per minute between donors data shown are mean ± SEM 
of measurements performed in triplicate of one representative out of four independent experiments with different 
patients showing similar results. (B) Fresh pDCs and CpG C activated pDCs were obtained from the same donor and 
compared in their capacity to induce KLH-specific T cell responses. KLH-specific T cell proliferation was determined by 3H-
Thymidine incorporation and is depicted as stimulation index. The stimulation index of T cells stimulated with pDCs-
mIgG-KLH is set to 1. Data shown are mean ± SEM of six replicates. One out of two independent experiments is shown. 
(A, B) Statistical significance determined by one-way ANOVA followed by Tukey’s multiple comparison test; * p<0.05; *** 
p<0.001. (C) Freshly isolated pDCs, CD1c+ mDCs and immature monocyte-derived DCs were obtained from the same 
donor and compared in their capacity to induce KLH-specific T cell responses. Data shown are mean ± SEM of six 
replicates. 
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 immature APCs take up antigens, undergo a 
process of activation and then present the 
encountered antigen to T cells45. Indeed, in 
mouse experiments it was demonstrated that 
simultaneously delivering antigen and 
maturation stimuli by administration of an 
anti-CD40 antibody and an anti-DEC-205 
antibody/Ag fusion protein induced potent 
antigen-specific CTL responses in mice22. 
Much less is known regarding DEC-205 in 
man. Surprisingly, we find that human pDCs 
presented antigen targeted to DEC-205 
irrespective of the pDC activation status. 
Furthermore, in line with increased 
expression and enhanced internalization, we 
found that targeting DEC-205 to activated 
human pDCs induced stronger antigen specific 
T cell responses when compared to targeting 
DEC-205 to freshly isolated pDCs. Whereas 
activated pDCs cannot take up and present 
immune complexes, they do present antigens 
encountered via DEC-205. This demonstrates 
that exogenous class II-restricted antigens are 
processed fundamentally different when 
taken up via DEC-205 than via CD32. This 
shows that, for class II-restricted antigens, 
vaccination strategies involving delivery of 
antigens to specific surface receptors may 
result in presentation by steady state and 
activated pDCs.  
Activation of pDCs leads to a variety of 
phenotypical and functional alterations, 
including activation-induced antigen 
processing and increased surface expression 
of MHC class I and MHC class II. Furthermore, 
co-stimulatory molecules are upregulated, 
and pDCs acquire the ability to secrete large 
amounts of cytokines such as type I IFNs. 
Expression of co-stimulatory molecules CD40, 
CD80 and CD86 and the secretion of IL-6 
remained unaffected after triggering DEC-205 
and TLR-induced activation. Interestingly, we 
demonstrate that DEC-205 triggering on pDCs 
resulted in a 40% reduction in TLR ligand-
induced IFN  secretion. Previously, we 
showed that triggering DCIR on human pDCs 
reduced TLR-9 induced IFN  secretion14. 
Moreover, it has been described that 
triggering BDCA-2 also exhibits inhibitory 
effects on TLR-9 induced IFN  secretion17. 
Apart from DCIR and BDCA-2, TLR-9 induced 
IFN  secretion remains unaffected upon 
BDCA-4 and CD32 receptor triggering2,30,36. 
DEC-205 now represents a third CLR on pDCs 
that modulates TLR-induced responses. 
Although this suggests a similar mode of 
action for all CLRs, there appear to be distinct 
ways by which CLRs induce signaling. CLRs 
such as BDCA-2 are associated with 
immunoreceptor tyrosine-based activation 
motif (ITAM)-containing adaptor molecules, 
like the Fc receptor γ chain or DAP1246. Other 
CLRs, such as DCIR, induce signaling pathways 
through activation of protein kinases or 
phosphatases that interact with their 
cytoplasmic domains 47. Whether DEC-205 
belongs to one of these two categories and 
whether the various signaling motifs of these 
receptors induce distinct responses remains 
to be determined.  
Taken together, we show that the endocytic 
receptor DEC-205 is expressed by human 
pDCs in a steady state and is upregulated 
upon maturation. Moreover, targeting DEC-
205 on fresh and activated pDCs with specific 
antibodies coupled to KLH leads to antigen 
delivery, resulting in presentation and antigen 
specific proliferation of T cells. Furthermore, 
we illustrate that triggering DEC-205 on 
human pDCs leads to impaired IFN  secretion 
after TLR induced activation. These findings 
have implications for using DEC-205 as a 
target receptor for the delivery of antigens 
and the induction of antigen specific T cell 
responses. Future research will be focused on 
the identification of the natural endogenous 
ligands that bind to DEC-205 and the role of 
DEC-205 in modulating immune responses 
after antigen uptake and TLR signaling. 
Identification of the intracellular interaction 
partners of DEC-205 will reveal how it 
modulates TLR signaling and whether it 
resembles other CLRs or follows a distinct 
pathway. Detailed information about receptor 
regulation, internalization and signaling is 
instrumental for the rational design of CLR- 
targeted therapeutics. 
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Supplementary figure 1 (A) Viability of human pDCs after mIgG2b or DEC-205 receptor triggering and subsequent 
overnight activation with either CpG C or R848 as determined by expression of Annexin V and propidium iodide. Data 
shown are mean values ± SEM of 3 independent experiments. (B) IFN  production by human pDCs after mIgG2b, DEC-205 
receptor or BDCA-2 receptor triggering and subsequent overnight activation with CpG C. (C) Relative IFN  production by 
human pDCs after mIgG2b, DEC-205 receptor or BDCA-2 receptor triggering and subsequent overnight activation with 
CpG C. 
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Supplementary figure 2 FACS gating strategy. (A) Forward scatter (FSC)-Sideward scatter (SSC) plot of 
cell population following MACS isolation. Staining of pDCs with CD123-FITC and BDCA-2-PE. MACS 
isolation yields a population of >95% pure pDCs (n=4). FSC vs SSC plots and gating of pDCs after 
incubation at different temperatures (B), after incubation with mIgG2b and triggering DEC-205 (C), and 
after various time points (D 
Targeted delivery of TLR agonists & antigens
62
 Chapter 5 
 
 
Human Plasmacytoid Dendritic Cells Phagocytose, Process 
and Present Exogenous Particulate Antigen 
 
 
 
 
 
 
 
Jurjen Tel* 
Annechien J.A. Lambeck* 
Luis J. Cruz 
Paul J. Tacken 
I. Jolanda M. de Vries 
Carl G. Figdor 
 
* Authors contributed equally 
 
 
 
 
 
 
 
 
 
 
 
Journal of Immunology (2010) 184 (8), 4276-4283  
 
  
Human plasmacytoid dendritic cells phagocytose, process and present 
exogenous particulate antigen  
 
Jurjen Tel*1, Annechien J.A. Lambeck*1,  
Luis-Javier Cruz*, Paul J. Tacken*,  
I. Jolanda M. de Vries* † ‡, Carl G. Figdor* 
 
 
*Department of Tumor Immunology, †Medical 
Oncology and ‡Pediatric Hemato-Oncology, 
Nijmegen Centre for Molecular Life Sciences, 
Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands.  
1Both authors contributed equally  
 
 
Abstract 
Plasmacytoid dendritic cells (pDCs) play a 
major role in shaping both innate and 
adaptive immune responses, mainly via their 
production of large amounts of type I 
interferons. PDCs are considered to primarily 
present endogenous antigens and are thought 
not to participate in the uptake and 
presentation of antigens from the 
extracellular environment, in contrast to their 
myeloid counterparts, which efficiently 
endocytose extracellular particulates. Here, 
we show that human pDCs are able to 
phagocytose and process particulate forms of 
antigen entrapped in poly(lactic-co-glycolic 
acid) (PLGA) microparticles. Furthermore, 
pDCs were also able to sense Toll-like 
receptor ligands (TLR-Ls) incorporated in 
these particles, resulting in rapid pDC 
activation and high IFN-α secretion. 
Combining a tetanus toxoid (TT) peptide and 
TLR-Ls (CpG C and R848) in these 
microparticles resulted in efficient pDC 
activation and concomitant antigen-specific T 
cell stimulation. Moreover, particulate 
antigen was phagocytosed and presented 
more efficiently than soluble antigen, 
indicating that microparticles can be exploited 
to facilitate efficient delivery of antigenic 
cargo and immunostimulatory molecules to 
pDCs. Together, our results show that in 
addition to their potency to stimulate innate 
immunity, pDCs can polarize adaptive 
immune responses against exogenous 
particulate antigen. These results may have 
important consequences for the development 
of new immunotherapeutic strategies 
exploiting antigen and TLR-Ls encapsulated in 
microparticles to target antigen presenting 
cell subsets. 
 
Introduction 
Dendritic cells (DCs) are considered key 
players in processing and presenting both 
endogenous and exogenous antigens, thereby 
triggering the immune system1. Human 
plasmacytoid DCs (pDCs) constitute a rare 
subset of circulating blood DCs and are 
considered as immunomodulating cells 
capable of shaping the immune response2. 
PDCs differ from myeloid DCs in their ability 
to produce large amounts of type I interferons 
(IFN-α and IFN-β), thereby providing an 
immunostimulatory environment for both 
innate and adaptive immune cells. Type I IFNs 
are known to be important for antiviral 
immunity, but several studies show that they 
also play a role in bacterial infections and 
cancer immunity3,4. While unstimulated pDCs 
promote an unbiased Th or a Th2 response, 
activated pDCs promote DC activation and 
trigger a Th1 response5-7. Recently, it was 
shown that not only viruses, but also whole 
live bacteria can induce pDC activation, 
resulting in Th1 polarization of naïve CD4+ T 
cells8,9. Furthermore, pDCs can interact 
synergistically with myeloid DCs by enhancing 
their priming ability in a contact-dependent 
manner, resulting in increased levels of 
antigen-specific CTLs3,10. Finally, activated 
pDCs abrogate cancer cell replication and 
induce tumor cell death11. Altogether, these 
findings indicate that pDCs can play a role in 
inducing immune responses against viruses as 
well as bacteria and cancerous cells. In 
addition, it implies that pDCs might be of use 
in immunotherapeutic regimens to evoke or 
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stimulate antigen-specific immune 
responses12. 
Nonetheless, human pDCs are considered to 
poorly present exogenous antigens. Although 
pDCs are well capable of presenting 
endogenous antigens, they appear to be less 
efficient in presenting antigens captured from 
the extracellular environment2. PDCs can take 
up and present soluble antigen from their 
environment, but this seems to require 
specific receptor-mediated endocytosis, as 
their macropinocytic capacity is poor13,14. We 
recently reported that pDCs are able to 
internalize soluble exogenous antigen bound 
to antigen-specific antibodies via the FcγRIIa 
receptor, resulting in CD4+ T cell activation15.  
Apart from processing exogenous soluble 
antigen, it remains highly controversial 
whether human pDCs phagocytose and 
process non-opsonized exogenous particle-
like structures independent from Fc 
receptors2. While some studies show that 
pDCs phagocytose apoptotic cells16,17, several 
report that pDCs hardly take up particulates, 
such as apoptotic cells18, latex beads17,19, 
zymosan granules14 or extracellular bacteria3. 
Human pDCs have been shown to prime 
functional T cell responses upon phagocytosis 
of apoptotic debris16. However, Piccioli and 
coworkers3 postulate that pDCs cannot 
phagocytose bacteria (Staphylococcus Aureus 
and Escherichia Coli) and require myeloid DCs 
to respond to bacterial stimuli. On the 
contrary, other studies show that pDCs can be 
activated by extracellular bacteria 
(Staphylococcus Aureus and Streptococcus 
pyogenes), but it was not established whether 
this was due to uptake of entire bacteria or 
mere bacterial components8,9. Furthermore, 
most vaccines, such as live attenuated or 
inactivated pathogen-based formulations, 
lipid emulsions, biocompatible and 
biodegradable nano- and microparticles, 
immunostimulatory complexes (ISCOMs), 
virosomes and virus-like particles, are 
particulate in nature and favor delivery of 
antigenic cargo and/or immunostimulatory 
molecules to phagocytic antigen presenting 
cells such as myeloid and monocyte-derived 
DCs20-23. Until now, it is not known whether 
pDCs can play a direct role in the immune 
response to such particulate vaccines. This 
prompted us to perform a study to elucidate 
whether pDCs play a direct role in taking up 
and processing antigens and sensing stimuli 
derived from exogenous particle-like 
structures, such as bacteria or particulate 
vaccines.  
In this study, we exploit poly(lactic-co-glycolic 
acid) (PLGA) microparticle-encapsulated 
antigen to investigate whether pDCs are able 
to phagocytose and present particulate 
antigen. We not only demonstrate that 
human pDCs take up microparticulates via 
phagocytosis and efficiently process the 
encapsulated antigen, but also that pDCs 
sense Toll-like receptor ligands (TLR-Ls) 
incorporated within these particles, resulting 
in pDC maturation and IFN-α production. 
Furthermore, human pDCs induce antigen-
specific T cell activation upon phagocytosis of 
microparticles, containing both antigen and 
TLR-Ls.  
 
Material and methods  
 
Materials 
PLGA (Resomer RG 502 H,  lactide:glycolide 
molar ratio 48:52 to 52:48) was purchased 
from Boehringer (Ingelheim, Germany). 
Solvents for peptide synthesis and PLGA 
preparation (dichloromethane, 2-propanol, 
N,N'-dimethylformamide and ethyl acetate) 
were obtained from Merck (Germany). 
Polyvinyl alcohol (PVA) was purchased from 
Sigma (St. Louis, MO, USA). The phospholipid 
2-(4,4-difluoro-5-(4-phenyl-1, 3-butadienyl)-4-
bora 3a, 4a-diaza-s-indacene-3-pentanoyl)-1-
hexadecanoyl-sn-glycero-3-phosphocholine 
and DQ-BSA were procured at  Molecular 
Probes (Leiden, The Netherlands). R848 and 
CpG C were purchased from Axorra (San 
Diego, CA, USA). Cytochalasin D  and 
chloroquine were purchased from Sigma. 
 
Synthesis of FITC-TT 
The TT epitope comprises the 830-844 region 
of tetanus toxoid. The TT peptide was 
synthesized manually according to standard 
protocols of solid-phase peptide synthesis, 
using the Fmoc/tert-butyl strategy24. The N-
terminus of the TT peptide was modified with 
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5(6)-Carboxyfluorescein (FITC) through linking 
via a Lys-Lys cathepsin-like cleavage site as 
described before25. 
 
Microparticle preparation 
Several PLGA microparticle formulations 
containing FITC-TT-peptide or DQ-BSA and 
TLR-Ls (R848 and CpG C) were prepared by 
double emulsion method26. In brief, 50 mg of 
PLGA in 1 ml of ethyl acetate containing FITC-
TT-peptide (2 mg in 100 µl H2O) or DQ-BSA (2 
mg in 100 µl PBS) and TLR ligands (R848 (0.08 
mg in 50 µL H2O-DMSO, 9/1) and CpG C (0.1 
mg in 50 µL H2O)) were emulsified under 
sonification during 60 seconds. This first 
emulsion was rapidly added to 1 ml of 1% 
PVA/7% ethyl acetate in distilled water and 
vortexed vigorously during 30 seconds. Next, 
the vortexed solution was immediately added 
to 200 ml of 0.3% PVA/7% of ethyl acetate 
and stirred overnight to evaporate ethyl 
acetate. The microparticles were rinsed three 
times with distillated water through 
centrifugation (3000 g at 4°C) and 
supernatant replacement. Finally, the 
microparticles were lyophilized during 3 or 4 
days. The prepared microparticles were 
completely spherical as characterized by SEM 
(Supplementary Fig. 1). 
 
Dynamic Light Scattering and zeta-potential 
Particle size and polydispersity of the 
microparticles were measured by dynamic 
light scattering (DLS). DLS measurements 
were performed on an ALV light-scattering  
instrument equipped with an ALV5000/60X0  
 
 
Table 1 Characterization of PLGA microparticles 
Multiple Tau Correlator and an Oxxius SLIM-
532 150 mW DPSS laser operated at a 
wavelength of 532 nm. A refractive index 
matching bath of filtered cis-decalin 
surrounded the cylindrical scattering cell, and 
the temperature was controlled at 21.5 ± 0.3 
°C using a Haake F3-K thermostat. For each 
sample the auto-correlation function, g2(τ), 
was recorded ten times at a detection angle 
of 90°. For each measurement the diffusion 
coefficient, D, was determined using the 2nd 
order cumulant and the corresponding 
particle diameter was calculated assuming 
that the particles were spherical in shape. 
Microparticles of 2 µm and with a relatively 
monodisperse diameter were produced 
(Table 1). Zeta potential of the microparticles 
was determined on a Malvern ZetaSizer 2000. 
The zeta potential of the particles ranged 
from -40 to -45 mV, largely due to the 
negatively charged carboxylic acid groups of 
the PLGA polymer (Table 1).  
 
Determination of antigen in the microparticles 
Entrapment efficiency of FITC-TT peptide was 
determined by digesting 10 mg microparticles 
in 3 ml 0.8 N NaOH overnight at 37 ºC, 
filtering with a 0.2 μm sterile syringe filter, 
and measuring fluorescence relative to a 
standard curve (492 nm excitation and 20 nm 
emission) using a CytoFluor II (Applied 
Biosystem, Foster City, CA). DQ-BSA 
entrapment was determined by Coomassie 
protein assay (Pierce, Rockford, IL, USA). 
Antigen loading was determined by dividing 
the amount of encapsulated antigen by the 
theoretical amount assuming that the entire 
added amount of antigen was encapsulated. 
Particle Particle diameter 
(nm) 
Polydispersity 
index 
Zeta Potential 
(mV) 
Loading efficiency (% w/w) 
    Antigen R848 CpG C 
PLGA-DQ-BSA 1984 ± 216 0.28 -42.6 ± 2.1 81.6 ± 3.5 - - 
PLGA-FITC-TT 2019±633 0.25 -44.7±1.6 89.4±2.1 - - 
PLGA-FITC-TT-R848-CpG C 1953±118 0.24 -40.4±2.2 82.2±2.1 56.8±2.5 42.8±1.6 
PLGA microparticles with DQ-BSA or FITC-TT peptide and TLR-Ls R848 and CpG C were characterized by dynamic light 
scattering (DLS) and zeta potential measurements. Particle diameter data represent the mean value ± SD and the 
polydisperisity index (PDI) as measured by DLS. Zeta potential data represent the mean value ± SD of 5 readings. Loading 
efficiency of DQ-BSA and FITC-TT peptide was measured by fluorescence method and Coomassie dye protein assay. Loading 
efficiency of  R848 and CpG C was determined by RP-HPLC analysis. The loading efficiency is calculated as the % encapsulated 
of the total amount added during particle preparation. 
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The entrapment efficiency of antigen was 80-
90% (Table 1).  
 
Determination of TLR ligands in the 
microparticles 
The encapsulation efficiency of TLR ligands 
was determined by high-performance liquid 
chromatography (HPLC). HPLC analysis was 
performed at room temperature using a 
Shimadzu system (Shimadzu Corporation, 
Kyoto, Japan) equipped with a reverse-phase 
Symmetric C18 column (250 mm x 4.6 mm). 
The flow rate was fixed at 1 ml/min and 
detection was obtained by UV detection at 
220 nm. A linear gradient of 0% to 100% of 
acetonitrile (containing 0.036% trifluoroacetic 
acid) in water (containing 0.045% 
trifluoroacetic acid) was used for the 
separation of R848 and CpG C. The peak of 
R848 was well separated from that of the CpG 
C in the established chromatographic 
condition. The retention times of the CpG C 
and R848 were approximately 17 and 26 min, 
respectively. The regression analysis was 
constructed by plotting the peak–area ratio of 
R848 or CpG C versus concentration (µg/ml). 
The calibration curves were linear within the 
range of 1 µg/ml to 10 µg/ml for R848 and 10 
µg/mL to 40 µg/mL for CpG C. The correlation 
coefficient (R2) was always greater than 0.99, 
indicating a good linearity. R848 and CpG C 
were extracted by dispersing 5 mg 
microparticles in 500 µl of 85% acetonitrile in 
water, followed by centrifugation at 12,000 
rpm for 10 min. The PVA was precipitated and 
the supernatant was subsequently assayed for 
RP-HPLC. The amount of R848 and CpG C was 
calculated by interpolation into the standard 
curves as described before. The encapsulation 
efficiency of R848 and CpG C was 40-60% 
(Table 1).  
Cells 
Peripheral blood mononuclear cells (PBMCs) 
were obtained from buffy coats of healthy 
individuals after informed consent and were 
purified using Ficoll density centrifugation. 
Monocytes were removed via adherence and 
pDCs were purified from the non-adherent 
cell population (peripheral blood 
lymphocytes) by positive isolation using anti–
BDCA-4–conjugated magnetic microbeads 
(Miltenyi Biotec, Bergisch Gladback, 
Germany). PDC purity was routinely up to 
95%, as assessed by double staining BDCA-
2/CD123. PDC were cultured in X-VIVO-15 
medium (Cambrex, Verviers, Belgium) 
supplemented with 2% human serum.  
 
Flowcytometry 
Uptake of particulate or soluble antigen and 
pDC phenotype were determined by flow 
cytometry. PDCs (105 cells/well in 100 µL 
medium) were cultured overnight at 37ºC 
with PLGA particles (0.25 mg/ml) containing 
encapsulated antigen (FITC-TT or DQ-BSA) and 
TLR-Ls (CpG C and R848) or with equal 
amounts of soluble antigen or soluble CpG C 
and R848. If no activation stimuli were added, 
pDCs were cultured with 10 ng/ml IL-3 as a 
survival stimulus. The following primary 
monoclonal antibodies (mAbs) and the 
appropriate isotype controls were used for 
pDC phenotyping: anti-CD80 (Becton 
Dickinson, Mountain View, CA, USA) and anti-
CD86 (Pharmingen, San Diego, CA, USA). PE-
labeled goat-anti-mouse IgG mAb was used as 
secondary antibody. Cells were analyzed by 
flow cytometry on a FACSCalibur (BD 
Biosciences, San Jose, CA, USA). 
 
Confocal microscopy 
Uptake of particulate FITC-TT was confirmed 
by confocal microscopy. Cells were fixed on 
poly-L-lysine coated glass slides and stained 
with anti-human MHC class II antibody (clone 
Q5/13), followed by a secondary goat-anti-
mouse IgG Alexa 647 mAb (Molecular Probes, 
Carlsbad, CA, USA). Cells were imaged with a 
Bio-Rad MRC 1024 confocal system operating 
on a Nikon Optiphot microscope and a Nikon 
60x planApo 1.4 oil immersion lens. Pictures 
were analyzed with Bio-Rad Lasersharp 2000 
and Adobe Photoshop 7.0 (Adobe Systems, 
Mountain View, CA) software. 
 
Antigen processing 
Antigen processing was measured with DQ-
BSA, a protein strongly labeled with a 
fluorescent BODIPY dye. DQ-BSA 
microparticles (0.25 mg/ml) were added to 
pDCs (105). Cells were cultured at 37°C and 
fluorescence was measured 
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spectrophotometrically in a CytoFluor II or by 
flowcytometry on a FACSCalibur.  
 
IFN-α and IL-6 ELISA 
IFN-α and IL-6 production was analyzed with 
murine monoclonal capture and HRP-
conjugated anti-IFN-α Abs (Bender 
MedSystems, Vienna, Austria) and anti-IL-6 
Abs (Sanquin, Amsterdam, The Netherlands) 
respectively, using standard ELISA procedures.  
 
Antigen presentation assay  
Peripheral blood lymphocytes (PBLs) from 
healthy donors were cultured for 8-10 days 
with TT830-844 peptide (3 µg/ml) and IL-2 (50 
EU/ml) to increase the number of TT-
responsive cells. Autologous pDCs (105) were 
incubated overnight at 37°C with different 
PLGA particle formulations (0.25 mg/ml) or 
equal amounts of soluble R848 and CpG C or 
soluble FITC-TT. Subsequently, pDCs were 
added to the prestimulated PBLs at a ratio of 
1:10 in 6-fold. After 4 days, proliferative 
responses were determined by adding 
tritiated thymidine (1 µCi [0.037 MBq]/well; 
MP Biomedicals, Amsterdam, the 
Netherlands) to the cell cultures. Tritiated 
thymidine incorporation was measured after 
16 hours in a scintillation counter. In addition, 
cytokine production (IL-1beta, IL-2, IL-4, IL-5, 
IL-6, IL-8, IL-10, IL-12 (p70), TNF-α, TNF-β, IFN-
γ) was measured in the supernatants of the 
antigen presentation assay after 4 days with a 
human Th1/Th2 Multiplex kit (Bender 
MedSystems) according to manufacturer’s 
instructions. 
 
Results 
 
Human pDCs phagocytose particulate antigen 
more efficiently than soluble antigen 
To investigate whether pDCs can phagocytose 
particulates, we produced distinct 
combinations of PLGA microparticles, 
containing tetanus toxoid (TT)830–844 peptide 
covalently linked to FITC (FITC-TT) or the 
fluorescent labeled protein DQ-BSA. PDCs 
were incubated in the presence or absence of 
particulate FITC-labeled TT-peptide or DQ-
BSA. Incubation of pDCs with particulate FITC-
TT resulted in an increase in FITC+ pDCs in 
time (Supplementary Fig. 2).  After overnight 
incubation, approximately 50% of the pDCs 
were FITC+, indicating that pDCs had taken up 
particulate FITC-TT (Fig. 1A, B). Incubating 
pDCs with particulate DQ-BSA resulted in 94% 
fluorescent pDCs, demonstrating that virtually 
all pDCs have taken up particulate DQ-BSA 
(Fig. 1A). Differences in the percentage of 
fluorescent pDCs are presumably due to the 
higher fluorescent labeling of DQ-BSA 
compared to FITC-TT. To demonstrate that 
particulate FITC-TT is actually taken up and 
not simply binding to the pDCs, cells were 
incubated with cytochalasin D prior to the 
addition of particulate FITC-TT to block 
phagocytosis.  As expected, cytochalsin D 
treated pDCs displayed a strongly reduced 
FITC signal, indicating diminished uptake of 
particulate antigen (Fig. 1A, B). Additional 
evidence for internalization was obtained by 
confocal microscopy. The majority of the pDCs 
showed diffuse fluorescent staining, indicative 
of intracellular release of FITC-TT from the 
PLGA particle (Fig. 1C). Upon z-stack analysis 
we could confirm that detected FITC signals 
were indeed located within the pDC (Fig. 1C). 
To investigate whether uptake of particulate 
antigen is more efficient than soluble antigen, 
pDCs were incubated overnight with an equal 
amount of either particulate or soluble FITC-
TT. Incubation with particulate FITC-TT 
resulted in 60% FITC+ pDCs, while incubation 
with soluble FITC-TT resulted in only 14% 
FITC+ pDCs (Fig. 1D). In addition, the mean 
fluorescence intensity of the pDCs is four 
times higher after addition of particulate 
compared to soluble FITC-TT (data not 
shown). These data reveal that pDCs are well 
equipped to take up particulate antigen and 
that particulate antigen is phagocytosed 
considerable more efficiently than soluble 
antigen. 
 
Particulate antigen is processed by human 
pDCs 
To determine whether pDCs are able to 
process phagocytosed particulate protein, the 
model protein BSA, labeled with a fluorescent 
BODIPY dye (DQ-BSA), was used. DQ-BSA is 
labeled to such high degree that the 
fluorescence is self-quenched. Quenching is 
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relieved upon release of antigen from the 
PLGA particles within the cell and subsequent 
processing of the antigen into fluorescent 
peptides by cellular proteases. Incubation of 
pDCs with particulate DQ-BSA resulted in an 
increase of fluorescent cells in time as 
analyzed by flowcytometry, demonstrating 
uptake and processing of particulate DQ-BSA 
(Fig. 2A). Antigen processing was also 
measured by spectrophotometry. Incubation 
of pDCs with particulate DQ-BSA resulted in 
an increase in fluorescence indicative of 
antigen degradation, while the fluorescence 
of particulate DQ-BSA incubated without pDCs 
did not increase (Fig 2B). In addition, 
processing of exogenous antigen was 
analyzed following CpG C-induced pDC 
activation. We previously demonstrated that 
pDC activation diminishes processing and 
presentation of exogenous immune 
complexes (27). In accordance with this result, 
CpG C-induced activation strongly diminished 
pDC fluorescence upon incubation with both 
particulate DQ-BSA or particulate FITC-TT as 
Figure 1 PDCs phagocytose particulate antigen Human pDCs were incubated with or without PLGA particles containing 
FITC-labeled TT peptide or DQ-BSA. Uptake of particulate antigen by pDCs was measured by flow cytometry after 24 hrs. 
In addition, uptake of particulate FITC-TT was blocked by incubating pDCs with the phagocytosis blocker cytochalasin D 
(2.5 or 10 µM). Representative dot plots of the fluorescence intensity of pDCs are shown. Values in the lower right 
quadrant represent the percentage of fluorescent pDCs (A). Combined data of 3 independent experiments. Data are mean 
values ± SEM (B). Uptake of particulate FITC-TT by pDCs was further confirmed by confocal scanning laser microscopy. 
Depicted are the merged pictures of the fluorescence of particulate FITC-TT (green) and MHC class II staining (red). PDCs 
only (upper left), pDCs incubated with particulate FITC-TT (C). Uptake of particulate versus soluble antigen. Human pDCs 
were incubated with particulate or soluble FITC-TT and uptake was measured by flowcytometry after 24 hrs. Data are 
mean values of 3 independent experiments ± SEM (D). Statistical significance was determined by ANOVA and Newman-
Keuls testing. **P<0.01, ***P<0.001 
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measured by flowcytometry (data not shown). 
As expected, pDC activation also strongly 
diminished fluorescence as measured by 
spectrophotometry, demonstrating that 
uptake of extracellular particulate antigen is 
decreased upon pDC maturation (Fig 2B).  
 
Human pDCs are activated via delivery of 
particulate TLR-Ls 
Activation of pDCs is essential for effective 
antigen presentation and activation of naïve T 
cells (10). Therefore, we investigated if pDCs 
are also able to sense encapsulated 
particulate TLR-Ls rather than soluble TLR-Ls. 
We decided to activate pDCs exploiting TLR-Ls 
that trigger TLRs located in the endosomal 
compartments (28). Binding of specific viral 
components, such as unmethylated CpG-rich 
DNA motifs or double-stranded RNA, to these 
TLRs is known to upregulate MHC and co-
stimulatory molecules and production of type 
I IFN (29). As pDCs predominantly express 
TLR7 and -9, PLGA particles containing the 
TLR7 agonist R848 and the TLR9 agonist CpG C 
were generated. Indeed, exposing pDCs to 
these PLGA particles induced activation as 
reflected by strong upregulation of CD80 (Fig 
3A,B) and CD86 expression (Fig 3A,C) and 
production of high levels of IFN-α (Fig 3D, 
mean IFN-α production: 5566 pg/ml) and IL-6 
(Fig 3E, mean IL-6 production: 2156 pg/ml). As 
expected, pDCs cultured with IL-3 or with 
PLGA particles containing only antigen (FITC-
TT) did not acquire an activated profile. 
Activation of pDCs by PLGA- encapsulated 
TLR-Ls could be blocked by cytocholasin D, 
indicating that activation depends on 
phagocytosis of the PLGA microparticles. (Fig. 
3 B,C,D, E). In addition, pretreatment with 
chloroquine, which blocks phagosomal 
acidification and thereby inhibits TLR 
triggering, also blocked pDC activation upon 
incubation with particulate TLR-Ls. Incubation 
of pDCs with particle free CpG C or R848 in 
combination with cytochalasin D or 
chloroquine also inhibited phenotypical 
maturation and IFN-  secretion (data not 
shown). Furthermore, blocking of particulate 
TLR-L-induced pDC activation both by 
cytocholasin D and chloroquine was 
concentration dependent (Supplementary fig. 
3 and data not shown). Importantly, 
particulate TLR-Ls consistently induced a 
comparable, with a tendency to higher, 
activation state compared to the same 
amount of soluble TLR-Ls in 6 independent 
donors, as reflected by the expression of the 
co-stimulatory markers CD80 and CD86 (Fig 
4A) and IL-6 production (Fig 4B). These results 
demonstrate that pDCs are efficiently 
activated upon phagocytosis of particulate 
TLR-Ls. 
 
Uptake of particulate antigen and TLR-Ls by 
human pDCs induces T cell proliferation 
Previously we have demonstrated that DCIR 
and FcγRII-mediated uptake of KLH protein 
induces efficient antigen presentation by 
Figure 2. Human pDCs process phagocytosed particulate antigen Human pDCs were incubated with PLGA particles 
containing the self-quenched model protein DQ-BSA for 2, 6 or 24 hrs. Fluorescence, caused by uptake and subsequent 
degradation of DQ-BSA, was measured by flowcytometry. The gray peak represents pDCs incubated without particulate 
DQ-BSA. Values represent the percentage of fluorescent pDCs (A). Human pDCs were incubated with particulate DQ-
BSA (▲) and fluorescence was measured spectrophotometrically during 48 hrs. As a control, fluorescence of pDCs only 
(), particulate DQ-BSA only () or pDCs activated with CpG C before adding particulate DQ-BSA (▼) was measured. 
Two independent experiments were performed with similar results. Data are mean fluorescence for one of the 
experiments. 
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human pDCs (15, 30). Here we showed that 
human pDCs are capable of processing 
phagocytosed particulate antigen, and in 
addition can be activated by particulate TLR-
Ls. We next investigated whether pDCs are 
capable of presenting ingested particulate 
antigen and induce T cell responses.  
PDCs incubated with PLGA particles, 
containing FITC-TT and TLR-Ls, induced higher 
proliferation of autologous TT-responsive T 
cells when compared to pDCs incubated with 
empty PLGA particles and soluble TLR-Ls (Fig. 
5A). This indicates that pDCs efficiently 
present particulate antigen to T cells, resulting 
in antigen-specific proliferative recall 
responses. Furthermore, particulate FITC-TT 
and TLR-Ls induced higher TT-specific T cell 
proliferation than soluble FITC-TT co-
incubated with soluble TLR-Ls, indicating that 
pDCs are more efficient in inducing specific 
immune responses towards particulate than 
soluble antigens.  
In order to gain more insight in the 
polarization of the induced T cell responses, 
Th1 and Th2 cytokines were measured. We 
observed that responding T cells produced 
both Th1 and Th2 cytokines (IFN-γ, IL-6, IL-10) 
and the pro-inflammatory cytokine IL-8 (Fig. 
5B). The other analyzed Th1/Th2 cytokines 
were not detected or only detected in a small 
part of the culture supernatants. We 
observed the highest cytokine production in 
the T cell cultures incubated with pDC 
activated with co-encapsulated antigen and 
TLR-Ls (mean IFN-γ: 262 pg/ml, IL-6:193 
pg/ml, IL-8: 3274 pg/ml, IL-10: 169 pg/ml). T 
cells incubated with pDCs activated with 
empty PLGA and soluble TLR-Ls produced 30-
40% less cytokines. Also, T cell cultures 
incubated with pDCs activated with soluble 
antigen and TLR-Ls produced 30-60% less 
cytokines, indicating that uptake of 
particulate antigen/TLR-Ls is more potent in 
inducing T cell proliferation and cytokine 
production than their soluble counterparts. 
 
Figure 3 Human pDCs are activated by particulate TLR-Ls Human pDCs were incubated with PLGA particles containing the 
TLR-Ls CpG C and R848. Expression of the maturation markers CD80 and CD86 was measured by flow cytometry at 
different time points. Values represent the relative receptor expression compared to IL-3 pDCs. Data are expression 
values of one out of two independent experiments that showed similar results (A). Human pDCs were incubated with or 
without PLGA particles containing FITC-TT peptide only (PLGA-TT) or FITC-TT peptide, CpG C and R848 (PLGA-TT-R848-CpG 
C). In addition, pDCs were incubated with cytochalasin D (5 µM) or chloroquine (0.05 mM) before adding PLGA-TT-R848-
CpG C. Expression of the maturation markers CD80 (B), CD86 (C) and IFN-α (D) and IL-6 (E) production was measured after 
24 hrs. Data are mean values of at least 3 independent experiments ± SEM. Statistical analysis was determined by ANOVA 
and Newman-Keuls testing. *P<0.05, **P<0.01, ***P<0.001 
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Discussion 
Human pDCs are regarded as immune-
modulating cells and have been described to 
induce immunity (31), as well as to promote 
regulatory T cell-mediated immuno-
suppression (32,33). In this study, we 
investigated whether pDCs can play a role in 
immune responses against exogenous 
particulates. Up to now, it was highly 
controversial whether pDCs are able to 
respond to stimuli entrapped in particle-like 
structures (3,8,9,14,16-19). We here 
demonstrate that pDCs are clearly capable of 
phagocytosing antigen entrapped within PLGA 
microparticles and subsequent processing of 
the encapsulated antigen. Furthermore, pDCs 
sense TLR-Ls entrapped in microparticles, 
resulting in efficient pDC activation as 
reflected by upregulation of co-stimulatory 
molecules and high IFN-α production. Finally, 
phagocytosis of a particulate vaccine, 
containing both antigen and TLR-Ls, results in 
induction of antigen-specific CD4+ T cell 
responses. Our results provide evidence that 
human pDCs can play a role in induction of 
adaptive immune responses induced by 
stimuli derived from phagocytosed exogenous 
particle-like structures such as vaccine 
preparations, but possibly also bacteria and 
other microorganisms.  
The observation that uptake of particulate 
antigen by pDCs was partially blocked by 
cytochalasin D, an inhibitor of actin 
polymerization, demonstrates that the 
microparticles are at least in part taken up via 
phagocytosis, an actin dependent process. 
Similar results were obtained with monocyte-
derived DCs (moDCs) (34), indicating that 
internalization of microparticles by moDCs as 
well as pDCs is a dynamic process involving 
actin filaments. Endocytic receptors most 
likely mediate the internalization of PLGA 
microparticles (34), but the nature of these 
receptors and the exact mechanism remain to 
be elucidated.  
Several factors may explain the disparity 
between studies investigating whether pDCs 
are able to take up particle-like structures. 
First, the composition of the studied 
particulates (apoptotic cells, beads, bacteria 
or PLGA microparticles) is diverse and uptake 
might require different receptors and uptake 
mechanisms, some of which may not be 
exploited by pDCs. Furthermore, some studies 
compared the phagocytic capacity of pDCs to 
that of moDCs and found that pDCs showed 
very little to no uptake compared to moDCs 
(3,14,18). We also found that moDCs were 
superior to pDCs in phagocytosing particulate 
antigen (Supplementary Fig. 4), 
notwithstanding that almost all pDCs engulfed 
particles. Because of this five to tenfold lower 
phagocytic capacity of pDCs compared to 
moDCs (Supplementary Fig. 4), the methods 
used to quantify particle uptake must be 
relatively sensitive and may explain why some 
studies concluded that pDCs cannot 
phagocytose. This is reflected in our 
experiments where PLGA particles containing 
highly fluorescent DQ-BSA were detected in a 
higher percentage of pDCs after 24 hours than 
PLGA particles containing the less 
fluorescently labeled FITC-TT peptide. 
Furthermore, it should be noted that uptake 
of PLGA-encapsulated fluorescent molecules 
is likely underestimated, since fluorescence is 
Figure 4 Particulate TLR-Ls are superior 
to soluble TLR-Ls in activating human 
pDCs Human pDCs were incubated with 
particulate TLR-Ls (CpG C and R848) or 
an equal amount of soluble TLR-Ls. 
Expression of the maturation markers 
CD80 and CD86 (A) and IL-6 production 
(B) was measured after 24 hrs. Values 
of CD80 and CD86 represent the 
relative receptor expression compared 
to IL-3 pDCs. Data are mean values of at 
least 3 independent experiments ± 
SEM. Statistical significance was 
determined by Wilcoxon signed rank 
testing (A) or by ANOVA and Newman-
Keuls testing (B). *P<0.05, **P<0.01 
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quenched or shielded by the PLGA 
surrounding the fluorescent antigen. This 
notion was supported by the observation that 
upon in vitro degradation of PLGA, thereby 
releasing its fluorescent content, fluorescence 
levels increased 150-fold (Tacken et al, 
unpublished results).  
In accordance with studies performed with 
moDCs (21,35,36), human pDCs take up and 
present particulate antigen more efficiently 
than soluble antigen, resulting in enhanced T 
cell stimulation. This is presumably caused by 
controlled release of encapsulated antigen 
from the PLGA particle resulting in prolonged 
and more efficient antigen presentation 
compared to soluble antigen (21,36). 
Furthermore, ex-vivo antigen loading of 
moDCs using microparticles is also more 
efficient than external loading of peptides in 
MHC molecules. Because of the rapid 
turnover of MHC-peptide complexes on the 
cell surface, the duration of T cell stimulation 
in vivo is prolonged upon uptake of 
particulate antigen compared to external 
loading of peptides (36). Finally, particulate 
TLR-Ls induced efficient pDC activation 
comparable to activation induced by soluble 
TLR-Ls. Taken together, microparticles are 
well suited to deliver antigenic cargo and 
immunostimulatory molecules to pDCs, 
thereby inducing the activation of pDCs 
expressing all the necessary characteristics for 
optimal T cell activation. To this end, PLGA 
particles may be equipped with antibodies 
directed against endocytic pDC-specific 
surface receptors to target these cells in vivo 
(37-39). Targeting antigens to different 
subsets of DCs is only recently explored (40) 
and has already proven to enhance and 
modulate immune responses (37,40). Our 
observation that pDC can phagocytose 
particulate antigen may also contribute to the 
previously described ability of pDCs to 
enhance myeloid DC mediated antigen 
presentation (10). In the end, a combined 
particulate vaccine could be created that 
targets different appropriate antigens and 
immunostimulatory molecules to different 
subsets of DCs, that can subsequently act 
synergistically in inducing an optimal immune 
response. 
PDCs have been found in several types of 
tumors: head and neck cancer, ovarian 
cancer, primary melanoma cancer, and breast 
cancer (4).  In tumors, the presence of pDCs 
correlated with an unfavorable prognosis and 
 
Figure 5 Human pDCs present 
particulate antigen, resulting in 
antigen-specific T cell responses 
Human pDCs were incubated with 
PLGA particles containing FITC-TT 
peptide and the TLR-Ls CpG C and R848 
(PLGA-TT-R848-CpG C) for 18-24 hrs. As 
a control, pDCs were incubated with 
PLGA particles containing no peptide or 
TLR-Ls (PLGA) in combination with 
soluble TLR-Ls or a combination of 
soluble TT-peptide and soluble TLR-Ls. 
Subsequently, autologous TT-
responsive PBLs were added. After 4 
days, T cell proliferation was measured 
by 3H-thymidine incorporation (A). 
Cytokine production was measured 
after 4 days by cytokine bead array (B). 
Data were calculated by subtracting by 
the CPM of the background (TT-
responsive PBLs incubated with IL-3 
pDCs) from the CPM of the 
experimental wells. Data are mean 
values of 3 independent experiments ± 
SEM. Significance was determined by 
ANOVA and Newman-Keuls testing. 
**P<0.01, ***P<0.001 
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is thought to promote T cell tolerance rather 
than T cell activation. Most likely, pDCs are 
not properly activated upon uptake of tumor-
derived substances because of the lack of 
danger signals (12). Recent studies have 
shown that in vivo TLR triggering with TLR 
ligands, such as CpG, induced pDC activation, 
resulting in anti-tumor immunity and partial 
tumor regression (41-43). Furthermore, 
activated human pDCs pulsed with a tumor 
antigen primed IFN-γ secreting antigen-
specific CTLs (44). We here show that pDCs 
produce high levels of IFN-α and IL-6 and 
induce proliferative CD4+ T cell responses 
against a universal T-helper epitope upon 
phagocytosis of PLGA microparticles, 
containing peptide antigen and TLR-Ls. The TT 
peptide is frequently used in clinical trials as a 
helper T cell epitope to increase 
immunogenicity of a vaccine (45). Altogether, 
this indicates that PLGA microparticles might 
be a promising tool to efficiently load pDCs 
with tumor antigens and helper epitopes and 
simultaneously activate them by co-
encapsulated TLR-Ls, resulting in fully 
functional pDCs capable of stimulating anti-
tumor responses via both production of IFN-α 
and direct induction of antigen-specific T cell 
responses.   
The in vivo function of pDCs as antigen-
presenting cells remains controversial and 
functional outcomes of pDC-T-cell interactions 
largely depend on the immunological context 
of the encounter (46). Activated pDCs have 
been demonstrated to promote Th1 (31,46) 
as well as Th2 responses (32,33), underlining 
their remarkable functional plasticity. PDCs 
were shown to prime specific CD4+ and CD8+ 
lymphocytes against endogenous and 
exogenous antigens (15,47), viruses (48) and 
tumor antigens (44). By contrast, when 
activated by CpG-B pDCs demonstrate a 
strong immune suppression and induce the 
differentiation of allogeneic CD4+CD25- T cells 
into CD4+CD25+ regulatory T cells (32). There 
is evidence that the presence of IFN-α 
stimulates the differentiation of pDCs into 
Th1-inducing pDCs, whereas the absence of 
IFN-α and presence of inflammatory signals 
stimulate differentiation in Th2-inducing pDCs 
inhibiting the Th1-immune response (49). In 
our study, pDCs stimulated with PLGA-
encapsulated antigen and TLR-Ls produced 
high amounts of IFN-α and induced T-cell 
mediated production of both Th1 (IFN-γ) and 
Th2 cytokines (IL-10, IL-6). Perhaps, the fact 
that the model antigen TT used here is a recall 
antigen, and therefore likely stimulated 
memory T cells, may cause this cytokine 
profile. It is well conceivable that by both the 
antigenic load and the pDC activating stimuli 
encapsulated in these PLGA microparticles, T 
cell activation and the resulting cytokine 
profile can be modulated. The ability of 
human pDCs to cross-present antigens to 
CD8+ T cells remains controversial (16, 50). 
Whether human pDCs can cross-present 
particulate antigens and induce functional 
CD8+ T cells is yet unknown and needs further 
investigation.   
In conclusion, our findings reveal the capacity 
of pDCs to respond to particulate stimuli, 
indicating that pDCs can play a role in immune 
responses induced by particulates. This calls 
for further studies on the role pDCs play in 
clearing bacterial infections and handling 
current particulate vaccines. Furthermore, 
antibody coating of these particulate ‘vaccine 
carriers’ offers perspectives for targeting 
specific subsets of antigen presenting cells 
and may lead to the design of novel vaccine 
strategies actively recruiting pDCs for cellular 
immunotherapy. 
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Supplementary Figure 1 Morphology of PLGA 
microparticles as analyzed by scanning electron 
microscopy 
 
Supplementary Figure 2 Kinetics of uptake of particulate FITC-TT Human pDCs were incubated with or without PLGA 
particles containing FITC-labeled TT peptide. The uptake of particulate FITC-TT was measured by flowcytometry at 
different time points. The upper row of dotplots show the fluorescence intensity of pDCs after incubation with 
particulate FITC-TT. The lower row of dotplots show the fluorescence intensity of the matching IL-3 cultured pDCs. 
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Supplementary Figure 3 Concentration dependant blocking of particulate TLR-Ls induced pDC activation by 
cytochalasin D Human pDCs were incubated with different concentrations cytochalasin D before adding PLGA particles 
containing TLR-Ls CpG C and R848 (PLGA-TT-R848-CpG C). Expression of the maturation markers CD80 (A), CD86 (B) and 
IFN-α production (C) was measured after 24 hrs. Values of CD80 and CD86 represent the relative receptor expression 
compared to IL-3 pDCs. Data are mean values of at least 3 independent experiments ± SEM. Statistical significance was 
determined by ANOVA and Newman-Keuls testing. *P<0.05, **P<0.01, ***P<0.001 
Supplementary Figure 4 Uptake capacity of pDCs compared to monocyte-derived DCs Human pDCs (black lined 
histogram) and immature monocyte-derived DCs (grey lined histogram) were incubated overnight with PLGA containing 
DQ-BSA.  Fluorescence, caused by uptake and subsequent degradation of DQ-BSA, was measured by flowcytometry. The 
gray filled histogram represents pDCs incubated without particulate DQ-BSA. (A). Human pDCs (▲) or immature 
monocyte-derived DCs () were incubated with particulate DQ-BSA and fluorescence was measured 
spectrophotometrically during 48 hrs. As a control, fluorescence of pDCs only () and  immature monocyte-derived DCs 
only (▼) was measured (B). 
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A pessimist sees the difficulty in every opportunity;  
an optimist sees the opportunity in every difficulty 
Winston Churchill 
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Abstract 
Synthetic oligonucleotide ligands that bind to 
toll-like receptors are known to modulate the 
immune response via the activation of antigen 
presenting cells, and were therefore proposed 
as a novel form of vaccine adjuvant. Clinical-
grade they are, however, not readily available. 
Here, we show that commonly used 
prophylactic vaccines for infectious diseases 
like measles, mumps and tuberculosis exhibit 
the same immune modulating behavior as 
synthetic CpG oligonucleotides in terms of 
their ability to stimulate IFN-  production and 
plasmacytoid dendritic cell maturation. 
Featuring the additional advantages of low-
cost and proven safety, these vaccines could 
therefore be attractive alternatives to CpG 
oligonucleotides as adjuvants for 
immunotherapy. This previously undiscovered 
characteristic of prophylactic vaccines also 
sheds new light on the mechanisms by which 
they operate and is extremely interesting for 
vaccine development. Moreover, the finding 
that prophylactic vaccines trigger TLRs like 
synthetic oligonucleotides opens the 
possibility to predict the immune response of 
new vaccines. 
 
Keywords: CpG oligonucleotides ; vaccines ; 
plasmacytoid dendritic cells, TOLL receptors, 
immune response 
 
Introduction 
Tremendous progress has been made in the 
fight against infectious diseases through the 
use of vaccines. Despite their efficacy, the 
mechanism by which these universally applied 
vaccines potentiate the immune system has 
not been fully elucidated1. Dendritic cells 
(DCs) are among the first immune cells to 
encounter vaccines through their pathogen-
recognition receptors, of which Toll-like 
receptors (TLRs) are the most prominent 
subclass3. Plasmacytoid DCs (pDCs), which link 
innate with adaptive immune responses by 
secretion of interferon (IFN) and induction of 
costimulatory- and antigen presenting 
molecules, play a prominent role in the initial 
process of pathogen recognition4-6. Besides 
cytokine secretion needed for B- and T-cell 
activation, TLR-activated DCs present 
processed antigens to stimulate antigen-
specific T-cells, ultimately leading to long 
lasting pathogen-specific T-cell memory and 
protective antibody production by B-cells. 
Stimulatory effects of bacterial and viral 
DNA/RNA are ascribed to unmethylated CpG 
oligonucleotide motifs8-10. Based on these 
motifs, different classes of synthetic CpGs 
were designed to stimulate the immune 
system11. These synthetic CpGs mimic the 
immune-stimulatory effects of bacterial DNA 
and are recognized through TLRs. 
Classification of CpGs is based on the immune 
cell subsets that recognize the CpG motifs via 
TLR9, each subset corresponding to a 
different downstream effect12. In man, the 
different CpG subclasses are based on their 
immunological effect on purified B-cells and 
pDCs – the only cells in the peripheral blood 
that express substantial levels of TLR9 13. To 
date, three classes of chemically modified 
CpGs with different sequence motifs were 
developed: the A-, B- and C-classes, each 
having a different immune-stimulatory 
activity14. These chemically designed CpGs are 
explored for their potential therapeutic 
effects, f.e., in immunotherapy for cancer, 
allergies and infectious diseases15,16. 
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 Somewhat surprisingly, universally applied 
vaccines, which are known to contain RNA 
and DNA motifs, have not previously been 
explored in respect to their capacity to direct 
immune responses through TLR9. In this 
study, we identified vaccines used in everyday 
clinical practice that exhibit remarkably 
similar behavior to chemically synthesized 
CpG classes in being able to skew immune 
response towards either the innate or the 
adaptive immune system. Our results unfold a 
new application17 for these clinically approved 
and widely used therapeutic vaccines. The 
fact that these vaccines are also cheap, safe 
and readily available strongly supports their 
use as adjuvants, providing clinicians with a 
valid alternative to the currently expensive 
and difficult to obtain clinical grade synthetic 
TLR ligands. 
 
 
 
 
Materials and Methods 
 
Cells and reagents 
Cells were obtained from healthy volunteers 
according to institutional guidelines. PDCs 
were purified using anti–BDCA-4–conjugated 
magnetic microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and adjusted to 
106 cells/ml in X-VIVO-15 (Lonza, Basel, 
Switzerland) in 5% human serum, 
supplemented with 10 ng/ml IL-3 (Cellgenix, 
Freiburg, Germany), 5 µg/ml CpG-A (ODN 
2216), or CpG-B (ODN 2006), or CpG-C (M362) 
(Alexis Biochemicals, Lausen, Switzerland) or 
vaccines (1:10) listed in Table 1. 
 
Phenotype  
Flowcytometric phenotyping was performed 
using monoclonal antibodies and isotype 
controls: anti-HLA-ABC (W6/32), anti-HLA-
DR/DP (Q5/13) and anti-CD80 
(Becton&Dickinson, Mountain View, CA, USA); 
anti-CD83 (Beckman Coulter, Mijdrecht, 
Listed are the 15 vaccine formulations tested for their capacity to stimulate pDCs. Freshly isolated pDCs need a signal like IL-3 
to survive in vitro. Eight vaccines (Prevenar, Tetanus, NEISVAC-C, HAVRIX, HbVaxPro, Infanrix, Pneumo and Influvac) 
appeared not to provide this survival signal and the cells died within 16 h. These vaccines were excluded from further 
testing. Seven vaccines were able to provide a survival signal to the pDCs, of which five vaccines were stimulatory either 
measured by enhanced cytokine production or by the upregulation of CD80 and cell-surface major histocompatibility 
complexes (Figure 1A and B). To further enhance antibody responses, in some instances adjuvants are added to vaccine 
preparations. To exclude the possibility that these vaccine adjuvants play a major role in the observed pDC activation, 
vaccine preparations that share the same adjuvant were compared. Since neither all the vaccines containing aluminium 
hydroxide nor all the vaccines containing aluminium phosphate induced pDC activation, a prominent role for the adjuvants 
per se can be excluded. 
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 Netherlands), anti-CD86 (Pharmingen, 
SanDiego, CA, USA), followed by goat-anti-
mouse PE. 
 
Chloroquine, TLR9 antagonist, Single stranded, 
PMXB 
Cells received 50 M Chloroquine 30 min 
before stimulation with CpG-A, CpG-C or the 
vaccines. The TLR9 antagonist TTAGGG 
(Invivogen, San Diego, CA, USA) was used for 
inhibition of CpG-A and CpG-C responses. 
Single-stranded CpG-A and the vaccine MMR 
were prepared by heating at 95ºC for 5 min 
followed by flash cooling in dry ice for 10 min. 
CpG-B and the vaccines Act-Hib and BCG were 
mixed with polymyxin B (PMXB, Sigma-
Aldrich; 100 g/ml) and allowed to aggregate 
for 30 min at room temperature. 
 
Cytokine detection 
Supernatants were collected from stimulated 
pDCs after 16 h culturing. IFN-  was analyzed 
using standard ELISA procedures (BenderMed 
systems, Vienna, Austria). 
 
Cellular responses 
Allogeneic T cells were co-cultured with CpG-
C- or FSME-matured pDCs (pDC:T-cell ratio 
1:20 with 1*105 peripheral blood 
lymphocytes). After 4 days of culture, 1 
µCi/well of tritiated thymidine was added for 
16 h and incorporation was measured. 
T-cell responses against keyhole limpet 
hemocyanin (KLH) were measured in a 
proliferation assay. KLH-specific T-cells were 
isolated from blood of patients previously 
vaccinated with KLH-loaded monocyte-
derived DC. Lymphocytes were cultured with 
autologous pDCs with or without KLH and 
matured with CpG-C or FSME. After 4 days of 
culture, 1 µCi/well of tritiated thymidine was 
added for 16 h at day four and incorporation 
was measured. 
 
Statistics 
All cultures were performed in triplicate and 
results are shown as the mean ± SD. 
Significant difference from control according 
to Student’s t test. 
 
 
Results 
 
Prophylactic vaccines activate pDCs in 
distinct manners 
Fifteen vaccines were tested for their immune 
modulating capacity on pDCs 18. As freshly 
isolated pDCs need a signal to survive in vitro 
this characteristic was tested as well. In man 
pDCs have a restricted TLR expression profile 
(TLR7 and TLR9) and, because of their 
secretion of high levels of IFN- , have the 
ability to link innate and adaptive immunity. 
Seven vaccines sustain pDC survival in vitro 
similarly to the cytokine IL-3, a pDC survival 
factor. In addition to prolonging survival, 
FSME, MMR and Rabies vaccine induced IFN-
 production (Fig.1A). FSME, Act-Hib and BCG 
upregulated MHC class I and II molecules, 
which are important for antigen presentation 
on pDCs along prolonging pDC survival 
(Fig.1B). FSME and to a lesser extent Act-Hib 
and BCG increased the expression of co-
stimulatory molecules such as CD80, CD86 
and the DC maturation marker CD83 (Fig.1B). 
This latter mature phenotype is of significance 
since non-activated pDCs are 
immunosuppressive rather than immune 
stimulatory 19.  MMR and Rabies vaccines 
exhibited no maturation effect (Fig.1B). Two 
other vaccines, Stamaril and Typhim, neither 
induced IFN-α secretion nor phenotypical 
maturation (Fig. 1A and 1B).  
These vaccines behaved remarkably similar as 
IL-3 stimulation, resulting in pDC survival 
without IFN-α secretion or phenotypical 
maturation.  Compared to freshly isolated 
pDCs upregulation of costimulatory molecules 
for some of the vaccines is evident (Fig. 1C). 
So, we concluded that selected vaccines 
effectively stimulate pDCs and 
simultaneously, these vaccines modulate pDC 
phenotype and function. Some vaccine 
preparations induced high levels of IFN-  (e.g. 
Rabies) or induced an immunostimulatory DC 
phenotype (e.g. Act-Hib), whereas others 
exhibited a combination of these effects (e.g. 
FSME). 
 
Prophylactic vaccines activate pDCs in the 
same manner as CpG oligonucleotides      
Surprisingly, the various properties of selected 
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 vaccine affecting pDC function and phenotype 
are remarkably similar to those of 
synthetically generated TLR9 targeting CpG 
compounds and compounds such as 
imidazoquinolines (e.g. R848), loxoribine and 
Bropirimines synthesized for TLR7 triggering 
20,21. Similar to the Rabies and MMR vaccines, 
stimulation of pDCs with CpG-A leads 
exclusively to the production of IFN-  
(Fig.1A), whereas identical to Act-Hib and 
BCG, stimulation with CpG-B promotes 
upregulation of antigen presenting MHC 
molecules (Fig.1B), supporting adaptive 
immunity 13. Stimulation of pDCs with CpG-C 
or all other to date described ligands for TLR7 
leads to cytokine production and maturation, 
bringing together the two properties 
(stimulating antigen presentation and 
stimulation of adaptive immunity) 14, a 
Figure 1 Stimulation of pDC by vaccines pDCs were cultured with indicated vaccines (10% v/v) for 
16 h. (A) Supernatants were harvested and IFN-  production was evaluated. Averages of three 
independent donors are shown. (B) Cells were stained with mAbs against CD80, MHC class I and 
MHC class II. A representative experiment is shown (n=6). Increase in mean fluorescence intensity 
induced by the indicated vaccines, (bold line) compared to fresh pDCs (thin line) is shown. 
(C) Vaccines were tested for their capacity to provide a maturation signal. Cells were stained with 
mAb against CD80, MHC class I and MHC class II. Expression of CD80 and MHC molecules was 
compared to expression of those markers on freshly isolated pDCs. One representative experiment 
out of three is shown. 
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 phenomenon we observed for FSME (Fig.1A 
and 1B). 
 
Prophylactic vaccines activation of pDCs is 
mediated via TLR 
This similarity between synthetic TLR ligands 
and vaccines prompted us to investigate 
whether the vaccine induced effects were 
indeed TLR mediated. Since. chloroquine 
effectively prevents endosomal maturation 
through inhibition of vesicular acidification, 
which has been proven essential prerequisite 
for CpG-induced signals 9, pDCs were 
stimulated with vaccine preparations in the 
presence and absence of chloroquine. 
Treatment of pDCs with chloroquine 
completely abolished IFN-  secretion and 
maturation of vaccine-activated pDCs (Fig.2 A, 
B, C), indicating that the effects induced by 
the selected vaccines are similar to the 
synthetic TLR ligands and dependent on 
endosomal maturation. TLR9 specificity is 
supported by complete elimination of Rabies-, 
MMR- and FSME-induced IFN-  production by 
pDCs by TLR9 antagonist TTAGGG (Fig.2 C). 
Also, simultaneous incubation of the FSME 
vaccine and the TLR9 antagonist showed no 
further upregulation of the costimulatory and 
antigen presenting molecules (Fig.2A, 2B). 
Together, these findings strongly indicate that 
immunomodulation by these vaccines is 
mediated through TLR9. No effect of the TLR9 
antagonist was observed on Act-Hib/BCG 
vaccine-induced MHC expression on pDCs. 
This is in accordance with earlier observations 
that TLR9 antagonists can inhibit CpG-A and 
CpG-C but not CpG-B induced effects 22. 
Indeed, both Act-Hib and BCG show a CpG-B 
like type of response. CpG-C induces both IFN-
 and maturation of pDCs, resulting in a 
potent antigen presentation to induce T-cell 
proliferation. FSME-matured pDCs were 
similar to CpG-C matured pDCs in their 
capacity to induce allogeneic (Fig. 2D) as well 
as autologous (Fig. 2E) T-cell responses 7,23. 
This underscores the similarity between FSME 
vaccines and synthetic CpG-C.  
 
Activation of pDCs by vaccines follows 
distinct CpG subclasses 
The activity of Rabies and MMR corresponds 
with CpG-A, which binds to TLR-9 localized in 
transferrin receptor positive early endosomes. 
Induction of IFN-  by CpG-A is likely due to 
the ability of this subtype to form aggregates 
via its poly-G tail. Single stranded CpG-A loses 
Figure 2 Vaccines exert their effect on pDC via TLR9 similar to chemically synthesized CpGs based on chloroquine 
treatment A-C. Purified pDCs were activated with CpG-C or FSME either alone or in the presence of chloroquine or a TLR9 
antagonist. Relative surface expression of CD80 (A) and CD86 (B) and IFN-α (C)  production are depicted. Activation of 
pDCs by FSME/CpG-C (white bars) induced expression of both CD80 (A) and CD86 (B). In the presence of chloroquine (grey 
bars) or TLR-9 antagonist TTAGGG (black bars) the upregulation of these m lecules was diminished. Likewise, the 
production of IFN-α (C) induced by stimulation with CpG-C or FSME was largely inhibited by chloroquine treatment and 
the TLR9 antagonist. D, E. Purified pDCs activated with either CpG-C or FSME are able to induce T cell proliferation 
measured by tritiated thymidine incorporation in cpm. (D) Allogeneic T cell proliferation induced by differently activated 
pDCs depicted as stimulation index. (E) PDCs were purified with BDCA-4 beads from patient material previously 
v inated with KLH-loaded monocyte-derived DCs2 and cocultured with aut logou KLH-responsive PBLs. Due to he 
presence of antibodies, pDCs are able to take up KLH and present it in MHC class II 7. KLH specific T cell  proliferation 
depicted as stimulation index calculated over unloaded pDCs. 
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 this capacity to induce IFN-  production but 
acquires the competence to induce pDC 
maturation 24. To underscore the argument 
that the effects of Rabies and MMR vaccines 
on pDCs are identical to those of synthetic 
CpG-A, Rabies and MMR were rendered single 
stranded. We demonstrated that single-
stranded MMR indeed resulted in a significant 
decrease in IFN-  production and enhanced 
phenotypic maturation (Fig.3A, B). Therefore, 
the ability of MMR to induce IFN-  directly 
depends upon multimeric structures, 
demonstrating the similarity between MMR 
and synthetic CpG-A. 
Along the same lines, Act-Hib and BCG 
vaccines share the same properties as CpG-B: 
very low IFN-  production although induction 
of pDC maturation (Fig 3C).  CpG-B in a 
Figure 3 Vaccines exert their effect on pDC via TLR9 similar to chemically synthesized CpGs based on quarternary state 
A-D. Purified pDCs were activated with the indicated CpGs or vaccines either alone or in the presence of chloroquine and 
TLR9 antagonist, after the stimuli were made single-stranded or were complexed with PMXB. (A) Expression of 
costimulatory molecules CD80 and CD86 and DC-specific molecule CD83 was not enhanced by stimulation with the MMR 
vaccine (white bars). Since the MMR vaccine by itself does not induce phenotypical maturation, the molecule expression 
levels were set at 1. Upon heating and flash cooling, the MMR vaccine was made single-stranded (black bars) and 
thereby gained the capacity to induce a mature phenotype characterized by the upregulation of CD80, CD83 and CD86 by 
pDCs. (B)  IFN-a production by pDCs induced by CpG-A or the vaccines Rabies and MMR (white bars) was completely 
inhibited by chloroquine treatment (light grey bars), TLR9 antagonist (dark grey bars) and after CpG-A and MMR were 
made single-stranded (black bars). The Rabies vaccine could not be made single stranded because it became semi-solid 
after heating and flash cooling (n.a. not analyzable). (C-D) CpG-B and the vaccines Act-Hib and BCG (white bars) induced 
phenotypical activation by upregulation of CD80, CD86, MHC class I and II (C) pDCs were hardly able to induce IFN-a 
production (D) After complexing with PMXB (black bars) these stimuli lost the capacity to induce full phenotypical 
activation (C), but gained the capacity to induce high levels of IFN-a production by pDCs (D). 
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 monomeric form localizes to LAMP-1-positive 
late endosomes 25. TLR9 ligands present in 
these endosomal compartments induce pDC 
differentiation. Complexing CpG-B molecules 
in large microparticles transforms this 
component into a potent inducer of IFN-  24. 
To extend the equivalence between CpG-B 
and the vaccines Act-Hib and BCG, they were 
mixed with polymyxin B (PMXB), resulting in 
large structures. Completely in line with CpG-
B, this PMXB treatment transformed the Act-
Hib and BCG vaccines into potent inducers of 
IFN-  and eliminated their ability to induce 
pDC maturation (Fig. 3D). Taken together, the 
vaccines Act-Hib and BCG are therefore 
equivalents of synthetic CpG-B. 
 
Discussion 
For decades vaccines have been proven 
invaluable in the fight against major infectious 
diseases. Despite their efficacy, limited 
information is available on the precise 
immunological mechanisms exploited by 
universally used vaccines 1. We investigated 
15 commonly used prophylactic vaccines for 
their immune modulating capability and their 
subsequent downstream effects on pDCs 18. In 
man pDCs have a restricted TLR expression 
profile (TLR7 and TLR9) and, because of their 
secretion of high levels of IFN- , have the 
ability to link innate and adaptive immunity. 
Triggering of TLR9 by vaccines and CpG 
oligonucleotides could be assigned to the 
same signaling pathways (Fig. 4). The effect 
on pDC of the prophylactic vaccines for Rabies 
and Mumps/ Measles/Rubella (MMR) 
corresponds with that of CpG-A, which binds 
to the early endosomes of TLR-9 and 
therefore induces IFN-  production by pDC 
and lacks the ability to induce pDC 
maturation. Recently, a fortified Rabies 
vaccine showed a better response due to the 
addition of CpG ODN (BW006), a CpG type B 
oligonucleotide responsible for pDC 
maturation 26. This indicates that the intrinsic 
CpG type A property of the vaccine is 
effectively upgraded by adding a synthetic 
CpG-B oligonucleotide. Recently, a huge list of 
vaccines was described that induced TLR 
activation, in all those cases this is due to 
addition of synthetic TLR ligands to the 
vaccine and not based on TLR activation by 
the vaccine itself 27. Completely in line is the 
finding that after hepatitis B prophylactic 
vaccination the antigen specific immunity is 
enhanced in the presence of CpG compared 
to the vaccine alone 28. Noteworthy is that the 
here tested hepatitis vaccine alone was not 
Figure 4 Signaling pathways exploited by the different prophylactic vaccines and CpG oligonucleotides. 
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 able to trigger a CpG-like response (Fig. 1). 
Prophylactic vaccines for meningitis and 
tuberculosis, Act-Hib and BCG, mimic CpG-B 
and traffic to late endosomes resulting in 
solely maturation of pDC. BCG-primed mice 
demonstrated a better protection against a 
challenge with Mycobacterium tuberculosis 
when a booster of BCG proteins 
supplemented with CpG-A was given 29. Again 
this shows that a combination of CpG, one 
attributed to the vaccine and one synthetic, 
has a synergistic effect. CpG-C is localized in 
both early- and late- endosomes and this 
location in specific organelles in pDCs 
resulting in both maturation and IFN-  
production. Based on the same type of 
reactivity as CpG-C we speculate that 
components of the FSME vaccine also reach 
both types of endosomes and this may play an 
important role in determining the nature of 
the immune response. Activation of pDCs and 
subsequent secretion of IFN-  has been 
demonstrated to activate natural killer cell 
lysis of tumor cells in vivo. Released tumor 
antigens will be phagocytosed by IFN- -
matured macro-phages. Furthermore, IFN-  
secreted by pDCs is known to promote cross-
presentation of tumor antigens by myeloid DC 
and induce T and B cell activation and survival 
30. Therefore, components such as FSME, with 
its dual effect on the immune response are 
extremely interesting for cancer vaccine 
development 31. Moreover, newly developed 
prophylactic vaccines can now be tested and 
classified into CpG subclasses and based on 
this their reactivity can be predicted or be 
optimized by the addition of synthetic CpG 
components. 
An obvious way to test the involvement of 
TLRs in the activation as seen with the 
vaccines is to use murine dendritic cells 
obtained from TLR knockout mice. However, 
murine DC show a complete other DC 
maturation profile when induced by the 
different vaccines (data not shown). This fits 
with the recent finding that in man nickel 
allergy is mediated via TLR4 while in mouse it 
is not 32. The currently valid paradigm is that 
TLR9 exclusively responds to unmethylated 
CpG DNA motifs found in certain bacteria and 
viruses 9. However recent findings indicated 
that the yellow fever virus (YF-17D), a single-
stranded RNA virus, induced DC activation 
was reduced in TLR9−/− DCs1. This raised the 
question whether contaminating DNA was 
present leading to DC activation. To exclude 
this possibility Querec et al. showed that 
DNase treatment of the YF-17D virus had no 
effect on the ability to induce IFNα secretion 
by DCs 1. These data in combination with the 
finding by Kato et al. that the Newcastle 
Disease virus, another single-stranded RNA 
virus, also activated DCs through TLR7 and 
TLR9, support the notion that TLR9 may not 
only recognize unmethylated, CpG-rich DNA, 
but also other microbial or viral derived 
components 33. Support for non-classical 
triggering of TLRs comes from recent 
evidendence that Ni2+ ions bind to TLR4 at a 
different location than its natural ligand LPS 
but display the same effects 32. Differences in 
CpG motifs in RNA due to different 
propagation can be excluded because CpG 
RNA does not induce IFN-  10. Apart from this 
concept, it is also important to bear in mind 
that commonly used vaccines not only contain 
viral or bacterial derived products, but also 
cellular contaminants derived from the cell 
lines in which the vaccines were generated 
1,34,35. These co-passengers in vaccine 
preparations can potentially induce immune 
activation, at first glance ascribed to the viral 
or bacterial components. This could in part 
explain the observation that in our hands the 
vaccine Stamaril does not induce human pDC 
activation (Fig. 1A, 1B), whereas Yellow fever 
propagated in the SW480 colon carcinoma 
cell line and purified by sucrose gradient 
centrifugation appeared  to evoke an 
abundant IFN response when incubated with 
PDCs 1,36. Those differences in propagation 
methods (chicken eggs versus a cell line) 
apparently can induce different TLR triggering. 
Since Yellow fever binds to heparin sulfate 
glyco-aminoglycans 37, the different 
glycosaminoglycan make-up of the human 
colon cancer cell line versus the chicken cells 
could cause this difference. 
To the best of our knowledge, we show for 
the first time that vaccines, apart from their 
antigen content, have a very explicit action on 
the immune system and behave remarkably 
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 similar as synthetic CpG-ODN-subclasses. This 
knowledge and the fact that vaccine 
preparations are cheap, safe and readily 
available may revitalize and broaden interest 
in the use of commonly used vaccines as 
adjuvants in vaccination studies aimed at the 
treatment of cancer, allergy and auto-
immunity 31,38. 
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Abstract  
Human plasmacytoid dendritic cells (pDCs) 
represent a highly specialized naturally 
occuring dendritic cell subset and are the 
main producers of type I interferons (IFN) in 
response to viral infections. We show that 
human pDCs activated by the preventive 
vaccine FSME specifically upregulate CD56 on 
their surface, a marker which was thought to 
be specific for NK cells and associated with 
cytolytic effector functions. We observed that 
FSME-activated pDCs specifically lysed NK 
target cells and expressed cytotoxic molecules 
such as TRAIL and granzyme B. Elevated levels 
of these molecules coincided with the 
expression of CD56, indicative for skewing 
human pDCs towards an interferon producing 
killer DC subset. Detailed phenotypical and 
functional analysis revealed that pDCs 
attained a mature phenotype, secreted pro-
inflammatory cytokines and had the capacity 
to present antigens and stimulate T cells. We 
here report on the generation of CD56+ 
human interferon producing killer 
plasmacytoid DCs with the capacity to present 
antigens. These findings aid in deciphering the 
role for pDCs in anti-tumor immunity and 
present a promising prospect of developing 
anti-tumor therapy using pDCs. 
 
Introduction 
Plasmacytoid dendritic cells (pDCs) are one of 
two major subsets of human DCs that 
circulate in the peripheral blood, and are 
characterized as BDCA-2+BDCA-
4+CD4+CD45RA+IL-3R +ILT3+ILT1-CD11c-lin- 
cells1,2. Upon viral stimulation and subsequent 
TLR-mediated signaling, human pDCs produce 
large amounts of type I IFNs (IFN-α/β) that 
stimulate T cell function of the Th1 type, 
stimulate NK cell cytolytic activity and 
promote differentiation and maturation of 
myeloid DCs3-5. In addition to scavenging 
pathogens and presenting antigens, pDCs 
secrete a large array of cytokines, which are 
all vital for proper functioning of both the 
acquired and the innate immune system. PDC-
derived type I IFNs are important for antiviral 
immunity, but also play a role in bacterial 
infections, allergy and anti-cancer immunity6-
8. In a resting state pDCs might induce 
unbiased Th, Th2 or regulatory responses 
whereas their activated equivalents have 
stimulatory capacities and trigger Th1 
responses9,10. Salio et al. demonstrated in 
vitro priming of naïve CD8+ T cells into 
melanoma specific CD8+ CTLs by CD40L 
activated pDC pulsed with short melanoma 
peptide11. In addition, Vicari et al. 
demonstrated murine anti-tumor CTL 
responses and tumor rejection in vivo after 
activating DCs with anti-interleukin (IL)-10 
mAb and CpG ODN12. Although pDCs generally 
circulate in the periphery they infiltrate tissue 
and organs in case of infections or 
inflammation13. Moreover, pDCs are also 
reported to infiltrate tumor lesions in head 
and neck cancer, lung cancer, breast cancer, 
ovarian cancer and skin cancer11,14-16. These 
tumor-infiltrating pDCs, which appear to be in 
a tolerogenic state contribute to the 
suppressive tumor microenvironment via the 
generation of regulatory T cells16 and are 
correlated with poor prognosis15,17. 
Nevertheless, Stary et al. elegantly 
demonstrated that topical imiquimod 
treatment, a TLR7 agonist, induced the 
activation of human tumor-infiltrating pDCs 
that exhibited tumoricidal activity and led to 
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 tumor clearance18. The existence of a hybrid 
cell type in mice that unifies DC and NK cell 
characteristics and functions was first 
described in 2006 by Taieb et al. and Chan et 
al.19,20. These natural killer DCs (NKDC) or 
interferon producing killer DCs (IKDC) exert 
the capacity to present antigens, to secrete 
cytokines and to have a cytotoxic effect, 
largely mediated by the expression of tumor 
necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL)19-22. Some studies 
demonstrated that human DCs, under 
appropriate stimulation conditions, can 
acquire cytotoxic effector functions. However 
in most cases these effector functions appear 
to be inferior compared to that of the more 
traditional cytotoxic immune cells (NK cells or 
cytotoxic T cells)18,22-28. Previously, we 
observed that commonly used preventive 
vaccines can activate human pDCs29. In this 
study we observed that human pDCs 
activated by the tick-borne encephalitis 
vaccine FSME specifically upregulated CD56 
surface expression, a classical marker for NK 
cells30. During the last decade, CD56 
expression was also reported on NKT cells31, 
activated T cells and IFNα cultivated 
monocytes22,32. The functional significance of 
CD56 expression on immune cells remains 
elusive. Interestingly expression of CD56 is 
often observed on immune cells with cytolytic 
activity. Our findings indicate that high 
expression of CD56 on FMSE-activated pDCs 
coincided with elevated levels of PD-L1, 
granzyme B and TRAIL. More importantly, 
FSME-activated pDCs were endowed with 
strong tumoricidal activity. The acquisition of 
NK cell behavior by pDCs adds an important 
effector function to the diverse repertoire of 
pDC functions and might have major 
implications on the functional role of tumor-
infiltrating pDCs. 
 
Material & methods  
Cells 
Buffy coats were obtained from 
healthy volunteers and PBMCs were obtained 
from patients enrolled in ongoing clinical trials 
after informed consent according to 
institutional and international guidelines. 
pDCs were purified by positive isolation using 
anti–BDCA-4–conjugated magnetic 
microbeads (Miltenyi Biotec, Bergisch-
Gladbach, Germany) and adjusted to 106 
cells/ml in X-VIVO-15 (Lonza, Verviers, 
Belgium) supplemented with 2% human 
serum (Sanquin, Nijmegen, The Netherlands). 
NK cells were purified by non-NK cell 
depletion (Miltenyi Biotec). NK cell and pDC 
purity was routinely up to 95%, as assessed by 
double staining with CD3/CD56 (Becton 
Dickinson) or BDCA-2/CD123 (Miltenyi 
Biotec). PDCs were activated through the 
addition of 10 ng/ml IL-3 (Cellgenix, Freiburg, 
Germany), 5 μg/ml ODN-CpG-C (M362, 
Axxora, San Diego, CA), 4 μg/ml R848 (Axxora, 
San Diego, CA), 10% v/v FSME-IMMUN® 
(Baxter AG), 10% v/v BMR (mumbs-measles 
and rubellavaccine, Nederlands Vaccin 
Instituut [NVI]), 10% v/v Rabies (Sanofi 
Pasteur MSD), 10% v/v Act-Hib (Aventis 
Pasteur) and 10% v/v BCG (NVI). After 
overnight incubation FSME-pDCs were sorted 
based on CD56 expression and CD56high- and 
CD56low- FSME-pDCs were used in a MLR and 
cytotoxicy assay where indicated. 
 
Phenotype 
The phenotype of the pDC 
populations was determined by flow 
cytometry. The following primary monoclonal 
antibodies (mAbs) and appropriate isotype 
controls were used: anti-BDCA2-PE and 
CD123-APC (both Miltenyi Biotec); anti-HLA-
ABC-PE, anti-HLA-DR/DP-FITC, anti-CD80-PE, 
anti-CD83-PE, anti-CD86-PE, anti-CD86-APC, 
anti-PD-L1-PE (all BD Bioscience Pharmingen, 
San Diego, CA, USA); anti-TRAIL-PE 
(eBioscience, Halle Zoersel, Belgium); anti-
Granzyme-B-PE (Sanquin); anti-ICOS-L-
Alexa488 (AbD Serotec); anti-CD40-PE 
(Beckman Coulter, Mijdrecht, the 
Netherlands). 
 
Mixed lymphocyte reaction 
The allostimulatory capacity of the 
pDC was tested in a mixed lymphocyte 
reaction (MLR). Allogeneic T cells were co-
cultured with differently matured pDCs in a 
96-well round bottom plate (pDC:T cell ratio 
1:20  or 1:100 with 1x105 PBLs (peripheral 
blood leukocytes)).  After 4 days of culture, 1 
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 µCi/well of tritiated thymidine (GE Healthcare, 
Eindhoven, The Netherlands) was added for 
16 h and incorporation was measured in a 
beta-counter. 
 
Specific KLH responses 
Cellular responses against the protein 
keyhole limpet hemocyanin (KLH) were 
measured in a proliferation assay. Peripheral 
blood mononuclear cells (PBMC) were 
isolated from blood samples taken from 
patients who received vaccination with KLH 
loaded mature monocyte-derived DCs 
(moDCs). CD4+ T cells were isolated with a 
CD4+ T cell isolation kit (Miltenyi Biotec) 
according to the manufacturer’s instructions. 
Purified T cells were plated in a 96-well tissue 
culture microplate with autologous pDCs that 
were cultured with or without KLH and 
matured with IL-3, CpG-C or FSME-IMMUN®. 
After 4 days of culture, 1 µCi/well of tritiated 
thymidine was added for 16 h and 
incorporation was measured in a beta-
counter. 
 
Generation of CD45RA+CD8+ gp100-specific T 
cells  
The vectors pGEM4Z-TCR 296 and 
pGEM4Z-TCRß296 encoding the TCR (T cell 
receptor)  and ß chains originating from a 
gp100:280-288/HLA-A2-specific CTL (cytotoxic 
T lymphocyte) clone were a kind gift from Dr. 
N. Schaft (University Hospital Erlangen, 
Germany). Gp100-specific T cells were 
generated by transferring the TCR  and ß 
chain to T cells by electroporation of mRNA, 
resulting in transient expression of the TCR 
chains as described previously33. Briefly, the 
DNA vectors were linearized with SpeI 
enzyme and purified by phenol/chloroform 
extraction and ethanol precipitation, and used 
as DNA templates for in vitro transcription. In 
vitro RNA synthesis was done with T7 RNA 
polymerase (mMESSAGE mMACHINE T7 kit; 
Ambion, Austin TX, USA) according to the 
manufacturer’s instructions. After DNase 
treatment, RNA was purified by 
phenol/chloroform extraction and 
isopropanol precipitation. RNA concentration 
was measured spectrophotometrically and 
the RNA was stored at -20 ºC. RNA quality was 
verified by agarose gel electrophoresis. 
CD8+CD45RA+ T cells were isolated 
from PBMCs from an HLA-A2.1 positive donor. 
Monocytes were removed via adherence and 
CD8+ T cells were isolated from the non-
adherent cell population by positive isolation 
using FITC-conjugated anti-human CD8 (BD 
Biosciences, San Jose, CA, USA) and anti-FITC 
microbeads (Anti-FITC Multisort kit, Miltenyi 
Biotec, Auburn, CA, USA) according to the 
manufacturer’s instructions. Subsequently, 
CD45RA+ T cells were isolated from the CD8+ T 
cell fraction by negative selection using 
CD45RO microbeads (Miltenyi Biotec). Purity 
of CD8+CD45RA+ T cells was 90-95%, as 
assessed by double staining using FITC-
conjugated anti-human CD8 and PE-
conjugated anti-human CD45RA mAbs (BD 
Biosciences). 
For RNA electroporation, the 
CD45RA+CD8+ T cells were washed once with 
PBS and once with OptiMEM without phenol 
red (Invitrogen Gmbh, Karlsruhe, Germany). 
10-12x106 cells were incubated for 3 min with 
15-20 µg of RNA in 200 µl OptiMEM in a 4-mm 
cuvette (Bio-Rad, Munich, Germany). 
Subsequently, cells were pulsed in a 
Genepulser Xcell (Bio-Rad). Pulse conditions 
were square-wave pulse, 500 V, 5 ms. 
Immediately after electroporation, the cells 
were transferred to X-VIVO-15 medium 
without phenol red (Cambrex) supplemented 
with 2% human serum. After 4 h incubation at 
37°C, cells were washed and frozen in fetal 
calf serum (FCS) and 10% (dimethyl sulfoxide) 
DMSO in liquid nitrogen. Expression of the 
gp100 TCR in the T cells was verified by flow 
cytometry using PE-conjugated anti-TCRVß14 
mAb (Coulter Immunotech, Marseille, France).  
 
Gp100-specific activation of CD45RA+CD8+ T 
cells  
PDCs from a HLA-A2.1+ donor were 
activated overnight with different maturation 
stimuli and then loaded with either specific 
peptide (gp100280-288) or control peptide 
(tyrosinase369-377) for 1h (1 μg/7x10
3 pDCs). 
PDCs (7x103 per well) were washed and co-
incubated with CD45RA+CD8+ gp100280-288-
specific autologous T cells (5x104 per well) in 
Plasmacytoid DC in cancer & cancer therapy
94
 round-bottom 96-well plates. After overnight 
incubation, CD69 expression was measured by 
flow cytometry using FITC-conjugated mouse 
anti-human CD69 (BD Pharmingen), and IFN  
production was measured using a standard 
sandwich ELISA. After 4 days of culture, 1 
μCi/well of tritiated thymidine was added for 
8 h, and incorporation of tritiated thymidine 
was measured in a beta-counter.  
 
Cytokine detection 
Supernatants were collected from 
pDC cultures after overnight stimulation, and 
IFNα production was analyzed with murine 
monoclonal capture and HRP-conjugated anti-
IFNα antibodies (BenderMed Systems, Vienna, 
Austria) using standard ELISA procedures. 
To analyze the T helper cell profile, 
supernatants were collected after 2 days of 
pDC-PBL coculture. Cytokine production (IL-
1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p70), 
TNF , TNFβ, IFN ) in the supernatant was 
analyzed with a human Th1/Th2 Multiplex kit 
(eBioscience) according to the manufacturer’s 
instructions.  
 
Cytotoxicity assay 
Killing of target cells was determined 
using a flow cytometric cytotoxicity assay34. 
K562, Jurkat, MEL624, Daudi and Glioma cells 
were labeled with PKH67 according to the 
Figure 1 FSME induces pDC maturation Human pDCs were incubated overnight with IL-3, CpG-C, R848 or FSME and the 
expression of various molecules was measured by flow cytometry. The graphs show the percentage (A) and the mean 
fluorescence intensity (MFI) (B) expression levels of surface molecules CD40, CD80, CD83, CD86, PD-L1, TRAIL, ICOS-L, 
MHC class I and II expression and intracellular granzyme B. The data are mean values ± SEM of at least 5 independent 
experiments with different donors. Supernatants of pDC cultures following incubation with IL-3,  CpG-C, R848 or FSME 
were analyzed for the presence of IFN  (C), IL-6 (D, left) and TNF  (D, right). Data shown are mean values of at least 5 
independent experiments ± SEM. 
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 manufacturer’s instructions (Sigma, Bornem, 
Belgium). PDCs or NK cells were cocultured 
with 5 x 103 PKH67-labeled K562 cells at 
different effector cell:target cell (E:T) ratios in 
200 µl IMDM (Invitrogen, Merelbeke, 
Belgium) supplemented with 10% fetal bovine 
serum (Perbio Science, Erembodegem, 
Belgium) in the presence of IL-2 (Invitrogen). 
Positive controls consisted of 1 x 104 NK-92 
cells cocultured with 1 x 104 K562 cells in the 
presence of 200 U/mL IL-2, negative controls 
of target cells without effector cells. After 
overnight cocultures, cell viability was 
measured following staining with propidium 
iodide (Sigma) and annexin V-APC or annexin-
V Fitc (BD Pharmingen, Erembodegem, 
Belgium) in annexin V-binding buffer (BD). 
Flow cytometric measurements of target cell 
viability were performed on a FACSAria flow 
cytometer (BD) or FACSCalibur (BD) and 
analyzed using FlowJo software (Tree Star, 
Ashland, USA). Specific killing of target cells 
was depicted relatively to the viability of 
target cells without effector cells, according to 
the formula34: 
 
 
 
 
 
Figure 2 Activated pDCs are potent stimulators of both CD4+ and CD8+ T cells Proliferation of T cells was measured by 3H-
Thymidine incorporation and depicted as proliferation in counts per minute. (A) 1x10
5
 peripheral blood leucocytes were 
stimulated for 4 days with either 5x10
3
 or 1x10
3 
allogeneic pDCs. IL-3-pDCs evoke lower T cell proliferation compared to 
pDCs activated with either CpG-C or FSME vaccine. The left graph shows the pDC:PBL ratio 1:20 and the right graph 1:100. 
Data are the mean values ± SEM of three independent experiments with different donors. (B)  1x10
5
 CD4
+
 T cells were 
stimulated with 5x10
3
  KLH loaded (black bars) and unloaded (blank bars) autologous pDCs. We loaded pDCs with KLH by 
using serum that contained KLH specific antibodies. KLH loaded pDCs were highly capable of inducing proliferative KLH-
specific recall responses. Data shown are the mean values ± SEM of one representative experiment. (C) Cytokine production 
by autologous T cells after stimulation was analyzed by a cytokine bead array and production is depicted in pg/ml. (D,E,F) 
Naïve CD45RA
+
CD8
+
 T cells specific for gp100280-288 were co-cultured with autologous pDCs activated through CpG-C or FSME 
vaccine and loaded with either gp100280-288 (black bars) or the irrelevant tyrosinase peptide (grey bars). After 16 hours of co-
culture, antigen-specific activation of CD8
+
 T cells was analyzed by measurement of CD69 (D) surface expression and by 
secretion of IFN  in the supernatant (E). Antigen-specific T cell proliferation was measured after 4 days of culture (F). Data 
shown are mean values ± SEM of one representative experiment out of 2 independent experiments performed with 
different donors. 
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 Cytotoxicity mechanism studies 
Cytotoxicity blocking experiments were 
performed as described above, except that 
effector cells (FSME-pDCs) were pre-
incubated at 37°C with either neutralizing 
CD56 mAbs (20 μg/0.5x106 pDCs), TRAIL mAbs 
(20 μg/0.5x106 pDCs; R&D Systems) or the 
perforin/granzyme-B inhibitor concanamycin 
A (100 nM/ 0.5x106 pDCs; Tocris Bioscience, 
Bristol, UK) before start of co-culture with 
PKH67-labeled K562 target cells. Control 
experiments were run in parallel using TRAIL 
isotype control mAbs (mouse IgG1, R&D 
Systems). K562 cells were added at an final 
E:T ratio of 20:1. Additionally, K562 cells were 
incubated with FSME-pDCs supernatant. 
Furthermore, 5 μm pore size polycarbonate 
membranes (Costar, London, UK)  were 
placed upon an aliquot of 600 μl RPMI 
medium containing 5 x 103 K562 cells. A total 
of 1x105 FSME-pDCs in 100 µl culture medium 
were seeded in the upper compartment and 
incubated for 18 hours to assess killing of 
K562 cells by soluble factors.  
 
Statistics 
All experiments were performed at least three 
times and results are shown as the mean ± 
SEM. Data sets were tested by a One-way 
ANOVA followed by the post-hoc test Tukey’s 
multiple comparison test or Dunnett test. 
 
Results  
 
FSME-IMMUN activates human pDCs 
Previously, we demonstrated that 
human pDCs can be stimulated by the 
preventive vaccine FSME29. Here we studied in 
more depth how FSME stimulation differs 
from the known pDCs stimuli IL-3 as well as 
the TLR7 and TLR9 agonists, R848 and CpG-C 
C, respectively. In accordance with 
literature28,35, we showed that pDC 
maturation was associated with high 
expression of CD40, CD80, CD83, CD86, PD-L1, 
TRAIL, ICOS-L, MHC class I and II and low 
expression of granzyme B (Figure 1A,B). IL-3 
stimulated pDCs had high expression of 
granzyme B, lower levels of CD40, CD80, 
CD83, CD86 and were negative for PD-L1 and 
TRAIL (Figure 1A,B). Human pDCs activated by 
FSME upregulated the costimulatory 
molecules CD40, CD80 and CD86 and the 
maturation marker CD83 to comparable levels 
as IL-3 stimulated pDCs (Figure 1A,B). 
Moreover, FSME-pDCs as well as TLR-
activated pDCs showed upregulated levels of 
PD-L1 and TRAIL (Figure 1A,B). On the other 
hand, granzyme B expression was higher in 
FSME-stimulated pDCs compared to TLR-
activated pDCs, and lower as compared to IL-
3-pDCs (Figure 1A,B). Furthermore, pDC 
activation with the TLR agonists or FSME led 
to the secretion of type I IFN (Figure 1C), IL-6 
Figure 3 FSME induces CD56 expression on human 
pDCs Human pDCs were incubated with various 
stimuli as indicated and the expression of CD56 was 
studied by flow cytometry. (A) The grey filled 
histograms show the expression of CD56 on pDCs 
after overnight stimulation compared to isotype 
control (black lined histograms). Data shown are of 
one representative experiment out of 3 performed. 
(B) The graphs show the percentage (left graph) and 
MFI (right graph) of CD56 expression on human 
pDCs after overnight stimulation.              ; overnight 
FSME stimulation with 10% v/v, 5% v/v and 2,5% v/v 
Data shown are mean values ± SEM of at least 4 
independent experiments performed with different 
donors. 
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 and TNFα (Figure 1D). Taken together, FSME, 
a preventive vaccine for tick-borne 
encephalitis virus infections, activates human 
pDCs. 
 
Activated pDCs are potent stimulators of T 
cell responses 
T cell expansion and activation is a 
crucial step in generating effective immune 
responses. All activated pDCs displayed a 
mature phenotype (Figure 1), therefore we 
determined the immunogenic capacity of the 
differently activated pDCs. CpG-C-pDCs 
induced stronger allogeneic T cell responses 
than both IL-3-cultured and FSME-pDCs 
(Figure 2A). Interestingly, lower numbers of 
FSME-pDCs (ratio 1:100) induced lower T cell 
responses then higher numbers (ratio 1:20; 
Figure 2A). Furthermore, both FSME-pDCs and 
CpG-C-pDCs were capable of stimulating 
antigen-specific autologous T cells as 
demonstrated by the KLH-specific 
proliferation of T cells from patients that had 
previously been vaccinated with KLH-loaded 
DCs (Figure 2B)36-38. In order to investigate 
whether the stimulated pDCs induced a Th1 
type effector response, we analyzed the 
cytokines in supernatants of the KLH 
response. FSME-pDCs and CpG-C-pDCs 
induced the secretion of high levels of IFN  
and TNF  by PBLs (Figure 2C). Differences 
between antigen-specific T cell cytokine 
production after pDC stimulation with FSME 
or CpG-C, were observed for IL-5 and IL-2. The 
production of IL-5 was slightly increased 
whereas IL-2 was decreased upon stimulation 
with FSME-pDCs compared to CpG-C-pDCs 
(Figure 2C). Taken together, activated pDCs 
Figure 4 CD56
high
 pDCs express higher levels of 
granzyme B, TRAIL and PD-L1 (A) The dotplots show 
(A) The dotplots show the gating strategy used to 
identify and distinguish CD56
low
 and CD56
high
 
expressing FSME-pDCs. Based on the gating strategy, 
phenotypical characterization was performed to study 
the percentage (B) and MFI (C) of the various 
molecules expressed by FSME-pDCs. (D) 1x10
5
 
peripheral blood leucocytes were stimulated for 4 
days with either 5x10
3
, 2x10
3
, 1x10
3
 or 0.5x10
3 
allogeneic CD56
high
 or CD56
low
 FSME-pDCs. (B,C,D) 
Data shown are mean values ± SEM of at least 3 
independent experiments performed with different 
donors (*: P<0.05, **: P<0.01, ***: P<0.001). 
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 exhibit the capacity to induce antigen-specific 
Th1 responses. 
Next we investigated the capacity of 
FSME-pDCs to induce CD8+ T cell responses. 
Therefore, pDCs were loaded with gp100280-288 
peptides and co-cultured with naïve 
autologous CD45RA+CD8+ T cells expressing 
the gp100280-288-specific T cell receptor. PDCs 
activated by IL-3, CpG-C and by FSME all 
demonstrated the ability to induce antigen-
specific T cell responses, as illustrated by the 
upregulation of the early T cell activation 
marker CD69 (Figure 2D), and the secretion of 
IFN  (Figure 2E) 24 hours after activation. 
Interestingly, although less IFN-  was 
produced in co-cultures of gp100-specific T 
cells with autologous FSME-pDCs compared to 
CpG-C-pDC, FSME-pDCs demonstrated the 
ability to induce stronger gp100-specific 
proliferative T cell responses than pDCs 
activated by CpG-C (Figure 2F). These data 
demonstrate that pDCs have the capacity to 
evoke antigen-specific naïve CD8+ T cell 
responses. 
 
FSME activated pDCs express CD56 
Interestingly, as we studied the expression 
level of CD56 on activated human pDCs we 
found that 53.1± 5.8% of FSME-pDCs acquired 
de novo CD56 expression (Figure 3A,B). 
Furthermore, we demonstrated that FSME-
induced upregulation of CD56 was dose-
dependent (Figure 3B). To our knowledge this 
is a new finding, as up to now CD56 
expression was described to be present on NK 
cells, NKT cells, IFN-activated moDCs and a 
small DC subset circulating in the blood, but 
so far never on pDCs22,39. Therefore, we 
sought to determine whether other stimuli 
known to induce pDC activation also induced 
CD56 receptor expression. Neither IL-3 nor 
the known TLR agonists, CpG-A, CpG-B, CpG-C 
or R848, induced CD56 expression (Figure 
3A,B). Moreover, also vaccines that previously 
induced pDC activation29, BMR, Rabies, Act-
Hib and BCG, did not induce CD56 expression 
(Figure 3A). Thus, FSME activation specifically 
induced the upregulation of CD56 expression 
on human pDCs. 
 
High CD56 expression coincides with higher 
levels of PD-L1, TRAIL, granzyme B and 
effector functions 
The finding that FSME upregulated CD56 
prompted us to study the phenotype of 
CD56high and CD56low FSME-pDCs (Figure 4A). 
Both populations showed an almost identical 
phenotypical pattern as we did not observe a 
difference in the expression of BDCA-2, BDCA-
4, MHC class I and II, CD123, CD40, CD80, 
CD86 and ICOS-L (Figure 4B,C and data not 
shown). However, the percentage of CD83-
expressing cells was slightly higher in the 
CD56high population (Figure 4B,C). 
Interestingly, CD56high pDCs expressed 
significant higher levels of TRAIL and 
granzyme B (Figure 4B,C). These data suggest 
that CD56high pDCs are endowed with the 
capacity to kill granzyme B- and TRAIL-
sensitive target cells. Next we analyzed 
whether CD56high pDCs are functionally 
different from CD56low pDCs. Previous studies 
showed that pDCs produce IFN  within 12 
hours after activation, and then become 
refractory to any further stimulation40-42, 
therefore isolated pDCs were activated for 6 
hours with FSME followed by intracellular 
cytokine staining. We did not detect 
differences in IFNα secretion nor in TNFα 
secretion between the two populations (data 
not shown). Furthermore, after overnight 
activation FSME-pDCs were sorted based on 
CD56 expression. Subsequent analysis 
revealed that CD56high pDCs are more potent 
inducers of allogeneic T cell responses (Figure 
4D). Taken together, these findings 
demonstrate that CD56high FSME-pDCs acquire 
strong effector functions. 
 
FSME activated pDCs abrogate tumor cell 
growth 
To determine whether our FSME-
pDCs also exhibit tumoricidal activity, cells 
were cocultured for 18h or 3 days with K562 
cells at different pDC:K562 ratios. Only FSME-
stimulated pDCs were able to specifically lyse 
K562 cells up to 59± 4.7% (ratio 20:1) after 18 
hours and up to 71± 6.6% (ratio 20:1) after 3 
days (Figure 5A). Moreover, the absolute 
number of K562 cells that was detected after 
18 hours or 3 days of co-culture with FSME-
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 pDCs was strongly decreased (Figure 5B). 
Although, we could not detect specific lysis of 
K562 cells by IL-3 pDCs or R848 pDCs we did 
observe that they inhibited malignant cell 
replication on 3-day co-culture (Figure 5B). 
Furthermore, CD56high pDCs were equally 
efficient in killing K562 cells compared to 
CD56low pDCs (data not shown). Plasmacytoid 
DCs activated with the other vaccines did not 
induce specific lysis. Next to FSME, also the 
MMR vaccine endowed pDCs with tumoricidal 
capacities (supplementary Figure 1).  
Since FMSE activated pDCs expressed TRAIL 
and granzyme B we evaluated the 
Figure 5 FSME activated pDCs are potent killer pDCs NK cells were stimulated with IL-2 and human pDCs were activated 
overnight with various stimuli as indicated and co-cultured with PKH-labeled K562 cells. After 18 hours or 3 days of co-
culture specific lysis was determined by studying the expression of annexin V and propidium iodide (A) and the absolute 
number (B) of K562 cells. Data shown are mean values ± SEM of at least 3 independent experiments performed with 
different donors (*: P<0.05, **: P<0.01). (C) FSME activated pDCs were co-cultured with PKH67-labeled K562 target cells at 
an E:T ratio of 20:1 in the presence of either anti-CD56, anti-TRAIL blocking mAb or the granule exocytosis inhibitor 
concanamycin A. Parallel experiments were performed using TRAIL isotype-matched control mAb. Furthermore, K562 cells 
were cultured in the presence of supernatant derived FSME-pDC cultures or in a transwell assay. (D) PDCs were activated 
overnight with FSME and co-cultured with PKH-labeled K562, Jurkat, MEL624, Daudi and Glioma cells. (C,D) Specific lysis of 
target cells was determined after 18 hours of incubation. Data shown are mean values ± SEM of at three independent 
experiments performed with different donors at least in duplo. 
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 contributions of these pathways to the 
cytotoxic effect of pDCs on K562 cells. We 
performed cytotoxicity blocking experiments 
using anti-TRAIL neutralizing antibodies and 
concanamycin A, a selective inhibitor of 
vacuolar-type H+-ATPase that prevents 
acidification and degranulation of 
perforin/granzyme-containing cytotoxic 
granules. Since cytotoxicity of FSME-pDCs 
against K562 cells was most prominent at high 
E:T ratios, we chose the E:T ratio of 20:1 for 
blocking experiments. As shown in Figure 5C, 
neutralization of TRAIL, granzyme B or the 
combination of TRAIL and granzyme B activity 
revealed that these cytotoxic molecules did 
not participate in the observed cytotoxicity. It 
has been suggested in literature that the 
expression of CD56 might promote effector-
target cell interaction43. Therefore, we 
performed additional blocking experiments 
where FSME-pDCs were pre-incubated with 
anti-CD56 antibodies. We demonstrate that 
blocking CD56 on FSME-pDCs did not result in 
diminished specific lysis (Figure 5C). 
Furthermore, FSME-pDCs specifically killed 
the MHC class I negative tumor cell lines K562 
and Daudi, but minimally the MHC class I 
positive tumor cell lines GliomaX, Jurkat and 
MEL624 (Figure 5D). Additionally, K562 cells 
could not be killed by supernatant from 
FSME-pDC cultures or in a transwell assay, 
indicating that the killing capacity of FSME-
pDCs is cell-cell contact dependent (Figure 
5C). Similarly, supernatants derived from 
FSME-pDC cultures did not affect Daudi cell 
viability (data not shown). Taken together, 
our data indicate that upon FSME activation 
human pDCs gain cytotoxic effector functions 
and specifically lyse NK target tumor cell lines 
in a cell-cell contact dependent manner. 
 
Discussion 
Here we show that human pDCs after 
FSME-induced activation attain a wide range 
of immunostimulatory and inhibitory 
molecules, secrete pro-inflammatory 
cytokines, present antigens and activate T 
cells, and display tumoricidal activity. 
Moreover, to the best of our knowledge, we 
identified for the first time a stimulus that 
specifically induces the expression of CD56, a 
molecule predominantly associated with NK 
cells. The implications of expression of CD56 
by the FSME-activated pDCs is very intriguing 
yet elusive as its exact function on NK cells is 
not known. Importantly, we demonstrated 
that high CD56 expression coincided with the 
expression of cytotoxic molecules. Evidence is 
emerging that upon proper activation DC 
subsets can express and secrete molecules 
associated with cytotoxic effector 
functions18,22-28. Just recently, Kalb et al. 
demonstrated that pDC-based anti-tumor 
immunity is mediated by IFNα and that 
imiquimod induced TRAIL expression44. These 
findings reveal that FSME as a stimulus turns 
freshly isolated pDCs in cells that share key 
features with previously described murine 
IKDCs19,20 and human CD56+ DCs with 
myeloid-lineage orientation. CD56-expressing 
cell types are generally equipped with 
cytotoxic functions, suggesting that 
hematopoietic expression of CD56 is confined 
to cells exhibiting cytotoxic properties. We 
therefore hypothesize that the expression of 
CD56 has a role in the special effector 
functions acquired by human pDCs upon 
FSME stimulation. As a cell adhesion 
molecule, it could help the pDCs to bind their 
targets, or as a homophilic binding protein it 
might promote cross-talk with other CD56-
expressing cells like NK cells or pDC 
themselves45. Recently the group of Thurnher 
et al demonstrated that CD56+ DC interact 
with and activate NK cells46,47. Furthermore, 
studies that used CD56-expressing NK cells 
and T cells, showed that CD56 may potentiate 
the cytotoxic activity of these cells by 
promoting effector-target cell interaction43. 
Our findings suggest that a role for CD56 in 
the observed cytotoxicity can be excluded. 
However, whether CD56 is involved in the bi-
directional crosstalk between different cells of 
the immune system remains to be elucidated. 
We observed a cytotoxic effect, up to 
50% specific lysis after 18 hours, of FSME- and 
MMR-pDCs on leukemic K562 cells. 
Interestingly, this effect was much stronger 
compared to IL-3, R848 and other vaccine 
activated pDCs. In line with the report from 
Matsui et al., differently activated pDCs 
inhibited malignant cell replication in a 3-day 
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 co-culture26. Interestingly, MMR induced 
activation did not lead to the expression of 
CD56, however these cells did obtain 
tumoricidal activity. Previous reports 
demonstrated that virus-activated pDCs can 
acquire cytolytic function that is mediated by 
the expression of TRAIL23-25. Upon FSME 
stimulation human pDCs upregulated TRAIL 
expression. However, in our hands the 
tumoricidal activity of FSME-pDCs could not 
be blocked by TRAIL-blocking antibodies 
(Figure 5C). Additionally, Jahrsdorfer et al. 
demonstrated that pDC-derived granzyme B 
impaired allogeneic T cell proliferation, which 
is in line with our observation where IL-3 and 
FMSE pDCs induce lower T cell proliferation as 
compared to CpG-C pDCs (Figure 2A)28. 
Although, FMSE-pDCs expressed granzyme B 
it was not involved in the specific lysis of K562 
cells (Figure 5C). Although, concurrent 
blocking of TRAIL and granzyme B did not 
diminish the tumoricidal activity, the 
possibility that other pDC-derived cytotoxic 
molecules act in synergy to exert their 
cytotoxic function cannot be excluded. We did 
however demonstrate that FSME-pDCs 
required cell-contact dependent mechanisms 
to directly lyse target cells. Furthermore, the 
need of long incubation for detectable 
tumoricidal effects of IL-3 and R848 pDCs 
hints towards the involvement of slow 
inducers of apoptosis like granzyme B 
(perforin-independent), TNF-α or FasL48. 
Moreover, we demonstrated that FSME-pDCs 
specifically lysed MHC class I negative NK 
target tumor cell lines. Underscoring that 
FSME-pDCs acquired NK cell effector 
functions. 
A remaining question is the 
immunological relevance of killer tumor-
infiltrating pDCs. It is generally accepted that 
macrophages and DCs outnumber the 
classical killers (NK and CTLs) in tumor 
tissues27. By their ability to secrete large 
amounts of type I IFN pDCs were already 
shown to mediate cross-talk with other 
immune cells, such as NK cells or T cells 
leading to superior anti-tumor immunity6,49. 
The here described cytotoxic effector function 
provides a new insight for a role of tumor-
infiltrating pDCs in tumors. Properly activated 
tumor-infiltrating pDCs might not only directly 
lyse cancer cells, but might also take up the 
released tumor-associated antigens and 
present them to T cells. Altogether, killer 
pDCs might represent a potential target for 
the development of new strategies to 
eliminate cancer. This property has already 
been underscored by Stary et al., who 
demonstrated that activation of human 
tumor-infiltrating pDCs resulted in tumor 
clearance18. Moreover, just recently Drobits et 
al. described that imiquimod-activated tumor-
infiltrating pDCs not only killed tumor cells in 
mice, but also that this was independent of 
the adaptive arm of the immune system50.  
Besides the acquired cytotoxic 
effector function, phenotypical 
characterization of human pDCs activated 
overnight with FSME revealed that pDCs 
acquired a phenotype that did not completely 
resemble TLR7/9-induced activation nor IL-3 
stimulation. Where FSME-pDCs displayed 
similar expression of CD40, TRAIL and PD-L1 
and secretion of IL-6, TNFα and IFNα as 
TLR7/9-activated pDCs, they more resembled 
IL-3-pDCs when considering expression levels 
of CD80, CD83, CD86 and granzyme B. 
Strikingly, based on their ability to activate 
antigen-specific naïve CD8+ T cells, FSME-pDCs 
resemble TLR-activated pDCs, whereas FSME-
pDCs induced similar allogeneic T cell and 
mixed antigen specific Th cell responses as IL-
3-pDCs. As the FMSE vaccine contains the 
inactivated TBEV (ssRNA virus), it is likely 
acting as a TLR7 agonist, although it is not 
completely mimicking the effects of the TLR7 
agonist R848 on pDCs. For the CpG-ODN 
classes it has already been described that 
different CpG-ODNs trigger TLR9 in different 
endosomal compartments resulting in 
functional differences. Whether FSME 
behaves similar to CpG-ODNs and triggers 
TLR7 in specific endosomal compartments or 
even triggers an yet unidentified receptor 
remains to be elucidated. Notwithstanding, 
based on the present data set we conclude 
that human FSME activated pDCs are inducers 
of antigen-specific T cell responses. 
In conclusion, the data presented 
here unequivocally demonstrates that human 
pDCs can acquire CD56 expression and 
Plasmacytoid DC in cancer & cancer therapy
102
 become killer cells. For the first time we 
reported on CD56-expressing IFN-producing 
killer pDCs that are equipped with an antigen 
presentation machinery.  
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Abstract 
Vaccination against cancer exploiting dendritic 
cells (DCs) has for more than a decade been 
based on DCs generated ex vivo from 
monocytes or CD34+ progenitors. Here, we 
report on the first clinical study of therapeutic 
vaccination against cancer exploiting activated 
naturally occurring plasmacytoid DCs (pDCs). 
Fifteen metastatic melanoma patients 
received intranodal injections of pDCs 
activated ex vivo and loaded with tumor-
associated peptides. In vivo imaging 
demonstrated that administered pDCs 
migrated and distributed over multiple lymph 
nodes. Several patients mounted anti-vaccine 
CD4+ and CD8+ T cell responses. Despite the 
limited number of administered pDCs, an IFN 
signature was observed after each 
vaccination. These results indicate that 
vaccination with activated natural pDCs is 
feasible with minimal toxicity, and that in 
patients with metastatic melanoma it induces 
favorable immune responses.  
 
Key words: plasmacytoid DCs, clinical study, 
immunotherapy, melanoma 
 
Introduction 
Dendritic cells (DCs) constitute a family of 
antigen-presenting cells defined by their 
morphology, phenotype and unique capacity 
to process exogenously encountered antigens 
and to present them to naive T cells. 
Following infection or inflammation, DCs 
undergo a complex process of maturation and 
migrate to lymph nodes to present antigens 
and activate T cells. This decisive role in 
inducing immunity was the rationale for DC 
based immunotherapy, in which DCs loaded 
with tumor antigens were injected into cancer 
patients to stimulate T cells to eradicate 
tumors1-3. So far, most DC-based vaccination 
studies were conducted in patients with 
metastatic melanoma because of the 
immunogenicity of this tumor and the 
characterization of antigens such as gp100 
and tyrosinase4,5. Although numerous 
vaccination studies demonstrated the 
immunogenicity of tumor antigen-loaded DCs, 
the number of objective clinical responses has 
been limited, hampering its implementation 
as a novel form of standard treatment6. 
Because of the limited number of naturally 
circulating DCs, virtually all vaccination studies 
have used DCs differentiated ex vivo from 
monocytes or CD34+ progenitors. Recently we 
proposed that these 'artificial' DCs may be less 
effective than their natural counterparts that 
circulate in the blood7. Two major subsets of 
natural circulating DCs can be found; 
plasmacytoid DCs (pDCs) and myeloid DCs.  
Plasmacytoid DCs are the major producers of 
type I interferon (IFN), which is of major 
importance in combatting viral infections. 
Freshly isolated pDCs have been associated 
with tolerance or Th2 responses8,9, but several 
groups have now demonstrated that human 
pDCs produced large amounts of type I IFNs 
and induced Th1 responses8,10. Human pDCs 
induced strong allogeneic T cell responses11, 
and primed CD4+ and CD8+ T cells against 
viruses or tumor antigens12,13. Preclinical 
studies showed that antigen-loaded pDCs 
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 protected against Leishmania major14, and 
induced anti-tumor responses that inhibited 
tumor growth15,16. Recently, Takagi et al 
demonstrated that pDCs were crucial for the 
initiation of inflammation and T cell 
immunity17. Together, these findings 
prompted us to test the capacity of activated 
human pDCs to elicit anti-tumor immune 
responses in patients.  
In this first-in-human study, we report on 
vaccinating metastatic melanoma patients, 
with autologous activated pDCs loaded with 
tumor-associated peptides. Despite their low 
abundance in peripheral blood, we succeeded 
in isolating sufficient numbers (0.3-3 million 
per vaccination) of highly purified cells to 
carry out this study. We used the inactivated 
thick-borne encephalitis virus vaccine as a 
natural TLR agonist to activate pDCs and used 
these antigens as an immunomonitoring tool. 
We demonstrate that these activated pDCs 
were safe to use and induced antigen-specific 
CD4+ and CD8+ T cell responses in patients 
suffering from melanoma. 
 
Material and Methods 
 
Patient characteristics 
Sixteen distant metastatic melanoma 
patients (according to the 2001 American 
Joint Committee on Cancer staging system)18 
were enrolled in this feasibility study. One 
patient did not complete the scheduled 
vaccinations and monitoring due to rapid 
progression of disease. Fifteen of the patients 
were considered evaluable. Eligibility criteria 
included measurable target lesions, HLA-A2.1 
phenotype, histologically documented 
metastatic melanoma expressing gp100 
(compulsory) and tyrosinase (non 
compulsory), no active infection or immune 
suppressive conditions, serum LDH 
concentration within normal limits (< 450 U/l) 
and WHO performance status 0 or 1. Primary 
endpoint was toxicity related to vaccination 
and immunological response. The trial, CMO 
2004/093, was approved by the local 
Institutional Review Board (Committee on 
Research involving Human Subjects Arnhem-
Nijmegen) and in accordance with the 
declaration of Helsinki. Written informed 
consent was obtained from all patients. The 
primary objective of this study was to 
generate clinical grade mature pDC 
preparations and to determine a safe and 
effective dosage of the vaccine. When the 
appropriate dosage of the vaccine was 
determined, we evaluated the efficacy of the 
pDCs to initiate anti-tumor T cell responses in 
stage IV melanoma patients. Clinical trial 
registration number is NCT 01690377. 
 
CliniMACS pDC isolation and immunization 
schedule 
Patients were vaccinated with 
autologous pDCs loaded with HLA-A2.1-
binding tumor peptides derived from the 
melanoma-associated antigens gp100 and 
tyrosinase. The following HLA-A2.1-restricted 
peptides were used: gp100-derived peptides 
gp100154-162 (KTWGQYWQV) and gp100280-288 
(YLEPGPVTA) and tyrosinase-derived peptide 
tyrosinase369-377 (YMNGTMSQV). The clinical 
study was designed as a feasibility study. The 
first patient received 0.3x106 pDCs per 
vaccination, patients 2 and 3 received 1.0x106 
pDCs per vaccination, and patients 4 and 5 
received 3x106 pDCs per injection. Considering 
the yield from pDC isolation, this is the 
maximum feasible dose, and was also given to 
patients 6 to 15. Three intranodal injections 
were given once every two weeks followed by 
a DTH challenge (Figure 1). In the absence of 
disease progression, patients were eligible for 
a maximum of two maintenance cycles 
consisting of three biweekly vaccinations and 
a DTH challenge, each with a 6 month 
interval.  
Plasmacytoid DCs were directly 
isolated from aphaeresis products using the 
fully closed immunomagnetic CliniMACS 
isolation system (Miltenyi Biotec, Bergisch-
Gladbach, Germany). GMP-grade magnetic 
bead-coupled BDCA4 antibodies were used, 
following the manufacturer’s guidelines. This 
procedure resulted in clinically applicable 
purified pDCs, which had an average purity of 
75% and a yield between 13x106 and 33x106 
(Supplementary Figure S1). Following 
aphaeresis and CliniMACS isolation, pDCs 
were cultured overnight at a concentration of 
106 cells/ml in X-VIVO-15 (Cambrex, Belgium)  
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containing 2% pooled human serum (HS) 
(Sanquin, Nijmegen, The Netherlands), 
supplemented with 10 ng/ml recombinant 
human interleukin-3 (rhIL-3) (Cellgenix, 
Freiburg, Germany). For the first vaccination, 
these pDCs were subsequently activated for 6 
hours by addition of FSME-IMMUN® (1:10 v/v) 
(Baxter AG). During the last 3 hours of 
activation, pDCs were loaded with the 
melanoma-associated peptides gp100154, 
gp100280 and tyrosinase
19. For subsequent 
vaccinations and DTH skin tests, overnight IL-3 
cultured pDCs were activated for 3 hours by 
addition of FSME-IMMUN® (1:10 v/v). 
Thereafter, these 3-hour activated pDCs were 
frozen in X-vivo 15 medium containing 10% 
DMSO. Upon subsequent vaccinations/DTH, 3-
hour activated pDCs were thawed and 
activated for an additional 3 hours with FSME-
IMMUN® (1:10 v/v) and loaded with the 
melanoma-associated peptides.  The peptide-
loaded pDCs were administered intranodally 
in a clinically tumor-free lymphnode region 
under ultrasound guidance20.  
 
 
Phenotype 
The purity of pDCs after CliniMACS isolation 
and the phenotype of the pDCs were 
determined by flow cytometry. The following 
primary monoclonal antibodies (mAbs) and 
the appropriate isotype controls were used:  
 
anti-CD45-FITC, anti-BDCA2-PE and anti-
CD123-APC (all Miltenyi Biotec); anti-HLA-
ABC-PE (W6/32), anti-HLA-DR/DP-FITC ( 
Q5/13), anti-CD80-PE and CD86-PE (all BD 
Bioscience Pharmingen, San Diego, CA, USA); 
anti-CD83 (Beckman Coulter, Mijdrecht, the 
Netherlands) and anti-CCR7 (R&D Systems); 
followed by goat-anti-mouse PE.  
 
Cytokine detection 
Supernatants were collected from pDC 
cultures after 6 h of stimulation, and IFNα 
production was analyzed with murine 
monoclonal capture and HRP-conjugated anti-
IFNα antibodies (BenderMed Systems, Vienna, 
Austria) using standard ELISA procedures. 
To analyze the T helper cell profile, 
supernatants were collected after 2 days of 
pDC-PBL coculture. Cytokine production (IL-
1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p70), 
TNF , TNFβ, IFN ) in the supernatant was 
analyzed with a human Th1/Th2 Multiplex kit 
(BenderMed System) according to the 
manufacturer’s instructions.  
 
111In-oxinate labeling and scintigraphic 
imaging 
Six-hour FSME-activated pDCs were labeled 
with 5 MBq 111In-oxinate (GE Healthcare, 
Eindhoven, The Netherlands) in 0.1 M Tris-HCl 
(pH 7.0) for 15 minutes at room temperature 
as described previously21,22. Cells were 
Table 1 Patient characteristics & clinical and immunological responses after pDC vaccination 
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01 M / 43 S M1b Lung, skin 0,3*106 ++ ++  + PD < 4 10 RT 
02 F / 45 - M1b Lymph nodes, lung 1*106 + ++  - PD < 4 3 CT 
03 M / 62 - M1c Liver, lung 1*106 ++ ++  + SD 6 36+ CT, IT1,2 
04 M / 35 - M1c Liver, lymph nodes, 
esophagus, omentum 
3*106 - ++  + SD 5 27 CT, IT1,3 
05 F / 53 S M1c Liver, lung, skin, spleen 3*106 - ++  + PD < 4 5 RT 
06 M / 59 S M1b Lung, skin 3*106 n.a. -  - PD < 4 6 RT 
07 M / 43 - M1c Lymph nodes, skin, testis 3*106 + ++  - PD 4 5 None 
08 F / 51 - M1b Lung 3*106 + ++  + PD < 4 13 None 
09 M / 36 - M1b Lung, skin 3*106 + +  + SD 5 23 CT, IT3,4  
10 M / 52 S M1a Lymph nodes 3*106 - +  - SD 7 28+ S 
11 M / 66 - M1c Liver, lymph nodes, lung 3*106 - ++  - PD < 4 12 CT 
12 F / 39 S M1b Lung 3*106 ++ ++  + SD 5 27+ RT, CT, IT1 
13 F / 56 S M1b Lung 3*106 ++ ++  + SD 15 26+ CT, IT1 
14 M / 69 S M1c Lung, skin, adrenal gland 3*106 + ++  - MR 14+ 24+ None 
15 M / 67 S, RT, CT M1b Lymph nodes, lung, skin 3*106 ++ -  - PD < 4 24+ IT1 
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 washed three times with PBS/1%HSA, and the 
labelling efficiency was calculated as the 
percentage of the activity that remained 
associated with the cell pellet. 111In-labeled 
pDCs (3×106; 4 MBq) in 200 µl saline were 
injected under ultrasound guidance directly 
into a clinically tumor-free lymph node.  
In vivo planar scintigraphic images (256  256 
matrix, 174 and 247 keV 111In photopeaks with 
15% energy window) of the injection depot 
and corresponding lymph node basin were 
acquired with a gamma camera (Siemens 
ECAM, Hoffman Estates, IL) equipped with 
medium energy collimators, 15 minutes, 24 
hours and 48 hours after injection. Migration 
was quantified by region-of-interest analysis 
of the individual nodes visualized on the 
images and expressed as the fraction of 111In-
labeled DC that had migrated from the 
injection depot to following lymph nodes after 
15 minutes, 24 hours and 48 hours. 
 
Immunomonitoring of patients 
Blood samples were obtained before 
the start of the vaccination regimen and after 
each individual vaccination. Each sample was 
tested for the presence of FSME-specific T 
cells by proliferation and 3H-thymidine 
incorporation, and for the presence of FSME-
specific antibodies in the serum using an ELISA 
specific for Tick-Borne Encephalitis IgG 
(Serion/Virio, Würzburg, 
Germany). Four days after 
the third vaccination, a DTH 
skin test was performed as 
described previously 123. 
moDCs pulsed with gp100 or 
tyrosinase peptides (1x106) 
and pDCs pulsed with gp100 
or tyrosinase peptides 
(0.2x106) were injected 
intradermally in the skin of 
the back of the patient at 4 
different sites. The maximum 
diameter of induration was 
measured after 48 hours. 
Punch biopsies (6 mm) were 
obtained from all DTH sites. 
Half of the biopsy was 
cryopreserved and the other 
half was manually cut and 
cultured in RPMI 1640 (Gibco-
BRL Life Technologies) containing 7% HS and 
IL-2 (100 U/ml, Proleukin®, Chiron, the 
Netherlands). Every 7 days, half of the 
medium was replaced by fresh medium 
containing HS and IL-2. After 2 to 5 weeks of 
culturing, T cells were tested for specificity 
against gp100 and tyrosinase 19. DTH-derived 
cells were stained with tetrameric-MHC 
complexes containing the gp100154-167, 
gp100280-288 or tyrosinase369-376 peptide 
(Sanquin, Amsterdam, The Netherlands) 
combined with CD8 staining as described 
previously 23. All samples were tested with 
HIV77–85-HLA-A2.1-tetramers recognizing the 
irrelevant HIV-peptide (SLYNTVATL) for 
background staining.  
 
Mixed lymphocyte-peptide cultures 
The presence of tumor antigen-specific CD8+ T 
cells was analyzed using mixed lymphocyte-
peptide cultures (MLPCs) as described 
previously24. Briefly, PBMCs isolated before 
and after one cycle of three pDC injections, 
were thawed and divided in three groups 
incubated for 1 h at room temperature in 
Iscove’s medium (Life Technologies, Carlsbad, 
CA, USA) with 1% HS and 2 µM of the peptides 
tyrosinase369 (YMDGTMSQV), wild-type 
                                                 
1
 For a detailed description of the DTH procedure visit 
http://www.labtube.tv/playvideo.aspx?vid=131825 
Figure 1 Schematic overview of the pDC culture protocol and vaccination 
strategy 
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 gp100154
 (KTWGQYWQV), or wild-type 
gp100280 (YLEPGPVVTA). These pulsed cells 
were then washed, pooled, and distributed at 
2 x 105 cells/0.2 ml in round-bottom 
microwells in Iscove’s with 10% HS, L-arginine 
(116 mg/l), L-asparagine (36 mg/l), L-
glutamine (216 mg/l), 1-methyl-L-tryptophan 
(100 µM),  IL-2 (20 U/ml), and IL-7 (10 ng/ml). 
On day 7, 50% of the medium was replaced by 
fresh medium containing IL-2 and peptides at 
4 µM. Tetramer labeling was performed on 
day 14 as described previously24. 
 
RNA isolation and qPCR 
To determine mRNA expression of IFN and 
IFN-stimulated genes (ISGs) blood was drawn 
from one patient during one cycle of 3 
vaccinations before each vaccination and at 4 
and 24 hours after each vaccination using 
PAXgene tubes. RNA isolation was performed 
using PAXgene blood RNA kit according to the 
manufacturer’s instructions (Qiagen). RNA 
isolations from PBMCs from healthy 
volunteers were done using the ZR RNA 
isolation kit (Zymo Research) according to 
manufacturer’s instructions. RNA was treated 
with DNase I (amplification grade; Invitrogen) 
and reverse-transcribed into cDNA by using 
random hexamers and Moloney murine 
leukemia virus reverse transcriptase 
(Invitrogen). To exclude genomic DNA 
contamination we included a “-RT” control in 
which the reverse transcriptase was replaced 
with RNase-free water. The “-RT” control was 
taken along in the qPCR analysis, and was 
used as a cut-off value. cDNA was stored at – 
20°C until further use. mRNA levels for the 
genes of interest were determined by 
quantitative PCR (qPCR) with a Biorad CFX 
apparatus (Biorad) with SYBR Green (Applied 
Biosystems). Analysis was done using Biorad 
CFX-1.6 software, and expression levels were 
determined relative to PBGD expression. 
Primer sequences are available on request 
and were from the Primer Bank database25. 
 
Matched historical controls  
Matched historical controls were identified 
from records of metastatic melanoma 
patients from the Radboud University 
Figure 2 Activated pDCs are mature and migrate to distinct lymph nodes in vivo (A) Expression levels of the surface 
molecules CD80, CD83, CD86, MHC class I and MHC class II on pDCs after 6 hours of activation with the FSME-vaccine. 
Surface receptor expression levels of all molecules of the pDC vaccines depicted in the percentage of positive cells (left 
graph) and mean fluorescence intensity (right graph) after 6 hours of activation with the FSME-vaccine (n=15). (B) IFNα 
production by pDCs after 6 hours of cultivation/activation with rhIL-3 or FSME-vaccine or after 6 hours of activation 
followed by a washing step and reconstitution of pDCs in fresh medium for an additional 12 hours (n=9; *: P<0.05, ***: 
P<0.001). (C) Tracking of pDC migration in vivo. Migration and biodistribution of 
111
In-labeled pDCs visualized by 
scintigraphical imaging. Forty-eight hours after administration, 11% (Pt 01), 3% (Pt 02) and 42% (Pt 03) of injected pDCs 
were distributed over up to 4 distant lymph nodes away from the injection depot. 
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 Nijmegen Medical Centre (Nijmegen, The 
Netherlands), The Netherlands Cancer 
Institute – Antoni van Leeuwenhoek Hospital 
(Amsterdam, The Netherlands) and University 
Hospital Essen (Essen, Germany) who had 
received first-line dacarbazine (DTIC) 
chemotherapy at 850–1000 mg/m2 i.v. at 3 
weekly intervals, between March 2000 and 
March 2010. All matched controls were HLA-
A*02:01 positive and were required to have 
received at least 3 infusions, a therapy time-
frame that is consistent with one cycle of 
vaccinations. 
Historical controls were matched to study 
subjects, in ratio 1:3, primarily for M substage 
at baseline according to AJCC criteria, number 
of distant metastases, number of metastatic 
sites, localization of distant metastases and 
baseline serum LDH. These criteria currently 
represent the most important prognostic 
factors for survival26. In case of more than 
three matches for one study subject, 
demographic criteria (age, gender) and 
systemic salvage treatment after progression 
on DTIC were used to select the closest 
match. 
 
Statistical analysis 
Significant differences from controls were 
determined according to one-way ANOVA 
analysis followed by the Tukey’s post-hoc test. 
Differences between the groups were 
evaluated using an unpaired t-test. 
Differences between pre- and post-
vaccination were evaluated with a Wilcoxon 
signed-rank test. Kaplan-Meier probability 
estimates of PFS and OS were calculated, 
statistical differences between groups were 
determined with a log-rank test. Statistical 
significance was defined as p<0.05. SPSS19.0 
was used for survival analyses. 
 
Results 
 
Vaccination of metastatic melanoma patients 
with activated pDCs is safe with minimal side 
effects 
It is of utmost importance that pDCs 
administered to cancer patients have an 
immunostimulatory phenotype19. Previously 
we demonstrated that the commonly used 
preventive FSME-vaccine induced both IFNα 
secretion and a mature pDC phenotype27. 
Thus FSME could be used as a clinically 
applicable natural TLR agonist. In this first-in 
human study we vaccinated 15 patients with 
increasing pDC numbers, ranging from 0.3 to 3 
million per vaccination, with three 
vaccinations at a bi-weekly intervals (Figure 
1). Patient characteristics are shown in Table 
1. The expression of CD80, CD83, CD86, MHC 
class I and II upon FSME-induced activation 
indicated that the generated pDCs were highly 
mature and capable of providing 
costimulatory signals needed for optimal T 
cell activation (Figure 2A). Furthermore, pDC 
activation for 6 hours led to the secretion of 
high levels of type I IFN (Figure 2B). 
Additionally, we also washed 6 hour activated 
pDCs and reconstituted the cells in fresh 
medium. Thereafter, pDCs were maintained 
for an additional 12 hours to demonstrate 
that pDCs have a sustained ability to secrete 
IFNα (Figure 2B). Thus, all patients received 
purified and activated peptide-loaded pDCs 
that met the predefined release criteria with 
the ability to secrete type I IFN in vivo6.  
Furthermore, the vaccines were well tolerated 
and no signs of severe toxicity (common 
toxicity criteria grade 3-4) were observed. Six 
vaccinated patients developed grade 1 flu-like 
symptoms and one patient reported grade 2 
non-treatment related pain resulting from 
progressive subcutaneous metastasis. In none 
of the vaccinated patients did we detect 
antibodies to the murine antibody used 
during the isolation procedure (data not 
shown). We conclude that it is feasible and 
safe to administer activated and tumor-
peptide loaded pDCs to patients. 
 
The migratory behaviour of activated pDCs in 
vivo 
For effective immunotherapy, it is essential 
that injected DCs migrate into the T cell areas 
of the draining lymph nodes to present 
antigens to naive T cells. Because of the 
limited amount of pDCs available, we opted 
for intranodal injection to maximize the 
number of pDCs in the lymph node. In three 
patients we examined the capacity of 
activated pDCs to migrate in vivo after 
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 labelling with 111In21,28. Forty-eight hours after 
intranodal injection of 111In-labeled pDCs, a 
significant proportion of pDCs remained at the 
site of injection but a distinct amount of 111In-
labeled pDCs could be identified in several 
distant lymph nodes (Figure 1C). Collectively, 
these data demonstrate that pDCs injected in 
a single lymph node distribute over 
subsequent nodes.  
 
Vaccination with activated pDC induce an IFN 
signature in vivo 
To verify whether activated pDCs also secrete 
significant quantities of type I IFNs in vivo, we 
investigated in one patient the IFN signatures 
in great detail (multiple time points / three 
vaccinations). We measured the expression of 
5 IFN-induced genes in blood mononuclear 
cells one hour before, four and 24 hours after 
vaccination in comparison of those of healthy 
individuals. Transcription of both IFNα and 
IFNβ genes was clearly induced four hours 
after vaccination, and subsequently decreased 
20 hours later (Figure 2A) indicative of a 
temporal high systemic induction of type I 
IFNs. Furthermore, we observed significant 
increases in the expression of the IFN-induced 
genes RIG-I, PKR, OAS-1, OAS-2 and IRF-7 after 
four hours, which as expected, increased even 
further after 24 hours (Figure 2B). These 
results clearly demonstrate that even small 
numbers of injected pDCs after each 
vaccination induced a systemic IFN signature 
in vivo.  
 
PDC vaccination leads to CD4+ T cell 
proliferation and antibody production 
We next analyzed the ability of activated pDCs 
to induce control (FSME) antigen-specific T 
cell responses. FSME-specific T cells were 
detected in 9 out of 15 patients after three 
pDC vaccinations (Figure 3A, Table 1). Analysis 
of cytokines revealed that T cells of 4 out of 6 
analyzed patients produced more IFNγ, IL-10 
and IL-6 after three vaccinations with 
activated pDCs (Figure 3B, and data not 
shown) than before vaccination. Furthermore 
we determined anti-FSME antibody 
production after each vaccination. The results 
show that 12 out of 15 patients had increased 
Figure 3 Vaccination with activated pDCs induces an IFN signature 
(A) The graphs show the IFNα and IFNβ gene expression levels in the 
blood relative to PBGD expression at indicated times after each 
vaccination. (B) The graphs show the mRNA expression of indicated 
ISGs determined as in (A). Healthy indicates steady state expression 
levels of indicated genes in 8 healthy individuals. n.a.: not analyzed, 
n.d.: not detected (* p<0.05; ** p<0.01; *** p<0.001). 
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 their anti-FSME IgG titers after three 
vaccinations (Figure 3C, Table 1). Although 
one patient (pt 14), exhibited anti-FSME 
antibodies before vaccination, suggesting a 
previous encounter with FSME, the antibody 
response still increased after vaccination. Only 
one of the 15 patients did neither develop a T 
cell nor a humoral response. In conclusion, 
the majority of patients developed de novo 
proliferative and humoral FSME-specific 
immune responses upon vaccination, 
indicative of a functional immune system that 
can be primed by activated antigen-loaded 
pDCs. 
 
Activated pDCs induce tumor antigen-specific 
CD8+ T cell responses in vivo 
We used tetramers to detect the presence of 
tumor antigen-specific CD8+ T cells in blood, 
and in biopsies taken from skin delayed-type 
hypersensitivity (DTH) reactions as described 
previously23. In blood, the proportions of total 
CD8+ T cells did not change following 
vaccination (Figure 5A), and ex vivo tetramer 
staining was negative both before and after 
vaccination (data not shown). We resorted to 
an in vitro restimulation of blood 
mononuclear cells in limiting dilution 
conditions over two weeks with the 3 
antigenic peptides, before screening all 
microcultures for the presence of CD8+ 
tetramer+ cells. This procedure allows to 
estimate the frequencies of blood CD8+ T cells 
that recognize a given antigen and proliferate 
in vitro in response to this antigen. As shown 
in Figure 5B, 7 out of 15 patients showed a 
significant increase (≥5-fold) of the frequency 
of gp100154-specific CD8
+ T cells in (Figure 5B). 
To evaluate the affinity of these anti-vaccine T 
cells, we derived anti-gp100154 T cell clones 
from pre- and -postvaccination PBMC and 
measured IFNg production after a stimulation 
with various concentrations of peptide. The 
concentration of peptide that stimulates a 
half-maximal cytokine production reflects the 
functional avidity of the T cells. As shown in 
Figure 5C, 2 out of the 8 post-vaccination 
clones had a higher (>10-fold) functional 
avidity than that of all the other pre- or post-
vaccanation clones, suggesting the efficacy of 
pDCs at priming high affinity T cells.  
In the skin, we observed in 10 out of the 15 
patients positive DTH responses with 
indurations of up to 22 mm at the sites of 
8 
Figure 4 Activated pDCs induce de novo FSME-specific cellular and 
humoral immune response in vivo  (A) Proliferation of anti-FSME blood 
T cells collected before and after three vaccinations with tumor-
peptide loaded pDCs. Proliferation of T cells was measured by 
3
H-
Thymidine incorporation and depicted as proliferation in counts per 
minute. (B) Cytokine production by pre- (white bars) and post-
vaccination (black bars) IFNγ, IL-10 and IL-5 production by T cells 
stimulated overnight by FSME-activated pDCs. (C) FSME-specific IgG 
detected in the serum of patients before and after the first, second and 
third vaccination. The dotted line represents the threshold (28 Units) 
for positivity. (ns, not significant; *** p<0.001). 
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 intradermal injection of 0.2 x 106 peptide-
loaded activated pDCs (Supplementary Table 
S1). Furthermore we detected anti-gp100154 
CD8+ T cells in one DTH biopsy obtained after 
one cycle of vaccination (pt 1) and in one 
obtained after two cycles (pt 13) (Figure 5D). T 
cells obtained from biopsies of DTH reactions 
to unloaded pDCs did not proliferate 
demonstrating the specificity of this response. 
We conclude that vaccination with small 
numbers of peptide-loaded and activated 
pDCs can induce tumor-specific CD8+ T cell 
responses in metastatic melanoma patients. 
 
Clinical outcome of late stage melanoma 
patients vaccinated with plasmacytoid DC  
Although the patient number does not allow 
to draw significant conclusions about the 
clinical outcome we did observed some 
interesting trends. Two patients (pt 13 and 
14) showed durable stable disease and were 
eligible for two additional cycles consisting of 
three pDC vaccinations. Patient 14 developed 
a mixed response with regression of lung 
Figure 5 Activated pDCs induce tumor-antigen specific CD8
+
 T cell responses in patients (A) Proportions of blood CD3
+
 
CD8
+
 T cells in a representative patient before and after 1 cycle of vaccination. (B) tested. (C) pDC vaccine-related CD8
+
 T 
cell responses are detected in the blood after MLPCs. The graphs show the blood frequencies of gp100154, gp100280 and 
tyrosinase tetramer
+
 CD8
+
 T cells before and after 1 cycle of vaccination. (D) pDC vaccine-related CD8
+
 T cell responses are 
detected in biopsies taken from DTH skin tests. Two weeks after the third pDC injection, a DTH skin test was performed by 
injecting intradermally pDCs and moDCs loaded with either the gp100 or the tyrosinase peptides. Biopsies taken 2 days 
later were cultured for 3-4 weeks in low dose IL-2, and proliferating T cells were stained with specific tetramers. FACS 
plots from patients 01 and 13 show DTH-infiltrating lymphocytes stained by gp100154 tetramers. (ns, not significant; ** 
p<0.01). 
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 metastases and progression of a nodal 
metastasis. Patient 10 had a documented 
progression but achieved complete remission 
after surgery and subsequently received 
maintenance treatment. To have an indication 
whether pDC vaccination has an influence on 
clinical outcome, we compared the clinical 
outcome of 15 pDC-vaccinated patients to the 
outcome of carefully selected matched 
control patients (n=72) who received standard 
DTIC (Dacarbazine) chemotherapy as a first 
line treatment (Supplementary Table S2). The 
median progression-free survival in the pDC 
group was 4.0 months versus 2.1 months in 
the control group (not significant; Figure 6A). 
Although the initial endpoint of this study was 
safety and feasibility, the median overall 
survival showed a remarkable improvement 
compared to matched control patients: 22.0 
months (95%CI 1.8 – 42.2) versus 7.6 months 
(95%CI 5.8 – 9.4), p=0.001. Furthermore, 7 out 
of the 15 patients were alive, even 2 years 
after the start of pDC vaccination, compared 
to 6 out of 72 patients treated with standard 
chemotherapy (Figure 6B).  
 
Discussion 
After almost 15 years of DC based 
immunotherapy, the clinical efficacy of the ex 
vivo generated monocyte- or CD34+ 
progenitor derived-DCs is disappointing. 
Therefore, properly activated naturally 
occurring dendritic cells might represent the 
next generation of anti-cancer cellular therapy 
to induce tumor-specific immunological 
responses and improve clinical efficacy. In this 
first clinical study with plasmacytoid DCs in 
metastatic melanoma patients, with activated 
pDCs injected into lymph nodes, we observed: 
1) distribution of injected pDCs over multiple 
lymph nodes, 2) enhanced systemic secretion 
of type I IFNs, 3) de novo T and B cell 
responses to control antigen, and  4) 
induction of tumor antigen specific CD8+ T 
cells, including some with high functional 
avidity.  
Plasmacytoid DCs are known to sense viral or 
self nucleic acids and to become activated to 
produce type I IFN at sites of inflammation. 
These IFNs initiate protective immunity 
through maturation of resident myeloid DCs 
and subsequent activation of infiltrating T 
cells and NK cells. By contrast, non-activated 
pDCs promote T regulatory cell-mediated 
immunosuppression29, and the presence of 
pDCs in tumors has been correlated with poor 
clinical outcome30,31. We hypothesized that 
properly activated pDCs, because of their IFN 
production, might stimulate myeloid DCs and 
enhance their ability to cross-prime CD8+ T 
cells, thereby inducing more efficient anti-
tumor T cell responses when compared to in 
Figure 6 pDC vaccination improves overall survival 
Clinical outcome to pDC vaccination was compared to a group of carefully matched historical control patients who 
received Dacarbazine as first line treatment. Progression-free survival for pDC vaccination was 4.0 months versus 2.1 
months in the control group. Median overall survival data showed a remarkable improvement compared to matched 
control patients; 22.0 months versus 7.6 months. Furthermore, the overall survival of pDC vaccinated patients was 
significantly improved compared to matched controls. Statistical significance between the survival of the groups was 
determined by a log-rank test, p=0,001.  
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 vitro generated DCs. This notion is supported 
by two independent studies demonstrating in 
mice that type I IFNs were critical for the 
induction of anti-tumor immune responses 
32,33. Therefore, to warrant clinical efficacy, 
pDCs should secrete type I IFN at the time of 
administration. Since previous studies showed 
that pDCs produced IFN  within 12 hours 
after activation and then became refractory to 
further stimulation34-36, isolated pDCs were 
maintained overnight in IL-3 and subsequently 
activated for 6 hours with FSME. Our 
approach resulted in clinically applicable pDCs 
with a stimulatory phenotype and secretion of 
type I IFNs in vivo. Accordingly, we now 
demonstrate that vaccination with such pDCs 
indeed induced an IFN signature based on the 
upregulated IFN-induced genes in the blood 
after vaccination, validating our approach. 
For an optimal immune response the injected 
pDCs should migrate to neighboring lymph 
nodes and then to T cell areas. The observed 
migratory behavior and distribution over 
multiple lymph nodes of the injected pDCs 
might be linked to the expression of CCR7 
(Supplementary Figure S2), the homing 
receptor for the chemokines CCL19 and CCL21 
that are expressed by high endothelial 
venules and stromal cells in the T cell 
areas29,37,38. The pDC migratory behavior is in 
agreement with previous studies, where 
although the majority of injected DCs reside 
at the injection depot22,28,39,40, a substantial 
fraction of the pDCs migrated to subsequent 
lymph nodes. It is important to consider that 
the microenvironment influences cell 
migration41. Therefore, a high number of pDCs 
at the injection site might affect the 
microenvironment. For example, pDC-derived 
IFNs could drive expression of chemokines 
resulting in the recruitment of immune cells, 
thereby circumventing the need for active 
migration of the pDCs themselves. 
Unfortunately, the clinical protocol did not 
allow lymph node resections, to further 
substantiate this important aspect. 
We used FSME as natural TLR agonist to 
activate pDCs. As FSME comprises a total 
inactivated virus we reasoned that during 
activation pDCs will process FSME-derived 
antigens and present antigenic peptides on 
HLA molecules. Indeed, we observed cellular 
as well as humoral responses against FSME in 
almost all patients. Therefore, commonly 
used vaccines are potentially interesting, to 
serve both as a TLR agonist and as a control 
antigen. In addition, it cannot be excluded 
that anti-FSME Th1 responses contribute to 
the expansion of CD8+ tumor specific T cells. 
We previously demonstrated that the 
presence of anti-vaccine CD8+ T cells at sites 
of vaccine-induced skin DTH reactions was 
correlated with favorable clinical outcome23,42. 
Several clinical studies in cancer patients have 
reported anti-vaccine T cell responses in the 
blood, but only in a minority of patients or 
after prolonged in vitro restimulation with 
antigen43-46. Here, we observed the specific 
induction of tumor specific CD8+ T cells, which 
indicates that even small numbers of pDCs 
can evoke antigen-specific immune responses. 
To verify if this tumor specific T cell response 
contributed to long-term tumor control, we 
compared the clinical outcome of our patients 
to that of carefully selected controls treated 
with standard DTIC chemotherapy. Although it 
must be emphasized that this study was not 
designed to evaluate clinical outcome, several 
interesting observations were made. First, 
progression-free survival in vaccinated 
patients was similar to that of the matched 
control patients, matching progression-free 
survival reported in literature47-49. 
Remarkably, the 1-year and 2-year survival 
rates were 60% and 45% after pDC 
vaccination compared to 30% and less than 
10% of the matched control patients 
respectively. To exclude that this discrepancy 
in survival might partially be influenced by 
subsequent salvage treatments, we carefully 
matched the total number of different 
treatments and the types of salvage 
treatments for both control group and the 
vaccinated patients (Supplementary Table S1). 
Secondly, we detected tumor-specific CD8+ T 
cells in 4 out of 6 patients who showed a 
clinical response (SD or MR) and had a long 
overall survival (defined as more than 24 
months). Therefore, we hypothesize that the 
improved overall survival is related to the 
priming or restimulation of anti-tumor CD8+ T 
cells, which would be in line with our previous 
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 findings23. Thirdly, given the low numbers of 
cytotoxic T cells that we detected, as 
compared to numbers reported in trials with 
monocyte- or CD34+ progenitor-derived DCs, it 
is tempting to speculate that other immune 
cells from the innate arm play an important 
role in assisting cytotoxic T cells. Therefore it 
would be extremely interesting to study the 
immune cell repertoire within resected lymph 
nodes in more detail. Comparable patterns, 
no effect on progression free survival but 
significantly extended overall survival, were 
recently described for other 
immunotherapies, especially anti-CTLA4 
blockade48. These findings support the notion 
that immunotherapy may act indirectly, 
rather than having a direct cytotoxic anti-
tumor effect.  
The interesting observation regarding the 
overall survival, albeit retrospectively, urge 
for a randomized phase II clinical trial to 
confirm the potential of natural pDCs as an 
anti-cancer vaccine. 
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Supplementary Figure 1 CliniMACS-based pDC isolation is feasible Purity (%) and yield 
(number of cells) obtained in 15 CliniMACS-based isolations on patients' material. The pDC 
vaccines were checked for contaminating cells by determining the presence of T cells 
(CD3) and B cells (CD19). T and B cells were routinely less than 3% and 10% of all cells, 
respectively (data not shown). 
 
Supplementary Figure 2 Plasmacytoid DCs acquire CCL21-driven chemotactic ability upon 
activation (A) In vitro CCL21-driven chemotactic ability of human pDCs. Receptor surface 
expression levels of CCR7 on human pDCs after overnight (black lined histograms) and after 6 
hours (grey lined histograms) of culture with rhIL-3 or activation with CpG-C or FSME. (B) 
1*10
5
 overnight cultivated/activated pDCs were allowed to migrate towards 100 ng/ml CCL21 
for two hours. Spontaneous migration was assessed through migration of pDCs in the absence 
of CCL21. Migration of pDCs is depicted as migration index (IL-3 n=5, CpG-C n=3, FSME n=10; 
*: P<0.05, **: P<0.01). 
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Supplementary Table 1 Patient characteristics and historical controls 
  pDC control p-value 
  N=15 N=72  
     
Gender    
 Male 10 (67) 31 (55.4) 0.62 
 female 5 (33) 25 (44.6)  
     
Age    
 Median (range) 53.3 (35.1 – 68.5) 57.6 (20.1 – 77.1) 0.76 
     
HLA typing    
 HLA-A2.1 pos 15 (100) 22 (39.3)  
 HLA-A2.1 neg 0 (0) 29 (51.8)  
 unknown 0 (0) 5 (8.9)  
     
Disease status at baseline    
 M1a 1 (6.7) 4 (7.0)  
 M1b 7 (46.7) 23 (42.3)  
 M1c/visceral 3 (20.0) 12 (21.1)  
 M1c/LDH 4 (26.7) 17 (29.6)  
     
Previous treatment regional mets    
 Radiation  2 (13.3) 8 (14.3) 0.93 
 Surgery (RLND) 7 (46.7) 21 (37.5) 0.86 
 Immunotherapy  0 (0) 2 (3.6) 0.46 
 Regional perfusion 1 (6.7) 1 (1.8) 0.31 
     
Previous treatment distant mets    
 Surgery  8 (53.3)  5 (8.9) 0.001** 
 Immunotherapy  0 (0) 11 (19.6) 0.062 
 Chemotherapy  1 (6.7) 1 (1.8) 0.31 
     
Subsequent treatment  distant mets    
 Radiation  4 (26.7) 8 (14.3) 0.32 
 Surgery  1 (6.7) 0 (0) 0.06 
 Immunotherapy  6 (40.0) 22 (40.0) 0.87 
 Anti-CTLA4 4 (26.7) 10 (13.9) 0.30 
 Chemotherapy  6 (40.0) 6 (10.7) 0.11 
     
PFS (months) Median  4.0 2.1 0.13 
     
OS (months) Median  22.0 7.6 0.001* 
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Abstract 
It has become evident that the tumor 
microenvironment plays a pivotal role in the 
maintenance of cancerous growth. One of the 
acquired functions of the tumor micro-
environment is the suppression of immune 
responses. Indeed, blocking the inhibitory 
pathways operational in the micro-
environment, results in enhanced T cell 
dependent, anti-tumor immunity. Chemo-
therapeutic drugs not only directly kill tumor 
cells but also shape the tumor micro-
environment and potentiate anti-tumor 
immunity. Here, we demonstrate that the 
chemotherapeutic compound oxaliplatin acts 
as a double edged sword. Besides killing 
tumor cells, oxaliplatin bolsters immuno-
suppressive pathways, resulting in decreased 
activation of T cells by human plasmacytoid 
dendritic cells (pDCs). Exposure to oxaliplatin 
markedly increased expression of the T cell 
inhibitory molecule Programmed Death 
Receptor-Ligand 1 (PD-L1) on human pDCs 
and also TLR9-induced IFNα secretion. 
Furthermore, oxaliplatin decreased TLR-
induced STAT-1 and -3 expression, and NF- B 
mediated responses. The oxaliplatin induced 
up-regulation of PD-L1 and down-regulation 
of costimulatory molecules CD80 and CD86 
resulted in decreased T cell proliferation. Our 
results demonstrate that platinum-based anti-
cancer drugs adapt TLR induced signaling in 
human pDCs and myeloid DCs (mDCs) thereby 
downgrading their immunostimulatory 
potential.  
 
Keywords: blood DC subsets, PD-L1, TLR, 
Oxaliplatin 
 
Introduction 
Dendritic cells (DCs) are the most potent 
professional antigen presenting cells (APC) of 
the immune system. Upon infection or 
inflammation, immature DCs are activated 
and differentiate into mature DCs that 
instruct and activate B and T lymphocytes, the 
mediators of adaptive immunity1. Two major 
types of DCs circulate in peripheral blood, 
myeloid DCs (mDCs) and plasmacytoid (pDCs). 
These DC subsets express a divergent set of 
surface molecules and have distinct 
functions2. In addition to scavenging patho-
gens and presenting antigens, DCs secrete a 
large array of cytokines, which are all vital for 
proper functioning of both the acquired and 
the innate immune system. 
Although these DC subsets reside in the 
peripheral blood they also infiltrate solid 
tumors, such as breast cancer3, head and neck 
cancer4 and ovarian cancer5. Soluble factors, 
secreted by the tumor and necrotic tumor 
material prevent differentiation and 
activation of infiltrating DCs, including pDCs6-8. 
These findings have been correlated with 
poor prognosis3,9. Furthermore, Curiel et al. 
demonstrated that in human ovarian cancer, 
infiltrating DCs express the immuno-
suppressive receptor program death ligand 1 
(PD-L1 also known as B7-H1 or CD274)10. PD-
L1 negatively regulates the delicate balance 
between T cell activation and inhibition 
through interaction with its receptor Program 
Death receptor 1 (PD-1) resulting in 
suppressed T cell activation11,12 and 
maintenance of the immunosuppressive 
environment. The negative regulation of T-cell 
activation via PD-1/PD-L1 is also supported by 
studies using blocking antibodies to PD-L1 
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 performed on DCs10,13-15. The importance of 
this pathway is further highlighted in studies 
showing that blockade of the PD-1/PD-L 
pathway results in enhanced tumor-specific T 
cell expansion and activation16,17. PDCs and 
mDCs circulating in the blood do not or hardly 
express PD-L1. However, upon TLR-induced 
activation or stimulation with type I or type II 
IFNs, PD-L1 is upregulated on pDCs and 
mDCs18. This upregulation has been linked to 
decreased T cell proliferation, IFN-  and IL-10 
secretion11 as well as the induction of 
tolerance and anergic T cells12,19. Blocking 
these inhibitory mechanisms resulted in 
enhanced anti-tumor immunity16,17.  
Recent data show that chemotherapeutic 
drugs not only affect the tumor cells but also 
the immunological tumor microenvironment 
resulting in a more robust anti-tumor 
response20,21. Widely used cytotoxic drugs 
such as doxorubicin, paclitaxel and gemcitabin 
have been shown to cause enhanced antigen 
cross-presentation, T cell expansion and T cell 
infiltration of tumors by to date unknown 
molecular mechanisms22,23. Furthermore, our 
own studies show that oxaliplatin increased 
the T cell stimulatory potential of monocyte-
derived DCs (moDCs) by impairing the IL-4 
induced upregulation of PD-L2 through 
dephosphorylation of STAT624.  
In the present study, we disclose that 
oxaliplatin has a different effect on blood DC 
subsets. We observed that exposure to 
platinum-based chemotherapeutics increased 
the T cell inhibitory molecule PD-L1 on TLR9 
activated human pDCs resulting in decreased 
T cell proliferation. Furthermore, platinum-
based chemotherapeutics markedly increased 
TLR9-induced type I IFN secretion and 
decreased the expression of STAT1 and -3 and 
the secretion of IL-6 and TNFα by human 
pDCs.  
 
Material & Methods 
 
Cells 
Buffy coats were obtained from healthy 
volunteers with informed consent according 
to institutional and international guidelines. 
PDCs were purified by positive isolation using 
anti–BDCA-4–conjugated magnetic micro-
beads and BDCA-1 mDCs were purified using 
anti-CD1c-conjugated microbeads (both 
Miltenyi Biotec, Bergisch-Gladbach, Germany) 
after B cell depletion. Thereafter both 
celltypes were adjusted to 106 cells/ml in X-
VIVO-15 (Lonza, Verviers, Belgium) 
supplemented with 2% human serum 
(Sanquin, Nijmegen, The Netherlands). PDC 
and mDC purity was routinely up to 95%, as 
assessed by double staining with BDCA-
2/CD123 or CD11c/CD1c (all Miltenyi Biotec). 
PDCs were activated through the addition of 5 
μg/ml ODN-CpG-C (M362, Axxora, San Diego, 
CA) or 4  μg/ml R848 (Axxora, San Diego, CA). 
Monocyte-derived DCs (moDCs) were 
generated from adherent peripheral blood 
mononuclear cells (PBMCs), by culturing in 
the presence of IL-4 (500 U/ml) and GM-CSF 
(800 U/ml) (both Cellgenix, Freiburg, 
Germany). Cells were cultured in X-VIVO 15 
medium supplemented with 2% of human 
serum and harvested on day 6 as immature 
DC. Immature DC or mDCs were activated 
through the addition of 4 μg/ml R848 and/or 
20 μg/ml Poly I:C (Sigma Aldrich). Oxaliplatin 
was added during DC activation, as indicated. 
 
Flow cytometry  
Purity of pDCs and mDCs after isolation and 
the phenotype of the pDC populations was 
determined by flow cytometry. The following 
primary monoclonal antibodies (mAbs) and 
the appropriate isotype controls were used: 
anti-BDCA2-PE and CD123-APC (all Miltenyi 
Biotec); mIgG1-PE, mIgG1-APC, anti-HLA-ABC-
PE (W6/32), anti-HLA-DR/DP-FITC (Q5/13), 
anti-CD40-PE, anti-CD80-PE, anti-CD86-PE, 
anti-CD86-APC, anti-PD-L1-PE, anti-PD-L2-PE,  
(all BD Bioscience Pharmingen, San Diego, CA, 
USA); anti-CD83-PE (Beckman Coulter, 
Mijdrecht, the Netherlands). Intracellular 
staining for STAT proteins: PDCs were 
harvested using TEN harvest buffer and fixed 
with 4% formaldehyde by 10 min incubation 
at 37°. Cells were permeabilized by incubating 
with ice cold 90% methanol for 30 min on ice. 
Permeabilized cells were washed and 
incubate with the following primary 
antibodies: rabbit-polyclonal-anti-STAT1, 
rabbit-polyclonal-anti-pSTAT1, rabbit-
polyclonal-anti-STAT2, rabbit-polyclonal-anti-
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 pSTAT2, rabbit-monoclonal-anti-STAT3, 
rabbit-monoclonal-anti-pSTAT3, rabbit-
polyclonal-anti-STAT6 (all from Cell Signaling), 
goat-polyclonal-anti-pSTAT6 (BD Bioscience). 
Cells were washed twice and incubated with 
Goat-anti-mouse-Alexa647 or goat-anti-
rabbitAlexa647 as secondary antibodies. 
Mean fluorescence intensity and percentage 
of positive cells were determined by flow 
cytometry on a FACSCalibur (BD Biosciences, 
San Jose, CA, USA). 
 
Mixed lymphocyte reaction 
Allogeneic peripheral blood lymphocytes 
(PBLs) were co-cultured with differently 
matured pDCs, mDCs and moDCs in a 96-well 
round bottom plate (pDC:PBL ratio 1:20 with 
1*105 PBL).  After 4 days of culture, 1 µCi/well 
([0.037 MBq]/well; MP Biomedicals, 
Amsterdam, the Netherlands) of tritiated 
thymidine was added for 8h and 
incorporation was measured in a beta-
counter. In some experiments blocking 
antibodies against PD-L1 (e-Bioscience, San 
Diego, USA) were added to the culture at a 
final concentration of 10 μg/ml. Normal 
mouse serum was used as isotype control. 
Antibodies against PD-L1 were pre-incubated 
with pDCs for 30 minutes before adding PBLs. 
T-cell proliferation data were normalized to 
account for intra-experimental differences. 
 
Cytokine detection 
PDCs and mDCs were cultured overnight at a 
concentration of 105 DCs/100 μl/well in a 96-
wells roundbottom plate. Supernatants were 
collected from DC cultures after 16 h of 
activation, and IFNα and IL-6 production was 
analyzed by murine monoclonal capture and 
HRP-conjugated anti-IFNα antibodies (Bender 
MedSystems, Vienna, Austria) or anti-IL-6 Abs 
(Sanquin, Amsterdam, The Netherlands) using 
standard ELISA procedures. TNFα, RANTES, IP-
10 and MIP-1α production was measured 
using a human Multiplex kit (Bender 
MedSystems) according to manufacturer’s 
instructions.  
 
Preparation of protein lysates and Western 
blotting 
2x105 cells were lysed in 20 μl lysisbuffer 
containing 10 mM Tris/HCl pH 7.8, 5 mM 
EDTA, 50 mM NaCl, 1 mM Na3VO4 10 mM 
pyrophosphate, 50 mM NaF, 1% Triton X-100, 
1mM PMSF, 10 μg/ml aprotinin, 10 μg/ml 
leupeptin and 1X Roche protease inhibitor 
cocktail (Roche Diagnostics Nederland BV, 
Almere, the Netherlands). Samples were 
subjected to polyacrylamide gel electro-
phoresis and further processed for Western 
blot analysis. After blocking, membranes were 
incubated with one the following antibodies: 
mouse-monoclonal-anti-β-actin (1:20,000; 
Sigma-Aldrich, St. Louis, MO), purified mouse-
anti-PTP1C/Shp-1 (1:250; BD), rabbit-
polyclonal-anti-STAT1, rabbit-polyclonal-anti-
pSTAT1, rabbit-mono-clonal-anti-STAT3, 
rabbit-monoclonal-anti-pSTAT3 (all from Cell 
Signaling). After washing, the membranes 
were incubated with one of the goat-anti-
mouseIRDye800CW (LI-COR Biosciences, 
Lincoln, NE) or polyclonal goat-anti-
rabbitAlexaFluor-680 (Molecular Probes, 
Eugene, OR) as secondary antibody, and 
analyzed with the LICOR Odyssey Imaging 
system (LI-COR Biosciences). Integrated 
intensities were analyzed using Excel 
(Microsoft Corp., Redmond, WA). 
 
Statistics 
All experiments were performed at least three 
times and results are shown as the mean ± 
SEM. Data sets were either tested by a 
Student t test or One-way ANOVA followed by 
Newman Keuls or Dunnett’s multiple 
comparison test. 
 
Results  
Oxaliplatin differentially regulates the 
allostimulatory capacity of activated human 
DC subsets 
When moDCs were exposed to the platinum-
based chemotherapeutic compound 
oxaliplatin during activation significantly 
higher T cell proliferation was induced 
compared to moDCs activated without the 
addition of oxaliplatin (Figure 1A and24). Since 
oxaliplatin is given intravenously to cancer 
patients, this finding prompted us to 
investigate the effect of this drug on blood DC 
function. 
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 In contrast to what we observed for moDCs, 
both Poly I:C (TLR3) and R848 (TLR7/8) 
activated CD1c+ mDCs induced lower 
allogeneic T cell proliferation when oxaliplatin 
was present during activation (Figure 1B). In 
line with TLR-activated mDCs, we observed 
that pDCs activated with the TLR9 agonist 
CpG-C in the presence of oxaliplatin displayed 
a significantly decreased capacity to induce 
allogeneic T cell responses (Figure 1C). 
Intriguingly, this effect was only observed 
when pDCs were activated through the TLR9 
signaling pathway using CpG-C but not 
through TLR7/8 signaling using the single 
stranded RNA analog R848 (Figure 1C). 
Oxaliplatin treated pDCs displayed similar 
viability compared to oxaliplatin treated 
moDCs (Suppl. Figure 1A, B) showing that the 
decreased T cell proliferation is not caused by 
toxicity. Thus, oxaliplatin impairs the ability of 
TLR activated blood DCs but not TLR7-
activated pDCs to induce allogeneic T cell 
responses.  
 
Oxaliplatin differentially affects the TLR 
induced cytokine secretion profile of blood 
DCs 
Next, we determined whether oxaliplatin 
modulates TLR induced proinflammatory 
cytokine and chemokine secretion by pDCs 
and mDCs. Our results show that oxaliplatin 
negatively affected the secretion of IL-6, TNF-
, IP-10 and RANTES by TLR8-activated mDCs 
(Suppl. Figure 2A), TLR7-activated pDCs 
(Figure 2A) and TLR9-activated pDCs (Figure 
2B). While oxaliplatin also negatively affected 
TLR3-induced IP-10 secretion by mDCs it had 
no effect on other cytokine and chemokine 
secretion by TLR3-activated mDCs (Suppl. 
Figure 2B). Furthermore, TLR-induced MIP-1α 
by mDCs remained unaffected upon 
oxaliplatin treatment (Suppl. Figure 2A, 2B). In 
contrast, oxaliplatin treatment affected TLR-
induced MIP-1α by pDCs (Figure 2A, 2B). A 
putative mechanism for the observed effects 
could lie in the modification of upstream 
players controlling NF- B activity, since it 
controls IL-6, TNF , RANTES, MIP-1  and IP-
10 secretion. Interestingly, we found that 
oxaliplatin had a divergent effect on the TLR-
induced IFN  secretion by pDCs. On the one 
hand, oxaliplatin treatment had no effect on 
TLR7-induced IFN  secretion, but it markedly 
increased TLR9-induced IFN  secretion by 
human pDCs (Figure 2A, 2B).  
 
Oxaliplatin modulates the TLR induced 
human blood DC phenotype 
The observations that oxaliplatin affects TLR 
induced cytokine secretion and decreased 
Figure 1 Effect of oxaliplatin on DC 
allostimulatory capacity 
Proliferation of T cells was 
measured by 
3
H-Thymidine 
incorporation and depicted as 
counts per minute. 1x105 
peripheral blood leucocytes were 
stimulated for 4 days with 5x103 
allogeneic (A) moDCs activated 
through the addition of R848 + Poly 
I:C or (B) CD1c+ mDCs activated  
through the addition of either R848 
or Poly I:C (C) pDCs activated 
through R848 or CpG-C. Where 
indicated DCs were treated with 
oxaliplatin during activation. Data 
are the mean values ± SEM of six 
measurements of at least three 
independent experiments with 
different donors (*: p<0.05; **: 
p<0.01; ***: p<0.001). 
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 blood DC allostimulatory capacity prompted 
us to investigate whether oxaliplatin had an 
effect on the phenotype of blood DCs. As 
expected, CpG-C, R848 and Poly I:C induced a 
complete activated phenotype characterized 
by upregulation of CD40, CD80, CD86, CD83, 
MHC class I and II (Figure 3 and Suppl. Figure 
3). Oxaliplatin modestly enhanced TLR-
induced upregulation of CD40 on mDCs, but 
had no effect on TLR-induced upregulation of 
MHC class I and II (Suppl. Figure 3A, B). 
Oxaliplatin did not affect expression levels of 
Figure 2 Oxaliplatin alters the TLR induced secretory profile in human pDCs Supernatants of pDC cultures following 
incubation with R848 (A) or CpG-C (B) with or without 7 μg/ml oxaliplatin were analyzed for the presence IL-6, TNF , 
IP-10, RANTES, MIP-1  and IFNα. The graphs show cytokine and chemokine production relative to pDCs activated in 
the absence oxaliplatin. Data shown are mean values ± SEM of at least three independent experiments with different 
donors (*: p<0.05; **: p<0.01). 
 
Figure 3 Oxaliplatin modulates the TLR induced human blood DC phenotype Freshly isolated CD1c+ mDCs and pDCs 
were activated overnight with either R848 or Poly I:C, for mDCs, and with R848 or CpG-C, for pDCs, with or without 7 
μg/ml oxaliplatin. Histograms show the TLR-induced receptor expression levels of the surface molecules CD80, CD83 
and CD86  on pDCs/mDCs (grey filled) compared to expression levels of oxaliplatin treated TLR-activated 
pDCs/mDCs(thick black lines) and the appropriate isotype control (thin black line). Graphs show the receptor 
expression levels of the surface molecules CD80, CD83 and CD86 of activated pDCs/mDCs relative to R848 (A), Poly I:C 
(B) activated mDCs or R848 (C), CpG-C (D) activated pDCs. Data shown are mean values± SEM of at least three 
independent experiments with different donors (*: p<0.05; **: p<0.01). 
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 CD40 and the molecules MHC class I and II on 
TLR-activated pDCs (Suppl. Figure 3C, 3D). 
However, oxaliplatin together with CpG-C 
significantly increased the expression levels of 
the maturation marker CD83 (Figure 3D). In 
contrast, R848- and Poly I:C-induced CD83 
expression was decreased after oxaliplatin 
treatment on pDCs and mDCs (Figure 3A, 3B, 
3C). Whilst oxaliplatin enhanced R848- and 
Poly I:C-induced CD86 expression on mDCs 
(Figure 3A, 3B), it impaired CpG-C-induced 
CD86 upregulation on pDCs (Figure 3C, 3D).  
Furthermore, oxaliplatin also impaired R848- 
and CpG-C-induced CD80 expression on pDCs 
(Figure 3D), although CD80 expression on 
mDCs and R848-activated pDCs remained 
unaffected (Figure 3A, 3B, 3C). These findings 
demonstrated that oxaliplatin differentially 
modulated the TLR3-, TLR7/8- and TLR9-
induced blood DC phenotype. 
 
Enhanced PD-L1 expression on pDCs after 
oxaliplatin treatment results in impaired T 
cell activation 
Besides T cell stimulatory mechanisms, DCs 
are also known to express and utilize a variety 
of T cell inhibitory mechanisms. Previously, 
we demonstrated that the enhanced T cell 
proliferation was due to the down regulation 
of PD-L2 receptor expression levels on moDCs 
24. Interestingly, as we evaluated the effect of 
oxaliplatin on TLR9 activated pDCs we found 
that PD-L1 expression was increased upon 
exposure with oxaliplatin (Figure 4A, B), while 
PD-L2 expression and other inhibitory 
molecules were not detected under any of the 
conditions tested (Figure 4B and data not 
shown). In contrast, PD-L1 expression levels 
remained unaltered upon TLR3 and TLR7/8 
stimulation and oxaliplatin treatment on pDCs 
and mDCs (Figure 4A). Inhibition of PD-L1 
signaling pathway by addition of anti-PD-L1 
blocking antibodies rescued the lost capacity 
of platinum treated CpG-C-activated pDCs to 
stimulate allogeneic T cells (Figure 4C). These 
data support the observation that 
upregulation of PD-L1, has a significant role 
on the decreased T cell stimulatory capacity of 
platinum treated pDCs. Thus, enhanced PD-L1 
and decreased CD80/CD86 expression on 
oxaliplatin treated CpG-C activated pDCs 
impairs T cell proliferation. 
 
Figure 4 TLR9 induced PD-L1 
expression is enhanced by 
oxaliplatin on human pDCs PD-L1 
and PD-L2 expression by pDCs 
activated overnight with R848 or 
CpG-C with or without 7 μg/ml 
oxaliplatin. (A) Graphs show the PD-
L1 receptor expression (MFI) by TLR-
activated pDCs/mDC with or without 
oxaliplatin. Data shown are mean 
values of at least three independent 
experiments ± SEM. (B) Histograms 
show the expression levels of PD-L1 
and PD-L2 (dark grey filled 
histograms) compared to isotype 
controls (light grey filled 
histograms)on TLR9 activated pDCs, 
of one representative experiment. (C) 
Mixed lymphocyte reaction with 
CpG-C activated pDCs in the presence 
or absence of 7 μg/ml oxaliplatin in 
the presence of blocking antibodies 
against PD-L1 or control IgG. Data 
shown are mean values ± SEM of four 
independent experiments performed 
with different donors. The effect of 
PD-L1 blocking in the various 
conditions was compared to CpG-C 
activated pDCs with IgG control 
antibodies that was set to 100% (*: 
p<0.05; **: p<0.01).  
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 IL-4 counterbalances oxaliplatin induced TLR 
modulation in pDCs 
Recently, we showed that pDCs stimulated 
with IL-4 together with a TLR9 agonist induced 
stronger allogeneic T cell responses than pDCs 
stimulated solely through TLR925. Therefore 
we sought to determine whether IL-4 could 
restore the decreased allostimulatory capacity 
of oxaliplatin treated pDCs. In accordance 
with previous findings, figure 5A illustrates 
that IL-4 enhanced the allostimulatory 
capacity of TLR9 activated pDCs. Interestingly, 
the addition of IL-4 during oxaliplatin 
treatment could partially restore the low 
allogeneic T cell proliferation by TLR9 
activated pDCs (Figure 5A). Additionally, we 
also observed that IL-4 was able to restore the 
by oxaliplatin impaired CD80 and CD86 
expression to basal levels (Figure 5B). This is 
in contrast to PD-L1 expression which 
remained high upon IL-4 stimulation 
(Figure5B). Besides inverting the 
allostimulatory capacity and expression of 
surface molecules, IL-4 also reduced the by 
oxaliplatin enhanced IFNα secretion (Figure 
5C). These data not only demonstrate that 
different environmental factors can modulate 
the functionality of TLR9-activated pDCs, but 
also show that different environmental cues 
can counteract each other during TLR9-
activation. Furthermore, these data also show 
that the balance between stimulatory and 
inhibitory signals provided by pDCs has a 
significant effect on T cell proliferation (Figure 
5D). 
 
Oxaliplatin impairs TLR9-induced STAT1 and 
STAT3 expression 
Recently, An et al. described that SHP-1 
differentially regulates the production of 
proinflammatory cytokines and type I 
interferon26. Therefore, we studied the 
potential involvement of phosphatases in 
order to pinpoint the potential candidate 
proteins responsible for the observed dual 
function of oxaliplatin on pDCs: an enhanced 
IFNα secretion and a decreased NF- B 
induced response. We hypothesized that 
oxaliplatin treatment might increase SHP-1 
expression in human TLR9 activated pDCs. In 
Figure 6A it is shown that SHP-1 expression is 
induced in human pDCs upon TLR9 activation 
Figure 5 IL-4 counterbalances oxaliplatin effects Freshly isolated pDCs were activated overnight through CpG-C in the 
presence or absence of IL-4 and/or 7 μg/ml oxaliplatin. (A) Mixed lymphocyte reaction with CpG-C activated pDCs in the 
presence and/or absence of oxaliplatin and IL-4. Data shown are mean values ± SEM of four independent experiments 
performed with different donors and normalized to CpG-C activated pDCs. Graphs show the surface receptor expression 
of (B) CD80, CD86 and PD-L1 on and (C) IFNα secretion by CpG-C activated pDCs in the presence and/or absence of 
oxaliplatin and IL-4. (D) Model; TLR-9 induced activation of human pDCs can be altered by the presence of 
environmental cues resulting in an enhanced or decreased expression profile of co-stimulatory and co-inhibitory 
molecules. This converted balances leads to more tolerogenic or immunogenic pDCs that largely influences the fate of 
the T cell response (*: p<0.05; **: p<0.01). 
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 with CpG-C. However, oxaliplatin in 
combination with CpG-C did not result in 
significant enhanced SHP-1 expression (Figure 
6A,B). Because the functional activity of SHP-1 
does not have a linear relation with its 
expression27, we also investigated the effect 
of SHP-1 inhibition using the inhibitor sodium 
stibogluconate. To exclude the involvement of 
other phosphatases we also tested the broad 
range phosphatase inhibitor suramin28,29. The 
presence of sodium stiboglucanate reduced 
the oxaliplatin induced IFNα secretion, but did 
not affect oxaliplatin induced CD80, CD86 and 
PD-L1 expression (Figure 6C). Interestingly, 
there was an increase in the effect of 
oxaliplatin in the presence of suramin hinting 
to the possibility that a phosphatase is 
involved (Figure 6C). Another recent study 
reported that oxaliplatin activates the NOTCH-
1 pathway by induction of the -secretase 
complex30. Therefore, we investigated the 
effect of pDC preincubation with a -secretase 
inhibitor on oxaliplatin induced effects. 
However, this inhibitor did not result in 
abrogation of the oxaliplatin induced effects 
(data not shown).  
Previously, Lesterhuis et al. demonstrated 
that oxaliplatin was able to dephosphorylate 
STAT624. That prompted us to investigate 
whether oxaliplatin also affects STAT signaling 
Figure 6 Oxaliplatin decreases TLR9 induced STAT1 and STAT3 expression (A) 2x105 cells were left untreated or activated 
with CpG-C or activated with CpG-C with or without Oxaliplatin (7 µg/ml). After overnight culture, cells were lysed and 
SHP-1 expression was analyzed by western blot. Data shown is of one representative experiment. (B) The graph shows 
SHP-1 expression by pDCs relative CpG-C activated pDCs. SHP-1 expression relative to actin was quantified as described in 
methods. Data shown are mean values of three independent experiments ± SEM. (C) PDCs were activated overnight by 
CpG-C without or with oxaliplatin and phosphatase inhibitors where indicated. The graphs show CD80, CD86 and PD-L1 
surface expression levels and IFNα secretion by pDCs relative to CpG-C activated pDCs. Data shown are mean values of 
three independent experiments ± SEM. (D) Freshly isolated, CpG-C activated +/- oxaliplatin pDCs were lysed and total and 
phosphorylated STAT1 and -3 expression was analyzed by western blot. One representative experiment is shown. (E) 
Histograms show the expression of total or phosphorylated STAT1, STAT2, STAT3 and STAT6 after overnight activation 
with CpG-C (grey filled; top and middle row) in the presence of oxaliplatin (thick black lines; top and bottom row) or IL-4 
(thick black lines; middle row: grey filled; bottom row). One representative experiment is shown. 
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 in TLR9 activated pDCs. We showed by both 
western blot and FACS analysis that 
oxaliplatin reduced expression levels of total 
STAT1 and STAT3 in TLR9 activated human 
pDCs (Figure 6D, 6E). However, total STAT2, 
STAT6 and expression of all phosphorylated 
STATs remained unaffected upon oxaliplatin 
treatment in TLR9 activated pDCs (Figure 6D, 
6E). In addition to oxaliplatin we also sought 
to determine the TLR9-induced STAT 
expression upon IL-4 exposure. As expected, 
IL-4 induced the phosphorylation STAT6 and 
STAT3 whereas expression and 
phosphorylation of other STATs remained 
unaltered (Figure 6E). Besides reducing the 
expression of total STAT1 and STAT3, 
oxaliplatin also impaired the IL-4 induced 
phosphorylation of STAT6 and STAT3 (Figure 
6E). All together, these data show that 
oxaliplatin affects STAT1 and STAT3 
expression and TLR9 induced signaling. 
 
Discussion 
Recent studies show that besides having a 
direct cytotoxic effect on tumor cells, 
chemotherapeutic drugs can also potentiate 
the immune system20,21.  Here, we show that 
the chemotherapeutic platinum compound 
oxaliplatin modulated TLR9 induced signaling 
in human pDCs. This modulation led to 
increased IFNα production, decreased 
inflammatory cytokine and chemokine 
secretion and decreased STAT1 and STAT3 
expression by human pDCs. Furthermore, we 
showed that oxaliplatin enhanced PD-L1 
expression levels on pDCs resulting in 
impaired T cell proliferation depending on the 
maturation stimuli. Generally, oxaliplatin is 
used in combination with other cytotoxic 
drugs as a treatment regimen for 
gastrointestinal, colorectal, esophago-gastric 
and/or pancreatic cancer. However, it 
remains to be elucidated whether the other 
active compounds in these treatment 
regimens may also affect the immunogenicity 
of human DC subsets.  
We studied STATs and protein tyrosine 
phosphatases, which are key regulators of 
intracellular signaling as an obvious 
mechanism exploited by oxaliplatin to 
modulate TLR-induced signaling. The protein 
tyrosine phosphatases SHP-1 was reported to 
block TLR-induced production of 
proinflammatory cytokines by inhibiting the 
activation of NF- B pathway and MAPKs by 
direct dephosphorylation26,31,32. Moreover, An 
et al. recently described that in mice SHP-1 
increased TLR- and RIG-I-induced type I IFN 
production by directly binding to the kinase 
domain of IRAK1 and thus inhibiting IRAK1 
activity in bone-marrow DCs, peritoneal 
macrophages and splenic CD11c+ DCs26. We 
obtained the same observations in the TLR9 
induced cytokine secretion profile after 
oxaliplatin treatment however, a role for SHP-
1 was excluded based on experiments which 
showed that sodium stiboglucanate had no 
effect. Interestingly, suramin, a broad 
phosphatase inhibitor, enhanced the 
oxaliplatin induced effects. These data 
indicate that oxaliplatin impairs the activity of 
a certain phosphatase rather than increasing 
the expression of a phosphatase. Besides 
phosphatases also kinases are involved in 
signaling upon ligand binding by TLRs33. 
Larangé et al. demonstrated that using 
specific inhibitors for JNK or JAK upon TLR7 or 
TLR8 stimulation significant changes were 
observed in the expression of certain surface 
molecules and the production cytokines33. 
These findings underscore that inhibition of 
mediators involved in downstream signaling 
after TLR stimulation have subtle but 
significant influences on cell functionality. The 
observed increased expression of PD-L1 
related to oxaliplatin treatment implicates 
undesired effects on the immunological 
elimination of tumor cells outcome in cancer 
patients. It was reported that tumor 
infiltrating dendritic cells which express PD-L1 
help to maintain the immunosuppressive 
environment10. PD-L1 expression has also 
been detected on the surface of a wide 
variety of human cancers including lung, 
colon, breast, ovary, renal cell, glioma, and 
melanoma13,34,35, and has been correlated 
with poor prognosis34,36-39. Tumors escape 
from the host immune system by attenuation 
of tumor-specific T-cell responses via PD-
L1/PD-1 interactions. Normally, PD-L1 
expression is controlled by STAT3 and 
becomes upregulated by tumor cells and 
Plasmacytoid DC in cancer & cancer therapy
130
 other immune cells upon IFN or IL-6 
stimulation34,40-43. Recently, a study showed 
that chemotherapeutic agents also induced 
PD-L1 surface expression in breast cancer cells 
and promoted PD-L1-mediated T cell 
apoptosis44. Additionally, we found that other 
platinum-based chemotherapeutic also 
induced PD-L1 and decreased CD80 and CD86 
expression on pDCs, and that oxaliplatin also 
induced PD-L1 expression on tumor cells 
(Suppl. Figure 4).  In summary, the expression 
of PD-L1 on tumors has a negative effect on 
the immunological outcome and is considered 
as a key feature of tolerogenic DCs43. 
In the present study we demonstrated that 
human pDCs, treated with oxaliplatin in the 
presence of TLR9 induced type I IFN, markedly 
increased expression levels of PD-L1. Aspord 
et al. demonstrated that in breast cancer 
tumors CD4+ T cells are present secreting IFNγ 
and IL-1345. These T cells provide an additional 
source of IFNs which in combination with 
chemotherapeutic agents can lead to 
enhanced PD-L1 expression on either tumor 
cells or on tumor-infiltrating pDCs. Moreover, 
infiltration of pDCs and expression of PD-L1 in 
severable tumors correlated with poor 
prognosis. Recently, Lesterhuis et al. 
described that platinum compounds positively 
affect the immune-stimulatory potential of 
myeloid DCs by impairing the upregulation of 
PD-L224. Together this demonstrates that 
platinum compounds have dissimilar effects 
on different DC subsets dependent on the 
presence of environmental cues. In cancer 
patients, the therapeutic off target effect of 
platinum compounds will depend on the 
presence and the amount of the different 
tumor infiltrating DC subsets, the TLR 
expression on those DC subsets, and the 
micro-environment in which they reside. 
Based on the present study, when tumors are 
infiltrated with high numbers of pDCs it would 
be beneficial to provide additional TLR7-
agonists rather than TLR9-agonists in 
combination with platinum-based 
chemotherapeutics. Combining chemo- with 
immunotherapy is already reported, showing 
that combining chemotherapy with 
immunotherapy improves patient survival 
compared to patients treated with only 
chemotherapy46. However, in order to 
become even more effective, therapeutic 
strategies should have direct cytotoxic effects 
but also be tailored based on the presence of 
tumor-infiltrating DCs and the TLR expression 
by those tumor-infiltrating DCs. This tailor-
made combination of chemotherapy with 
additional immunotherapy has great potential 
in inducing superior anti-tumor responses and 
ultimately will lead to enhanced tumor 
clearance and patient survival. 
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 Supplementary Figure 1 (A) Viability, percentage PI-/Annexin V-, of pDCs after overnight incubation with CpG C (■), 
CpG C + 4 μg/ml oxaliplatin (♦) and CpG C + 7 μg/ml oxaliplatin (▼). (B) The graph shows the percentage cell death 
of moDCs or pDCs cultured in the presence or absence of oxaliplatin after 48 hours culture. 
 
Supplementary Figure 2 Oxaliplatin modulates the TLR-induced mDC cytokine profile Supernatants of mDC cultures 
following incubation with R848 (A) or Poly I:C (B) with or without oxaliplatin were analyzed for the presence IL-6, TNF , 
IP-10, RANTES, MIP-1  and IFNα. The graphs show cytokine and chemokine production relative to pDCs activated in 
the absence oxaliplatin. Data shown are the results of one experiment.  
 
9 
133
  
  
 
 
 
Supplementary Figure 3 Oxaliplatin modulates the TLR induced human blood DC phenotype Freshly isolated CD1c
+
 
mDCs and pDCs were activated overnight with either R848 or Poly I:C, for mDCs, and with R848 or CpG-C, for pDCs, 
with or without 7 μg/ml oxaliplatin. Histograms show the TLR-induced receptor expression levels of the surface 
molecules CD40, MHC class I and II on pDCs/mDCs (grey filled) compared to expression levels of oxaliplatin treated 
TLR-activated pDCs/mDCs (thick black lines) and the appropriate isotype control (thin black line). Graphs show the 
receptor expression levels of the surface molecules CD40 and MHC class I and II of pDCs/mDCs relative to R848 (A), 
Poly I:C (B) activated mDCs or R848 (C), CpG-C (D) activated pDCs. Data shown are mean values of at least three 
independent experiments ± SEM.  
 
Supplemental Figure 4 Platinum compounds impair CpG-C induced CD80 and CD86, but enhance PD-L1 expression 
on human pDCs Freshly isolated pDCs were activated overnight with CpG-C with or without 7 μg/ml oxaliplatin, 80 
μg/ml carboplatin or 5 μg/ml cisplatin. Graphs show the receptor expression levels of the surface molecules CD80, 
CD86 and PD-L1 of pDCs relative to CpG-C activated pDCs. Data shown are mean values of at least three 
independent experiments ± SEM.  
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If we knew what it was we were doing, it would not be called 
research, would it?  
Albert Einstein 
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Abstract  
The ability to cross-present exogenous 
antigens and prime naïve CD8+ T cells has 
primarily been attributed to the professional 
antigen presenting dendritic cells (DCs). The 
current dogma that within this DC-family 
powerful cross-presenting ability is reserved 
for specialized DC subsets is firmly rooted in 
immunological literature. We performed an 
extensive literature search on the 
characterization of mouse DC subsets and 
their ability to cross-present different types 
and forms of antigens in diverse inflammatory 
conditions. From the available data we 
advocate that cross-presentation does not 
represent an exclusive trait of (a) distinct DC 
subpopulation(s) but rather is a common 
feature of the DC family in mouse as well as in 
men. Furthermore, the data imply that the 
cross-presenting ability of each subset is 
tuned and dependent on DC resident location, 
the type of antigen and antigen formulation, 
DC activation status, the presence and 
duration of inflammatory signals, and the 
phase of the response. Further insight in the 
DC mix-panel for activation and presentation 
pathways is likely to yield improved tools and 
targets to exploit the DC family’s unique cross-
presenting capacity in immunotherapy. 
 
1. Introduction  
Dendritic cells (DCs) are the professional 
antigen presenting cells of the immune system 
with the unique capacity to attract and 
activate naïve CD4+ and CD8+ T-cells 1. 
Following infection or inflammation, DCs 
undergo a complex maturation process, and 
migrate to lymph nodes where they present 
their antigens to T cells. Immature DCs are 
able to acquire various types of exogenous 
antigens through a wide range of different 
processes; (macro)pinocytosis, phagocytosis, 
receptor-mediated endocytosis, gap junctions 
or through membrane nanotubular structures 
(recently reviewed by 2). Internalized antigens 
are presented in the context of MHC class II 
molecules on the surface of APCs that are 
recognized by antigen-specific CD4+ T cells. 
Dendritic cells are refferred to as 
‘professional’ APCs as they possess the 
capacity to also present exogenous antigens in 
MHC class I molecules via the process of cross-
presentation. Antigen cross-presentation is 
crucial for the priming of CD8+ cytotoxic T cell 
responses against pathogens and tumors, but 
is also required for maintenance of self-
tolerance.  
It is generally accepted that DCs constitute a 
heterogeneous family. Different DC subtypes 
are equipped with a diverse repertoire of 
antigen capture mechanisms and innate 
sensing mechanisms 3. As such, different DC 
subsets may differ in their capacity to process 
internalized antigens, produce cytokines and 
activate T cells in response to distinct 
microorganisms. An intriguing question is 
whether cross-presentation is dictated by the 
specific DC subset or that the nature of the 
antigen or other factors affects the DC’s cross-
presenting ability.  
Many studies so far used human monocyte-
derived DCs or mouse spleen- or bone 
marrow-derived DCs to study cross-
presentation of a limited set of model 
proteins, like chicken ovalbumin (OVA), that 
are provided as cell-associated or soluble 
antigens. These studies have been front 
running and have provided the essential basis 
for our current understanding of antigen 
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 cross-presentation mechanisms. However, at 
the same time it may have skewed our 
thinking and our research into the cross-
presenting abilities of other DC subsets for 
different antigen sources. We here review the 
capacities of mouse DC populations to cross-
present cell-associated and soluble antigens, 
immune complexes, particulate antigens and 
antigens derived from non-viral intruders like 
bacteria, parasites or fungi in different 
locations and under (non)-inflammatory 
conditions. Furthermore, we extrapolate 
these finding to the recent data on human DC 
subsets. 
 
2. Phenotype and cross-presentation capacity 
of dendritic cell subsets in mouse  
 
Since Steinman’s 1973 publication 4 on the 
discovery of DCs, evolving insights in DC 
biology led to the discovery of many genetic, 
phenotypic and functional markers in DCs. 
Recent genetic profiling was tremendously 
valuable for identifying the common origin of 
many of these DC appearances and the 
transcription factors important in lineage 
commitment 5,6. Dendritic cell subsets are 
characterized by a profound expression of 
MHC class II molecules and the lack of most 
lineage-specific markers (CD3, CD19, CD56). 
Mouse DCs are currently divided into 
plasmacytoid DCs (pDCs) and conventional 
(cDCs). Plasmacytoid DCs express 
intermediate levels of CD11c, and high levels 
for CD45RA (B220), Siglec H and/or mPDCA1 
(BST-2, 120g8). Conventional DCs express high 
levels of CD11c and are further subdivided in 
blood-derived resident DCs and migratory 
DCs. The first group resides in spleen and 
lymph nodes and is generally subdivided in 
CD8α+ and CD11b+ or CD4+. Cells deficient in 
CD8α and CD11b/CD4 are often simply 
designated ‘double negative’ DCs (Figure 1). 
The characterization of DCs is an ongoing 
process that is especially complicated for the 
migratory DCs located in peripheral tissues 
and lymphoid organs (lymph nodes) due to 
tissue-specific and inflammation-dependent 
expression kinetics of the phenotypic markers. 
That this discrimination is not flawless is 
exemplified by reports showing that pDCs and 
activated migratory DCs 7 can express CD8
as well. The use of a combination of markers 
(all non-exclusive by themselves) is therefore 
advised to study the selective characteristics 
of DC subsets. The question arises whether 
efficient cross-presentation is an exclusive 
trait of some DC subpopulations or a common 
feature of many or even all DCs.  
 
2.1 CD8α+  
CD8α+-expressing DCs have been identified in 
spleen and lymph nodes and selectively 
express the transcription factor Batf3 8 and 
IRF8 9. They generally express high levels of 
CD24, CD205 (DEC-205), the chemokine 
receptor XCR1, and Clec9A. CD103 has been 
variably found, mostly on migratory CD8α+ DCs 
and may relate to an activation or 
developmental state of the CD8α+ DCs 7. 
Analyses of CD24+ DCs in CD8α-deficient mice 
and FLT3L-stimulated bone marrow-derived 
DCs revealed that CD8α –which is expressed 
as CD8αα homodimers– is dispensable for the 
characteristic functional capacities of this 
subset 10, while CD24 may provide a co-
stimulatory signal for both CD8 and CD4 T cells 
11. Since CD8α is expressed relatively late in DC 
development, is has been suggested that 
CD24+CD8α- cells may develop into CD8α+ DCs 
12.  
 
CD8α+ DCs are generally recognized as the 
dominant, if not exclusive, cross-presenting 
DC subset irrespective of the type of antigen 
(Table 1). In 2000, Den Haan et al. isolated low 
density splenocytes from mice primed with 
OVA- -/- cells and showed that ex 
vivo depletion of CD8αhigh but not CD11b+ cells 
abrogated cross-presentation to OT-I cells 13. 
Since then, an impressive body of evidence 
shows the outstanding cross-presenting ability 
of splenic CD8α+ DCs not only for cell-
associated antigens, but also for proteins, 
OVA-coated latex beads, immune complexes 
and many pathogens, including  (Plasmodium 
bergei 14, Salmonella typhimurium 15, 
Escherichia coli 16, Listeria monocytogenes 17, 
and Saccharomyces cerevisiae 18) (Table 1). 
Interestingly, an exception to the supremacy 
of CD8α+ DCs over other DC subsets came to 
light in experiments using E. coli and S. 
cerevisiae 16,18 in which CD8α+ DCs were able 
to cross-present but performed less well than 
10 
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 CD8α- DCs. This suggests that the immune 
stimulatory features of distinct pathogens 
may determine the cross-presenting capacity 
of DC subsets that evolved to acquire a 
specific armamentarium to fight that 
particular pathogen. As such, the intrinsic 
function of DCs may be largely dependent on 
environmental factors, the type of pathogen 
and the location where the DCs reside. 
This is also illustrated by the finding that 
CD8α+ DCs isolated from skin-draining lymph 
nodes failed to cross-present intra-membrane 
antigens (i.e. cell-associated antigens) in the 
K5.mOVA transgenic mouse model 19. In this 
model, the transgene ‘OVA’ is fused to the 
transmembrane domain of the transferrin 
receptor under the control of the K5 keratin 
promoter 19. In contrast, in a model where 
transgenic mice express yellow fluorescent 
protein (YFP) linked to CTL epitopes for 
glycoprotein B (gB) of herpes simplex virus 
under the rat insulin promoter (RIP), the 
CD8α+ lymph node DCs were instrumental in 
cross-tolerization of gB-specific hybridoma T 
cells 20. In contrast, CD8α+ DCs from 
mesenteric lymph nodes poorly cross-
presented intestinal soluble OVA 21. The cross-
priming function of CD8α+ DCs in lymph nodes 
might be dictated by the stimulatory activity 
in the immune environment. CD8α+ DCs in 
skin-draining lymph nodes were potent cross-
presenters of OVA-TLR7 conjugates 22 and 
Saponin-formulated antigens 23, emphasizing 
the potential of PRR-ligands and adjuvants in 
cDC function.  
Recent studies revealed that splenic 
CD8α+CD103+ DCs presented cell-associated 
and soluble antigens more efficiently than 
CD8α+CD103- DCs 24, suggesting even more 
additional functionally discrepant roles within 
the CD8α+ subset. The above-mentioned 
studies did not distinguish the CD103+ and 
CD103- CD8α+ DCs, which hampers the 
interpretation of the results for these subsets 
in lymph nodes or for other types of antigen. 
Although CD8α is not expressed in in vitro-
generated FLT3-L DCs cultures, the use of 
CD24 enables the identification of CD8α+ DC 
equivalents showing potent cross-presenting 
capacity for cell-associated 10,25,26 and soluble 
25-27 antigens, and antigen-coated latex beads 
26. Moreover the cross-presentation of cellular 
28,29 and soluble 28 antigens resided 
predominantly in the CD103+ DCs. The 
expression of CD103 per se seems however 
not equivalent to a cross-presenting 
phenotype 28. 
In conclusion, CD8α+ are able to cross-present 
a broad spectrum of antigenic formulations at 
steady state conditions, but environmental 
factors may affect that function in the 
peripheral lymphoid organs, in particular in 
responses to non-sterile infections. 
 
2.2 CD11b DCs 
The transcription factor RelB drives the 
development of cDCs 8 that lack CD8α but 
Figure 1 Phenotyping of 
mouse spleen DCs. 
Spleens were isolated from 
mice harboring a B16 tumor 
transfected to continuously 
produce FLT3-L. Spleens were 
digested using 
collagenase/DNase and single 
cell suspensions were 
prepared. After OptiPreg 
density gradient, cells were 
labeled with CD11c, B220, 
CD172, CD11b, CD8, CD4, BST-
2, CD205, and 33D1. Cells 
were selected based on 
forward/side scatter following 
exclusion of duplicates. 
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 express CD11b. CD11b expression coincides 
with CD172a (Sirp-α) 30, DCIR2 (33D1) and may 
show some overlap with the expression of 
Dectin-1 (Clec7a) 31. Less than 50% of 
CD11b/CD172a express CD4 (Figure 1), but no 
clear discrimination has been found in the 
function between CD4+ and CD4- CD11b+ DCs.  
 
Studies using steady state splenic DCs that 
lack CD8α 32-34 or express CD11b 10,13,20,35-37 or 
CD4 38-40 unanimously conclude that these 
cells are inefficient in cross-presenting cell-
associated antigens (Table 1). Similar results 
were found for soluble proteins 21,25,32,34,39,41-43 
or antigen-coated beads 11,39,42. Furthermore, 
CpG-matured CD11b+ DCs loaded with dying 
cells failed to cross-present their cargo in vivo  
35. Based on these studies, it was suggested 
that these DCs generally have poor cross-
presenting capabilities. Interestingly, CD8α- 44 
and CD11b+ DCs induced potent responses 
when immune complexes were used instead 
of cell-associated or soluble antigens 43. 
Moreover, CD4+ DCs were potent cross-
presenters of soluble antigens when 
administered in the presence of saponin-
based adjuvants 23 and initiated CD8 T cell 
responses to E. Coli 16,39. DCs identified by the 
lack of CD8α expression were further efficient 
in cross-presenting OVA antigens from 
Salmonella typhimurium (more than CD8α
DCs) 15 and yeast (Saccharomyces cerevisiae) 
18. These data emphasize the importance of 
specific immune activation signals to acquire 
the ability to cross-present. The exact 
mechanism for the stimulation of cross-
presentation by saponin-based adjuvants is 
not clear yet. Elucidation of this mechanism is 
of interest as, in contrast to most clinically 
used adjuvants, these adjuvants seem to 
particularly stimulate CD8 T cell responses 
23,45. 
 
2.3 CD8α-CD11b- DCs 
In 2007, Vremec et al. described a population 
of spleen DCs that expressed CD24, but no 
CD4, CD8 and CD11b/CD172α. The cross-
presenting capacity of these cells was 
however largely similar to that of the CD8α+ 
DCs. Forty-two percent up-regulated CD8α 
after overnight culture 46 and 80% of 
CD24+CD8α- cells expressed CD8α four days 
after transfer 12, suggesting that these cells 
were ‘in transit’ towards a CD8α+ DC 
phenotype. Janssen et al. isolated splenic 
CD11b- DCs, sorted these cells in CD8α+ and 
CD8α- subsets, and found that CD11b-CD8α- 
DCs were even more potent cross-presenters 
of cell-associated antigens than CD8α+ DCs 
under steady state conditions 47. However, 
these cells did not show CD8α upregulation 
upon transfer, which makes it difficult to 
conclude whether they are the same cells as 
described by Vremec and Bedoui (unpublished 
data EJ). In additional experiments the CD11b-
CD8α- DCs were found to preferentially 
internalize small particles derived of dying 
cells (and were accordingly designated: 
merocytic DCs) that are stored in non-acidic 
compartments with reduced lysosomal 
degradation for prolonged periods of time. 
The size of internalized particles by merocytic 
DCs seems favorable for cross-presentation 
(0.5 and 3 μm) 48. These traits resulted in 
sustained antigen presentation to both CD4+ 
and CD8+ T cells with enhanced effector 
functions and memory formation when 
compared with CD8α+ DCs 36,37. Merocytic and 
CD8α+ DCs have comparable reactive oxygen 
species production in the resting and 
activated states and express mRNA for all 
genes of the NAPDH complex at similar or 
even higher levels than CD8α+ DCs 
(unpublished data EJ). These data suggest that 
they could possibly exploit a comparable 
mechanism as CD8α+ DCs to delay antigen 
degradation and enhance their Ag-presenting 
capacity.  
The differences in function, location, and 
migratory pattern of DCs not only point to 
specialized roles in immune responses but 
also signify additive and interdependent 
relationships. Notably, the cross-presenting 
capacity of merocytic DCs was also most 
increased after cross-talk with pDCs when 
compared to CD8α+ and CD11b+ DCs 35. It 
would be very interesting to dissect the role of 
merocytic DCs in responses against bacterial 
or viral infections and other sources of 
antigens in vivo. Remaining questions 
regarding this subset are whether CD103 and 
CD207 can be induced and, most importantly, 
if there is a human equivalent of this 
powerful, novel cross-presenting DC subset. 
10 
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2.4 Mouse pDCs 
In contrast to the abundant amount of 
literature on cross-presentation by splenic 
cDCs, the ability of pDCs to contribute to the 
cross-presentation remains largely 
understudied. The few executed studies 
demonstrated that splenic murine pDCs do 
not cross-present cell-associated antigens 
36,37,47, soluble OVA and peptide-coated beads 
49 in a steady state (Table 1). There was also 
no CD8+ T cell priming by pDCs in response to 
Listeria monocytogenes 17, Plasmodium 14 or 
by pDCs from mesenteric lymph nodes after 
intragastric administration of protein 21. In 
vitro-generated FLT3-L pDCs also showed low 
responses when loaded with cell-associated 
antigens 47 or soluble antigens 50,51. In 
contrast, one study showed that activation of 
pDCs by TLR7/8 ligand R848 and to a lesser 
extent CpG (TLR9) led to efficient cross-
presentation of soluble antigens and antigen-
coated beads 49, again emphasizing the 
significance and strength of specific 
stimulation of distinct DC subsets to induce 
the cross-presenting capacity. 
 
2.5 Migratory DCs  
Migratory DCs may differ in phenotype 
dependent on the microenvironment where 
they reside, such as skin, intestine or lung 
tissues. In skin, Langerhans cells (LCs) 
abundantly express the C-type lectin Langerin 
(CD207) and were initially reported to cross-
present OVA in the K5.mOVA transgenic 
mouse model 52. Later findings indicated that 
CD207 was also expressed by (CD103+) dermal 
DCs, which were actually the only DCs to 
cross-present OVA derived from keratinocytes 
19. Cross-presentation of cell-associated 
antigens by LCs has thus never been observed 
despite their location in the region where the 
antigen is present 19,53. Langerhans cells 
however stimulated CD8+ T cell responses 
against a TLR7-conjugated antigen 22 and were 
efficiently targeted in vivo for cross-
presentation of anti-DEC205-coupled OVA. 
Remarkably, LCs targeted through langerin 
failed to stimulate T-cell proliferation 54.  
Mice expressing eGFP under the control of the 
langerin gene showed that CD207 is also 
expressed (although at lower levels) in dermal 
(d)DCs, and in some CD8α+ DCs in cervical and 
mesenteric lymph nodes and spleen. Dermal 
DCs are generally subdivided into CD207+ and 
CD207- dDCs. CD207+ dDCs in skin and lymph 
nodes contain a population of CD103+ that, 
similar to CD8α+ DCs, co-express XCR1. Skin-
derived CD103+ dDCs however failed to cross-
present TLR7-conjugated antigens, which 
were presented instead by CD103-CD205-
CD326- DCs and to a lesser extent by 
CD11b+CD205-CD326- DCs (claimed to be 
resident CD11b DCs) 22. CD207- dDCs differ in 
their expression of CD11b 53. The expression 
of CD11b is quite promiscuous hampering the 
discrimination of dDCs and blood-borne 
CD11b DCs residing in the lymph nodes. The 
lack of CD205 and CD326 expression has been 
suggested as a feature of CD11b-resident DCs 
55.  
DCs have been identified in intestinal tract (in 
Peyer’s patches, mesenteric lymph nodes and 
lamina propria) and the lung mostly using the 
markers CD11c(+), CD11b(-and+), CD103(+) and 
F4.80(-) 55,56. CD11b+ DCs in the mesenteric 
lymph nodes cross-presented intra-gastric 
administered antigen better than CD8α+ DCs 
21. In contrast, CD103+ DCs, and not 
CD11b+CD205int DCs, presented soluble 
antigens in lung draining lymph nodes 55. Due 
to the limited number of, and experimental 
diversity in these studies it is hard to draw 
conclusions on the functional properties of 
specific migratory DC subsets. In general, 
more in depth studies should be undertaken 
to elucidate the role and cross-talk between 
different lymph node DCs to efficiently make 
use of the intrinsic ability of DCs in specific 
vaccination settings.  
 
2.6 Mouse bone marrow-derived DCs  
The in vitro generation of DCs from bone-
marrow cells using GM-CSF alone or in 
combination with IL-4 has a long history as a 
DC-model system. These cells clearly possess 
cross-presenting ability of cell-associated 
antigens 25,47,57,58, immune complexes 59-64, 
PLGA-particles 65 or polystyrene beads 66, and 
can be efficiently targeted with anti-DEC205 59 
or anti-DC-SIGN 67. Responses to soluble 
protein vary from no 63,64 65, low 62, to high  
25,59,60,67-70 reactivity. The sub-optimal results 
with soluble antigen may be overcome by 
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 using an adjuvant, such as saponin-based 
adjuvants 45,71. Administration of long peptides 
72-74, which can result in the presentation of 
multiple epitopes in association with both 
MHC class I and II molecules, might also be a 
promising alternative 75. Schreurs et al. 
showed that mouse bone marrow-derived DCs 
display similar morphology, phenotype and 
immunostimulatory activity as compared to 
blood monocyte-derived DC. These results, 
combined with the relatively high numbers of 
cells that can be generated in vitro, still 
furthers the use of Mo-DCs in DC vaccines in 
patients.  
The in vivo identification of the exclusive 
phenotype and function of Mo-DCs is a 
trending topic of research in both mouse and 
man. Mo-DCs isolated from spleen were 
characterized by the expression of 
(CD11b+Ly6c+CD11c+MHCII+) and efficiently 
cross-presented soluble antigens 34,76. A recent 
study from the Steinman laboratory describes 
that fully differentiated Mo-DCs are marked 
by DC-SIGN/CD209a expression and also 
reported cross-presentation of soluble 
antigens and E. Coli-OVA 25. These cells were 
CD11c+CD11b+ but showed no positivity with 
the Gr1 antibody, suggesting that fully 
differentiated Mo-DCs lose their Ly6c 
expression. The overlap in these populations 
and the so-called TNF/iNOS producing (TiP 
DCs) needs to be established, which is 
complicated due to the timely expression of 
markers, such as Ly6c, in different phases of 
monocyte-to-DC differentiation and 
maturation. New markers, such as Fc receptor 
phenotypes might be helpful for better 
discrimination. 
 
3 Human DC subsets   
Phenotyping dendritic cell subsets in human 
lymphoid tissues and blood 
In human blood, both pDCs and cDCs are 
generally characterized by the lack of lineage 
marker expression (CD3, CD14, CD19, CD56) 
and a high expression of the HLA-DR molecule. 
Human pDCs are discriminated by the 
expression of BDCA2, BDCA4 or CD123 and 
the lack of CD11c expression. The circulating 
DCs are CD11c+ and are divided according to 
the specific and non-overlapping expression of 
CD1c (BDCA1) and CD141 (BDCA3). In some 
studies CD16highCD14lowHLA-DR+ cells have 
been described as a subset of DCs, whereas 
others identify them as non-classical 
monocytes 77,78. The Nomenclature Committee 
of the International Union of Immunological 
Societies does not recognize CD16+ (Lin-
MHCII+) cells as a separate DC subset, but 
leave the opportunity for additional subsets 
within blood DCs 77. 
Segura et al. recently characterized DCs in 
human lymph nodes, tonsil and spleen in 
untreated breast cancer patients and 
described pDCs (BDCA4), LCs (Epcam+), CD1a+ 
DCs, CLEC9a+ DCs and two populations of 
BDCA1+ DCs showing differential expression of 
CD206. Three of these DC subsets (LCs, CD1a+ 
and CD206+ DCs) were absent from cervical 
LNs draining the oropharynx, iliac LNs, tonsils, 
and spleen suggesting that these cells 
specifically drain from the skin 79. Finally, 
differentiation of monocytes to DCs can be 
mimicked in vitro by culturing total bone 
marrow cells, adherent PBMCs mainly 
consisting of monocytes or purified 
monocytes in medium containing GM-CSF 
supplemented with or without other cytokines 
like IL-4, IFN- - -15. At last, the 
generation of DCs from CD34 precursors may 
represent a potential model system closely 
resembling both cDCs and pDCs 72.  
 
Cross-presenting capacity of human dendritic 
cell subsets 
Based on genetic profiling studies BDCA1+ DCs 
are presented as the human counterpart of 
murine CD11b+ DCs 5,6,80. However, there are 
some discrepancies between the findings in 
these equivalent cell types. In contrast to 
CD11b+ DCs, BDCA1+ DCs cross-present cell-
associated 81-85, long peptides  79, soluble 
antigens 71,83,85,86, as well as immune 
complexes 84 (Table 2). In some studies these 
responses were however rather low in steady 
state conditions, and could be enhanced by 
either TLR ligands 82 or saponin-based 
adjuvants 71,81,84. Direct comparison indicated 
that the BDCA1+ DCs are less efficient in cross-
presentation than BDCA3+ DCs. Of note, low 
levels of CD14 are expressed on BDCA1+ DCs, 
which should be taken into account when 
CD14 is used as a lineage marker as CD14+ 
cells will thus be excluded from the sample.  
10 
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 In contrast to murine pDCs, human pDCs 
cross-present cell-associated antigens 81,82,87 
and a vaccinal lipopeptide preparation 81, but 
fail to cross-present immune complexes or 
antigens packed within an saponin-based 
adjuvants formulation 84. Soluble antigens 
were also not very efficiently presented by 
pDCs 84,85, although one report shows slightly 
increased numbers of IFN-
after stimulation with either blood or splenic 
human pDCs 86.  
In 2010, analyses by different groups showed 
that the human BDCA3+ and the murine CD8α+ 
DCs not only shared gene expression patterns 
but also showed overlapping functionality in 
the cross-presentation of cell-associated 
antigens 82,83,85, long peptides 79 and soluble 
proteins 83,85,86. It was observed that blood DCs 
are very poor cross-presenters unless properly 
activated by TLR-agonists 79,82,83 emphasizing 
these cells require activation to gain cross-
presenting functions. Poulin and colleagues 
set up a culture method to generate BDCA3+ 
DCs from cord blood HSCs that were able to 
cross-present long peptides when matured 
with the TLR3 ligand Poly I:C 72. These studies 
fostered the suggestion that targeting BDCA3+ 
DCs could lead to the most efficient induction 
of CTL responses against cancer or viral 
infections. The extremely low numbers of 
BDCA3+ DCs circulating in peripheral blood 
may however limits the ex vivo modulation of 
these cells and asks for efficient in vivo 
targeting strategies. Alternatively, adaptation 
of the protocol used by Poulin et al. 72 may 
lead to generation of cord blood DCs enriched 
for this specific subset. 
The few studies that took along CD16+ cells 
showed very low induction of responses 
against cell-associated and soluble antigens 
85,86. Their efficacy to cross-present immune-
complexed antigens or pathogenic material 
remains to be elucidated. Studies with human 
Mo-DCs differentiated in vitro with GM-CSF 
and IL-4 report very variable results with 
regard to effective cross-presentation 71,72,84,88-
92. Ex vivo data on cross-presenting function of 
monocytes is not readily available. 
 
 
 
4. Factors influencing cross-presenting 
capacity 
 
Based on the aforementioned data analysis 
the capacity to cross-present exogenous 
antigens appears not simply restricted to a 
specialized DC subset. Rather, the DC’s cross-
presentation program can be initiated in most 
if not all subsets depending on the specific 
conditions a DC subset encounters. Although 
still little is known regarding this 
programming, emerging factors important for 
the modulation of the cross-presentation 
functions of specific DC subsets are: 1) the 
type of antigen, 2) the presence of DC 
stimulatory factors, which can be dramatically 
altered by the pathogen or adjuvants, and 3) 
the timing and phase of the immune 
response. Given the central position of DCs in 
the maintenance of immune homeostasis, 
improved insights into the factors regulating 
DC cross-presentation will be of great value 
for the development of novel immune 
therapeutic strategies. 
 
Type of Antigen 
Dendritic cells encounter antigens in many 
shapes and sizes, derived from various 
different sources, e.g. soluble peptides, 
proteins, cell-associated, bacterial, etc. The 
ability of DCs to handle all these different 
types of antigens is largely determined by the 
repertoire of antigen uptake receptors, and 
the ability to engulf antigens through receptor 
independent processes, such as (micro) 
pinocytosis. The current paradigm of superior 
cross-presentation by murine CD8α+ DCs is 
mainly derived from the preferential use of 
specific antigen types such as cell-associated, 
a restricted number of soluble model antigens 
or bead-bound antigens (mostly OVA). An 
underrepresented number of studies found 
that CD8α+ DCs actually perform relatively 
poorly in cross-presenting immune-complexes 
when compared with CD8α- DCs. The same 
was observed for presentation of yeast- 18 and 
Salmonella-derived antigens 15. In some cases 
results may be affected by the disregard of 
additional markers to distinguish CD11b+ cells 
from merocytic cells, which are even more 
potent cross-presenters of cell-associated 
materials in direct comparison analyses. This 
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 may affect results in studies where DCs are 
isolated from FLT3-ligand treated mice as 
CD8α-CD11b-DCs are preferentially enriched in 
these animals 12,37.  
It has been established that DCs exploit 
endocytic receptors, such as the mannose 
receptor (recognizing OVA), to transport 
antigens into early endosomes in which 
subsequently the cross-presentation 
machinery will be recruited. Uptake by FcRn 
was essential for the uptake (and thus 
presentation) of immune complexes by 
CD11b+ DCs. The same was true for OVA-
coated beads that were only cross-presented 
when opsonized with IgG 43. Similarly, human 
blood BDCA3+ DCs induced strong T cell 
activation upon internalization of soluble 
protein, indicative for a potent cross-
presenting machinery, whereas pDCs hardly 
induced T cell activation 85. The finding that 
pDCs did not cross-present soluble protein is 
not unexpected because an earlier study 
showed that pDCs inefficiently take up soluble 
proteins in a receptor independent fashion. In 
contrast, pDCs very efficiently internalized and 
presented antigens from immune complexes 
93. Klechevsky et al. demonstrated that when 
antigens are targeted trough the C-type lectin 
receptor DCIR, all tested human DC subsets 
including ex vivo-generated DCs, skin-isolated 
LCs, and blood myeloid DCs and pDCs were 
able to cross-present antigens and activate 
CD8+ T cells 94. These studies underscore the 
notion that virtually all DCs have the 
machinery to cross-present antigens provided 
that the antigen is offered to the DC in a 
suitable format at the appropriate conditions. 
Hence, when analyzing the functional 
characteristics of DCs, the capacity to handle 
different types of antigens should be carefully 
taken into account. 
 
Stimulatory factors regulating DC cross-
presentation 
Each DC subset contains a restricted set of 
(inducible) pathogen recognition receptors 
that may have developed to react to a 
particular group of pathogens expressing a 
unique set of pathogen-associated molecular 
patterns. The recognition of such patterns (for 
example, by activation of TLRs) leads to the 
upregulation of co-stimulatory molecules, 
secretion of inflammatory cytokines and 
enhanced cross-priming. Furthermore, TLR-
induced activation enhances peptide loading 
onto MHC class I molecules by the 
recruitment of the cross-presentation 
machinery to the endosomes 70. 
Detailed comparison of cross-presentation of 
antigens derived from diverse pathogens is 
currently missing. Data on the function of 
distinct DC subsets in lymph nodes upon 
pathogenic infections is particularly lacking. At 
this point it is uncertain whether the immune 
stimulatory features or other properties of 
pathogens are decisive in the functional 
characteristics of the DCs. The trick may not 
always be found in cell activating molecules. 
Co-expression of LLO, a lysosome-disrupting 
haemolysin from Listeria monocytogenes, 
enhanced cross-presentation of OVA-E. coli 16, 
illustrating that specific proteins/enzymes 
enable access of antigens to the cytosol and 
thereby improves the cross-presenting 
capacity of a DC. This means altogether that 
care should be taken when generalizing the 
capacities of DCs in immune responses against 
certain groups (intra- or extracellular) of 
pathogens.  
The stimulation of cross-presentation by 
specific adjuvants has been established for a 
large set of TLR-ligands 49,50,72,83,95, illustrating 
that conclusions on antigen-presenting 
capacities between subsets are very 
dependent on the stimulatory agents used in 
different studies. The timing of stimulation 
relative to antigen encounter is a crucial 
factor. TLR stimulations shut down the ability 
to internalize certain antigen uptake receptors 
96,97 and may impair cross-presentation 24,98, 
and thus limit the clinical efficacy of otherwise 
potent adjuvants 99. 
 In addition, it is becoming evident that DCs do 
not work as stand-alones in combating 
infections as their surrounding environment 
can significantly alter their cross-presenting 
and cross-priming potential. For example, type 
I interferons are shown to improve the 
capacity of DCs to store and process 
exogenous antigens leading to enhanced 
cross-presentation and activation of antigen 
specific CD8+ T cell responses 100-102. 
Furthermore, also other soluble factors or 
immune cells that reside at different locations 
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 can have a major impact on the 
immunological outcome. DCs that reside in 
the gut are embedded in a completely 
different micro-milieu compared to DCs that 
are found in the skin or that circulate in the 
blood. Therefore, the location and the micro-
milieu at the location also largely determine 
the cross-presenting potential of DCs. The 
CD141+ DCs in blood only cross-present when 
matured (Poly I:C), whereas CD141+ DCs that 
have differentiated further and migrated to 
the skin are already cross-presenting without 
additional stimulation 103. It remains a major 
challenge to identify these checkpoints in the 
regulation of DC functions. 
 
Timing of antigen entry and stage of immune 
response 
The timing of analyses can also bias the 
conclusions on the cross-presenting capacity 
of DCs after exposure. Harvesting DCs from 
antigen-challenged mice after 18 hours 
showed cross-presentation by CD8α+ and 
dDCs, whereas CD8α+ DCs were unable to 
prime CTLs when isolated 36 hours after 
stimulation 22. Similar results were found by 
Bedoui et al. who investigated the capacity of 
DCs in brachial lymph nodes at day 2 (primary 
infection site) and axillary lymph nodes at day 
6 (secondary site) to cross-present HSV-1 
antigens to gBT-I cells ex vivo and found that 
CD8α+ DCs presented antigens on both time 
points, whereas the cross-presenting capacity 
of migratory CD103+ DCs was only visible at 
day 6 post infection 19. Also immunization in 
the presence of saponin-based adjuvants led 
to a dominant role for CD8α+ DCs after 12 
hours, while migratory DCs joined in and 
efficiently cross-presented antigens after 24 
hours, and even after 48 hours  23. These data 
emphasize the significance of separate DC 
subsets that are all instrumental for cross-
priming but at different time points during the 
initiation of an immune response. 
Another important factor, which should be 
taken into account when studying cross-
presentation, is the phase of the immune 
response. As mentioned above, pDCs 
inefficiently take up soluble proteins, but do 
take up protein immune-complexes. These 
data suggest that pDCs may not be first in line 
with respect to MHC class I presentation of 
soluble proteins, but rather play a role in the 
second line of defense when the immune 
system has generated specific antibodies 
against this protein. Of note, in the initial 
phase of the immune response pDCs produce 
large amounts of type I interferons that not 
only signal foreign invaders but also trigger 
antigen cross-presentation by conventional DC 
101. It can be appreciated that this is a general 
phenomenon that does not solely account for 
pDCs or Fc receptors. Therefore, it should be 
emphasized that not only the antigen and the 
stimulatory environment, but also the timing 
and the phase of the immune response are 
crucial factors that determine the cross-
presenting potential. 
 
5. Conclusion 
 
In all, the available data is in line with the idea 
that all the classically characterized DC 
subsets have the ability to cross-present 
exogenous antigens. The antigen formulation 
appears to be of crucial importance and 
determines which DC subset is most eligible 
for the job. In addition, the microenvironment 
as well as the inflammatory signals present in 
the environment are decisive factors 
determining which DC subsets will be involved 
as they co-determine the programming of DC 
and their activation/differentiation into fully 
functional cross-presenting DCs. 
Understanding the genetic reprogramming of 
distinct DC subsets under different 
inflammatory conditions should provide 
further insight into the plasticity and 
exclusivity of functional specializations of DC 
subsets, including their ability to cross-present 
exogenous antigens. Increased know-how on 
the identification of dents on the keys to kick-
start the desired antigen-presentation 
pathways will be instrumental for vaccine 
adjuvant development and should ultimately 
lead to effective vaccination strategies against 
cancer and infectious diseases.  
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 Table I: Mouse spleen 
Subsets defined by: Cell-associated Soluble Protein IC Particulate Bacteria/Yeast/Parasite 
CD8α+CD11b- Yes, High  
den Haan, 2000 
Schulz, 2002 
Schulz, 2002 
Iyoda, 2002 
Naik, 2005 
Schnorrer, 2006 
Wilson, 2006 
Janssen, 2006 
Bedoui, 2009 
Reboulet, 2010 
Nierkens, 2011 
Dresch, 2011 
Hoves, 2011 
Zhan, 2011 
Diamond, 2011  
Yes  
Pooley, 2001 
Iyoda, 2002 
Schnorrer, 2006  
Chung, 2005, 
Lin, 2008 
Savina, 2009 
Segura, 2009 
Cheong, 2010 
Baker, 2011  
Dresch, 2011 
Zhan, 2011  
Wilson, 2011 
 
Yes, High  
den Haan, 2002 
Low  
Baker, 2011 
Yes  
Schnorrer, 2006 
Askew, 2008 
Savina, 2009 
Yes  
(e.Coli) 
Schulz, 2002 
Schnorrer, 2006 
(rLM) 
Belz, 2005 
(Plasmodium)  
Lundie, 2008 
(Salmonella)   
Yrlid, 2002 
Intermediate 
(yeast)  
Backer, 2008 
CD8α+CD103- No 
Qiu, 2009 
Low 
Qiu, 2009 
   
CD8α+CD103+ Yes  
Qiu, 2009 
Yes 
Qiu, 2009 
 
 
  
CD8α- No  
Iyoda, 2002 
Hoves, 2011  
Segura, 2009 
Yes  
Iyoda, 2002 
Low  
Lin, 2008  
Segura, 2009 
Chung, 2005 
Savina, 2009 
High  
den Haan, 2002 
No  
Schnorrer, 2006 
Low  
Savina, 2009  
Yes  
(yeast)  
Backer, 2008 
(Salmonella) 
Yrlid, 2002 
CD8α-CD11b+ No  
den Haan, 2000 
Belz, 2002  
Naik, 2005 
Nierkens, 2011 
Low  
Reboulet, 2010 
Hennies, 2011 
Low  
Baker, 2011 
No  
Cheong, 2010 
Yes  
Baker, 2011 
  
CD4-CD8- Low  
Schulz, 2002 
Schnorrer, 2006 
 
Low   
Schnorrer, 2006 
Only mature   
Pooley, 2001 
  No  
(Plasmodium) 
Lundie, 2008 
CD4+ No  
Schulz, 2002  
Schnorrer, 2006 
Diamond, 2011 
No   
Pooley, 2001 
Low  
Schnorrer, 2006 
Yes (ISCOMETRIX) 
Wilson, 2011 
 No  
Askew, 2008 
Yes 
(e.Coli) 
Schulz, 2002 
Schnorrer, 2006 
Low  
(Plasmodium)  
Lundie, 2008 
CD8α-CD11b- Highest 
Janssen, 2006 
{Reboulet, 2010 
Hennies, 2011 
    
CD8α-CD11b-CD24+ Yes  
Bedoui, 2009 
Nierkens, 2011 
    
pDCs No    
Janssen, 2006 
Reboulet, 2010 
Hennies, 2011 
Yes  (Act) 
Mouriès, 2008 
 Yes (Act)  
Mouriès, 2008 
No  
(rLM)   
Belz, 2005  
(Plasmodium)  
Lundie, 2008 
Mo-DCs 
(CD11b+Ly6c+CD11c+ 
MHCII+) 
 Yes   
Segura, 2009 
Zhan, 2011 
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 Table II: Human DC subsets 
 
Subsets defined by: Cell-associated Soluble Protein IC 
CD1c (BDCA1) 
 
 
 
 
Low  
Jongbloed, 2010V 
Bachem, 20100 
 
Yes    
Crozat, 2010V* 
No 
Robson, 20100/* 
Hafinna, 20120 
Low  
Schnurr, 20050 
Bachem, 20100 
Robson, 2010Sap 
Yes  
Jongbloed, 20100/* 
Mittag, 20110/* 
Schnurr, 2005Sap 
 
 
 
 
 
 
 
Yes  
Schnurr, 20050 
 
 
CD141 (BDCA3)  
 
 
 
Yes  
Crozat, 2010V* 
Jongbloed, 2010V 
Bachem, 20100 
No/Low 
Jongbloed, 20100 
Mittag, 20110 
Haniffa, 20120 
Yes  
Jongbloed, 2010* 
Mittag, 2011* 
Bachem, 20100 
Hanifa, 2012* 
 
CB-DCs CD141/DNGR1  No 
Poulin, 20100 
Yes  
Poulin, 2010* 
(long peptide) 
 
CD16 Low  
Bachem, 20100 
No/Low  
Bachem, 20100 
Mittag, 20110/* 
 
pDCs  
 
 
Yes  
Hoeffel, 2007V* 
Lui, 2009V 
Crozat, 2010V* 
No  
Bachem, 2010 0 
Schnurr, 2005 0/* 
Yes   
Mittag, 20110/* 
No  
Schnurr, 20050/* 
Mo-DCs (IL-4/GMCSF) 
IN VITRO 
 
 
 
 
 
 
Yes   
Marañón, 2004V 
Arrode, 2000V 
Arrode, 2002V 
Weck, 2007V 
Weck, 2008V 
No   
Schnurr, 20050 
Robson, 20100 
Low  
Poulin, 20100/* 
(long peptide) 
Yes  
Audran, 20030 
Schnurr, 2005*/Sap 
Robson, 2010Sap 
Spadaro, 20120 
 
 
 
 
 
 
Yes  
Schnurr, 20050/* 
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 Summarizing Discussion & Perspective 
 
Melanoma is a highly malignant melanocyte-
derived tumor with an incidence that is 
increasing; at present it is the 8th diagnosed 
cancer in European females and 17th in 
males. Being frequently diagnosed in young 
people, it is one of the worst cancers in terms 
of “years of potential life lost per death”. 
Melanoma is the most fatal of skin cancers, 
representing only 4% of all cases, but 
accounting for more than 75% of all skin 
cancer related deaths. The survival of patients 
largely depends on the stage of disease at the 
time of diagnosis. Successful treatment is 
surgical removal of the tumor but only in early 
stages of the disease. Patients with metastatic 
disease are poorly served by current 
therapies, with limited approved treatment 
options. Despite its relatively low response 
rate (below 15%), with a median overall 
survival between 6 to 10 months, first-line 
chemotherapy treatment based on 
dacarbazine (DTIC) is commonly used to treat 
metastatic melanoma. Therefore, novel 
strategies of treatment including 
immunotherapy and targeted therapies are 
explored worldwide. In this chapter 
arguments are put forward that 
immunotherapy based on the administration 
of ex vivo activated and peptide-loaded 
human pDCs is a very promising strategy to 
treat metastatic melanoma patients as a 
mono-therapy, but also as a component in a 
combined treatment modality. Furthermore, 
a roadmap is presented how to harness 
human pDCs for the induction of immune 
responses by directly targeting them in vivo. 
 
Treatment modalities for metastatic 
melanoma 
Ipilimumab and biologics based 
immunotherapy 
New FDA approved therapeutic strategies, 
such as ipilimumab1,2 or multi-agent 
biochemotherapy combining standard 
chemotherapy or immunotherapy with 
biologics such as interleukin-23-6 or interferon-
alpha (IFNα)7-9 have achieved improved 
responses. Nevertheless, for IL-2 and IFNα 
such responses are only seen in a small 
selected group of patients and are often 
associated with high levels of toxicity and 
severe adverse effects. However, a small 
subset of melanoma patients receiving IFNα, 
who are also predisposed to autoimmunity, 
exhibited impressive survival response10. So 
far it has been difficult to pre-identify these 
patients, which limits the use of the approach. 
For patients with distant metastasis 
ipilimumab recently proved to be an effective 
treatment modality, resulting in its use as the 
new first-line treatment modality for 
metastatic melanoma patients. Twenty 
percent of the ipilimumab treated patients 
become long term survivors. However, 
treatment can be associated with immune 
related adverse effects which could have a 
major impact on the quality of life. 
Ipilimumab is an antibody directed against 
cytotoxic T-lymphocyte antigen 4 (CTLA4), 
which is a co-receptor expressed by activated 
T cells, memory T cells and regulatory T cells. 
CTLA-4 plays a crucial role in abrogating 
immunity and thereby provides a feedback 
mechanism to regulate immune 
homeostasis11,12. Blockade of this inhibitory 
pathway results in enhanced T cell activation, 
and has shown to be effective in cancer 
immunotherapy. An important drawback of 
treatment with anti-CTLA4 is the lack of 
specificity: the T cell activation threshold is 
lowered in an antigen non-specific manner. 
This is also apparent by the significant rate of 
toxicity profiles of anti-CTLA4 antibodies 
consisting of diverse auto-immune 
phenomena. However, toxicity does not 
accurately predict positive therapeutic 
outcome, indicating that many patients will 
experience inflammatory pathology without 
benefiting from an antitumor effect.  
 
Targeted therapy 
In melanoma several signal transduction 
pathways are over-activated due to 
mutations. Mutations in the BRAF gene are 
detected in 50-60% and mutations in the 
NRAS gene in 10-20% of cutaneous 
melanomas, both leading to uncontrolled 
activation of the mitogen activated protein 
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 kinase (MAPK) pathway. Recent evidence 
shows that BRAF mutations lead to immune 
escape. In addition to immunotherapy, 
several clinical trials explored the effects of 
targeted therapy. Targeting strategies with 
small molecule inhibitors directed against the 
MAPK pathway, have recently demonstrated 
clinical efficacy in metastatic disease13,14. For 
patients bearing the V600E activating 
mutation of BRAF, the inhibitor vemurafenib 
has been shown to yield a marked response in 
more than 50% of patients13,14. Despite the 
reported high response rates, the initial 
enthusiasm for targeted therapies in 
metastatic melanoma patients has been 
tampered by the development of drug 
resistance in the vast majority of patients, 
which clearly is an obstacle to achieve long 
term tumor control. A potential approach to 
circumvent drug resistance could lie in the 
combination of vemurafenib with another 
small molecule inhibitors for example 
targeting MEK. However, it is tempting to 
speculate that the tumor will also develop and 
utilize new alternative pathways to evade this 
treatment modality. 
 
DC-based immunotherapy 
Obviously there is a need for improved 
treatment modalities, due to the low 
response rates to the current therapies for 
metastatic melanoma. One of the modern 
experimental therapies against melanoma is 
DC-based immunotherapy, because of 
melanoma’s immunogenicity, with several 
well characterized melanoma-associated 
antigens, such as gp100 and tyrosinase. DCs 
are professional antigen presenting cells that 
can be loaded with these melanoma-
associated antigens and used to mount an 
immune response against tumor cells by 
activating killer T cells. During the last decade 
this approach was implemented in our 
institute and over 300 patients were 
vaccinated. DC-based immunotherapy has 
been introduced in the clinic, and proved to 
be feasible, nontoxic15-21 and effective in some 
patients, particularly if the DCs have been 
appropriately matured and activated. Several 
patients displayed objective clinical responses 
after DC-based immunotherapy, but their 
proportion remains low and this treatment 
modality needs further improvement22-24. 
Thus far, most clinical studies have been 
performed with ex vivo differentiated 
monocyte-derived DCs (moDCs)21,25-28. In this 
thesis, several facets of plasmacytoid DC 
(pDC) biology, one of the naturally occurring 
DC subsets in the blood and main producers 
of IFNα upon activation were unraveled. It 
was postulated that moDCs may be less 
effective than naturally occurring DC subsets 
circulating in the blood for DC-based 
immunotherapy. It is therefore that other DC 
subsets are being explored as alternatives for 
moDC. The translation of these unique 
subsets into immunotherapy protocols was 
long hampered by the limited availability of 
clinical grade components that induce pDC 
activation. In Chapters 6 and 7 it is described 
that commonly available preventive vaccines 
induce the activation of human pDCs. In 
particular the Früh-Sommer-Meningo-
Encephaltis (FSME) vaccine was able to 
generate pDCs that secreted IFNα, presented 
antigens to CD4 and CD8 T cells and also were 
endowed with tumoricidal activity. We 
translated this rare blood DC subset in the 
first phase I clinical trial (Chapter 8). Although 
the trial was initially setup as a feasibility 
study, and not designed to evaluate clinical 
outcome, some unforeseen, but very striking 
observations were made. The progression 
free survival in vaccinated patients was similar 
to matched control patients who received 
standard chemotherapy. However, the 1-year 
and 2-year survival rates were as high as 60% 
and 45% respectively compared to 35% and 
10% for matched control patients. Moreover, 
none of the pDC-treated patients developed 
signs of toxicity. Succinctly, although no direct 
effect on progression free survival was 
observed, a long term tumor control was 
established. Furthermore, in contrast to the 
toxicity after systemically administered IFNα, 
toxicity was not observed after pDC-based 
immunotherapy. This indicates that 1) locally 
produced cytokines are more efficient and 2) 
that pDC vaccination is well tolerated without 
severe toxicity. In a small scale study with 
autologous pDCs we observed similar 
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 Figure 1 Understanding treatment modalities for melanoma. In the past we put effort in understanding the 
tumor and how to harness the immune system to attack the tumor. At present, treatment modalities have 
induced promising results but real efficacy is still lacking. In the future we face the challenge to introduce and 
investigate a multimodal approach for the treatment of metastatic melanoma patients. 
 
improved survival as with the new treatment 
(ipilimumab) with minimal toxicity. 
More importantly,  Leonhartsberger et al. 
demonstrated that the quality of life of 
(metastatic renal cell carcinoma) patients 
treated with DC-based immunotherapy, in 
terms of side effects and toxicity, is better 
compared to that of chemotherapy and/or 
biologic additives20. These exciting findings 
urge for the development of new pDC-based 
immunotherapy protocols. A randomized 
phase II clinical trial could be executed to 
evaluate the efficacy of pDC vaccination 
compared to the standard first line treatment 
consisting of chemotherapy with or without 
ipilimumab. 
 
Combined treatment modalities 
Chemotherapy & DC-based immunotherapy 
During the last decade it became apparent 
that besides having a direct cytotoxic effect 
on tumor cells, chemotherapeutic drugs can 
also potentiate the immune system29,30. 
Widely used cytotoxic drugs such as 
doxorubicin, paclitaxel and  gemcitabin were 
shown to cause enhanced antigen cross-
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 presentation, T cell expansion and T cell 
infiltration of tumors by to date unknown 
molecular mechanisms31,32. Furthermore, 
Lesterhuis et al. showed that platinum 
compounds increased the T cell stimulatory 
potential of moDCs by impairing the IL-4 
induced upregulation of PD-L2 through 
dephosphorylation of STAT633. Combining 
chemo- with immunotherapy is already 
reported, showing that combining 
chemotherapy with a TLR agonist improves 
patient survival compared to patients treated 
with only chemotherapy34. In Chapter 9 it was 
demonstrated that the chemotherapeutic 
compound oxaliplatin acts as a double edged 
sword. Besides killing tumor cells, oxaliplatin 
bolsters immunosuppressive pathways, 
resulting in decreased activation of T cells by 
human plasmacytoid pDCs. Exposure to 
oxaliplatin markedly increased expression of 
the T cell inhibitory molecule PD-L1 on human 
pDCs. The oxaliplatin induced up-regulation of 
PD-L1 and down-regulation of costimulatory 
molecules CD80 and CD86 resulted in 
decreased T cell proliferation. Our results 
demonstrate that platinum-based anti-cancer 
drugs adapt TLR induced signaling in human 
pDCs thereby downgrading their immuno-
stimulatory potential. However, current 
knowledge dictates that combining pDC-
based immunotherapy and chemotherapy 
might not be favorable for anti-cancer 
immunity.  
 
Targeted therapy & pDC-based 
immunotherapy  
Recent developments in immuno- and 
targeted therapy have opened new 
therapeutic avenues for metastatic melanoma 
patients. A multimodality approach will likely 
result in further progress in melanoma 
treatment (Figure 2). Both modalities act via 
distinct mechanisms; targeting aberrant 
MAPK pathway induces rapid responses and 
fast reduction of the tumor burden with 
increased expression of tumor associated 
antigens35. However, drug resistance develops 
in the vast majority of patients resulting in a 
minimal overall survival benefit. On the other 
hand, response rates to immunotherapy are 
rather low, but typically, responding patients 
in general have long-lasting clinical benefit, 
without any severe side effects or toxicity. We 
now face the challenge to exploit and 
combine these novel approaches selectively 
and effectively in order to achieve long-term 
tumor control before drug resistance 
develops (Figure 2). The prospect of 
generating long-lasting protective immunity 
during the remission period is intensely 
attractive and trials combining vemurafinib 
with immunotherapy are ongoing. 
Importantly, blocking the MAPK pathway 
leads to enhanced expression of tumor 
associated antigens35. Recognition and 
presence of these antigens on melanoma cells 
is a crucial factor in the success of 
immunotherapy, in particular tumor-antigen 
specific DC-based immunotherapy. Another 
benefit of vemurafinib-induced death of 
tumors is the expected release of endogenous 
tumor antigens. These released antigens can 
be taken up by resident DCs thereby leading 
to a more broad activation of T cells directed 
against the tumor. It is possible that the small 
molecule and immuno-therapeutic 
approaches may synergize, with BRAF 
inhibition acting to help the priming of de 
novo T-cell responses. Armed with the 
exciting findings using vemurafenib13 and 
pDC-based immunotherapy (Chapter 8) we 
should gear up to investigate and implement 
this combined treatment modality. The 
understanding and targeting of mutated 
signaling pathways combined with the 
potency of our pDC-based therapy greatly 
aims at enhancement of the treatment 
efficacy. A combined treatment modality 
might turn this lethal disease into a chronic 
disease with a good quality of life, or even 
lead to complete remission. Therefore, the 
results of such a study will have a major 
impact, not only for metastatic melanoma 
patients but also on the design for new 
treatment modalities in a wide variety of 
immunogenic tumors with known mutations.  
 
Targeted delivery: which receptor to aim for? 
DC-based immunotherapy is based on the 
principle of isolation, generation and 
manipulation of DCs ex vivo followed by the 
administration of these manipulated DCs back 
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 into the patient. Early clinical trials clearly 
show the potency of DC therapy, but there 
are still too many variables preventing its 
introduction as a standard cancer 
treatment24. Extensive culturing, proper 
activation, the dose and route of 
administration are some examples of those 
variables. Some of these variables can be 
tackled by circumventing the laborious 
process of ex vivo manipulation, by directly 
targeting DCs in vivo. Facilitating the targeted 
delivery of particulate vaccines to DCs in vivo 
via receptor mediated endocytosis seems an 
interesting opportunity, since this mechanism 
allows the specific and simultaneous delivery 
of maturation factors and antigens. In 
Chapter 10  we concluded that all DC subsets 
have the capacity to cross-present antigens 
and thereby activate cytotoxic T cells, 
provided that the antigen and stimulus is 
properly administered to the DC. Knowing 
this, which receptor should be selected to 
obtain a potent immune response when 
considering antigen presenting pDCs? 
Several studies identified receptors for in vivo 
targeting of pDCs. In mice, Siglec-H and bone 
marrow stromal cell antigen 2 (BST2) were 
identified as pDC specific receptors which opt 
for interesting targets36-38. Although specific 
for murine pDCs, human pDCs do not express 
Siglec-H39. Freshly isolated as well as activated 
human pDCs do express BST240. However, in 
man expression of BST2 is not restricted to 
pDCs as it is also expressed by B cells. 
Moreover, it is upregulated on various cells 
upon IFNα treatment. Therefore, other 
receptors expressed by pDCs might be better 
suited40. Regarding the characteristics of the 
different surface receptors expressed by 
pDCs, specifically targeting antigen to the 
ITAM-containing Fc RIIa seems to be a 
promising strategy to induce immunity, since 
Fc RII is involved in T cell priming, and 
moreover triggering Fc RIIa does not 
negatively affect type I IFN production, as 
described in Chapter 3. One disadvantage of 
Fc RIIa is that it is not uniquely expressed by 
pDCs, meaning that pDCs cannot be 
specifically targeted by triggering Fc RIIa41. In 
Chapter 4  we demonstrated that targeting 
antigen to DEC-205 and DCIR led to induction 
of antigen specific T cells. Although DEC-205 
expression is largely restricted to DCs in mice, 
it is broadly expressed on different immune 
cells in man42. In this respect, DCIR is 
expressed by less diverse immune cell types, 
making this receptor more potent for specific 
targeting of pDCs. Nevertheless, targeting 
DCIR might also activate other DC types like 
myeloid DCs. Combining the stimulation of 
both DC types unlocks an interesting 
approach to potentially establish a more 
potent vaccine, since interaction between 
pDCs and mDCs has been demonstrated to 
increase antigen specific immune responses. 
Activating pDCs along with mDCs leads also to 
induction of innate immune responses, likely 
resulting in an intensified adaptive immune 
response. PDCs are found to stimulate and 
enhance the cytokine secretion and cross-
presentation of antigens leading to CD8+ T cell 
priming by mDCs and induction of an antiviral 
immune response by moDCs43-45. In turn, pDCs 
cocultured with mDCs are capable of inducing 
an immune response against bacteria where 
they fail to respond on their own46. In mice, 
an enhanced anti tumor response was found 
when mDCs and pDCs were cocultured during 
pulsing with tumor antigens47. Moreover, 
pDCs were found to cross talk indirectly with 
mDCs, via activation of specific lymphocyte 
subsets which can interact with, and might 
thereby stimulate, mDCs48. Together, these 
observations strongly suggest that combining 
pDC activation with the activation of other DC 
subsets might be advantageous and result in a 
more powerful immune response. Triggering 
DCIR could potentially establish such a 
synergetic immune response, while triggering 
pDC specific receptors, like BDCA-2, initiate a 
more restricted induced immune response. 
Moreover, triggering DCIR does not 
completely inhibit TLR-induced type I IFN 
secretion by pDC as would be caused by 
BDCA-2 ligation. We hypothesize, that the 
locally secreted type I IFN is important to 
establish an effective immune response, since 
type I IFNs links innate and adaptive immune 
responses by cross-talk with mDCs, natural 
killer T cells, natural killer cells and B cells.  
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 In vivo delivery systems  
Delivering antigens to pDCs in vivo can be 
accomplished by fusing antigens to receptor 
ligands or antibodies against a chosen 
receptor49-51. In this way, the antibody-ligand 
complex is internalized, while TLR agonists 
can be administered systemically. However, 
systemic administration of TLR agonists 
potentially leads to undesired toxicity or side 
effects52. Therefore, it would be advantageous 
to generate a ligand-antigen complex 
including TLR agonists to target pDCs, thereby 
inducing cell activation and antigen loading. 
Schlosser et al. already provided evidence 
that antigens and TLR agonists need to be 
delivered contemporaneously for effective 
induction of functional CD8+ T cells53. Several 
other studies also showed that specific 
delivery of TLR agonists enhanced an effective 
immune response when TLR agonists are 
linked to antigens, than when administered as 
individual entities systemically54,55. 
Accordingly, both particle and/or conjugate 
delivery mechanisms that contemporaneously 
deliver both antigens and TLR agonists, would 
exclude the possibility that targeted cells 
prematurely become activated before the 
antigen reaches the cell which is known to 
disable efficient antigen uptake. In Chapter 5 
we described that human pDCs have the 
capacity to phagocytose PLGA microparticles 
and process and present the encapsulated 
content. Therefore these carriers can be 
exploited to facilitate the specific delivery of 
antigens and TLR agonists simultaneously. 
Tacken et al. showed that targeted delivery of 
antigens and TLR agonists is more efficient 
when using nanoparticles than 
microparticles50,56,57. Antigens encapsulated in 
PLGA nanoparticles were shown to induce 
CD8+ T cell responses by moDCs in human, 
confirming that the particle content can be 
cross-presented after engulfing the particle58. 
Simultaneously triggering multiple surface 
receptors on human pDCs impairs type I IFN 
secretion, thereby decreasing the list of 
potential candidates for targeted delivery. 
However, using particulate structures 
containing TLR agonists and antigens might 
overcome the inhibitory effect. In summary, 
receptor-mediated targeting of pDCs 
exploiting nanoparticles is a potent 
mechanism to activate pDCs, leading to 
antigen presentation and cytokine secretion. 
As discussed above, DCIR seems one of the 
most potent receptor for targeting strategies, 
considering its expression profile and that 
activating this receptor does not completely 
inhibit TLR-induced type I IFN secretion. 
Nevertheless, when simultaneously releasing 
antigens and TLR agonists in pDCs overcomes 
the type I IFN secretion inhibiting effect upon 
receptor triggering, BDCA-2 will be the most 
potent receptor for specific targeting of pDCs. 
Moreover, the combination of targeting both 
pDCs and mDCs by receptors generally 
expressed by DCs like DCIR could 
simultaneously establish the activation of 
different arms of the immune response and a 
more profound anti-tumor immunity. 
 
Concluding remarks 
It is generally well conceived that pDCs, by 
their production of type I IFNs, play an 
important role in the generation of immune 
responses. However, their role as professional 
antigen presenting cell was often regarded 
inferior compared to other DC subsets. In this 
thesis evidence is provided that human pDCs 
have the ability to exploit antigen uptake 
receptors and thereby facilitate the induction 
of antigen specific T cell responses. 
Furthermore, we described the first clinical 
trial in which metastatic melanoma patients 
were vaccinated with peptide-loaded 
activated pDCs. Herein, we showed that 
vaccination with peptide-loaded pDCs 
enhanced the frequency of  tumor-specific T 
cells and IFN signatures in vivo. More 
importantly, we observed a markedly 
improved overall survival upon pDC-based 
immunotherapy. These findings pave the way 
towards the use of these rare cells for cellular 
therapy. In my view there are still many roads 
that we can explore to understand the exact 
role that pDCs play in the initiation and 
continuation of immune responses in health 
and disease.  
 
 
 
 
11 
161
 References 
1. Hodi, F.S., et al. Improved survival with ipilimumab in 
patients with metastatic melanoma. N Engl J Med 363, 
711-723 (2010) 
2. Robert, C., et al. Ipilimumab plus dacarbazine for 
previously untreated metastatic melanoma. N Engl J Med 
364, 2517-2526 (2011) 
3. Schwartzentruber, D.J., et al. gp100 peptide vaccine and 
interleukin-2 in patients with advanced melanoma. N Engl 
J Med 364, 2119-2127 (2011) 
4. Atkins, M.B., et al. High-dose recombinant interleukin 2 
therapy for patients with metastatic melanoma: analysis 
of 270 patients treated between 1985 and 1993. J Clin 
Oncol 17, 2105-2116 (1999) 
5. Tarhini, A.A., Kirkwood, J.M., Gooding, W.E., Cai, C. & 
Agarwala, S.S. Durable complete responses with high-
dose bolus interleukin-2 in patients with metastatic 
melanoma who have experienced progression after 
biochemotherapy. J Clin Oncol 25, 3802-3807 (2007) 
6. Tarhini, A.A., Kirkwood, J.M., Gooding, W.E., Moschos, S. 
& Agarwala, S.S. A phase 2 trial of sequential 
temozolomide chemotherapy followed by high-dose 
interleukin 2 immunotherapy for metastatic melanoma. 
Cancer 113, 1632-1640 (2008) 
7. Flaherty, L.E., et al. Outpatient biochemotherapy with 
interleukin-2 and interferon alfa-2b in patients with 
metastatic malignant melanoma: results of two phase II 
cytokine working group trials. J Clin Oncol 19, 3194-3202 
(2001) 
8. Kirkwood, J.M., et al. Mechanisms and management of 
toxicities associated with high-dose interferon alfa-2b 
therapy. J Clin Oncol 20, 3703-3718 (2002) 
9. Cole, B.F., et al. Quality-of-life-adjusted survival analysis 
of interferon alfa-2b adjuvant treatment of high-risk 
resected cutaneous melanoma: an Eastern Cooperative 
Oncology Group study. J Clin Oncol 14, 2666-2673 (1996) 
10. Gogas, H., et al. Prognostic significance of autoimmunity 
during treatment of melanoma with interferon. N Engl J 
Med 354, 709-718 (2006) 
11. O'Day, S.J., Hamid, O. & Urba, W.J. Targeting cytotoxic T-
lymphocyte antigen-4 (CTLA-4): a novel strategy for the 
treatment of melanoma and other malignancies. Cancer 
110, 2614-2627 (2007) 
12. Fong, L. & Small, E.J. Anti-cytotoxic T-lymphocyte antigen-
4 antibody: the first in an emerging class of 
immunomodulatory antibodies for cancer treatment. J 
Clin Oncol 26, 5275-5283 (2008) 
13. Chapman, P.B., et al. Improved survival with vemurafenib 
in melanoma with BRAF V600E mutation. N Engl J Med 
364, 2507-2516 (2011). 
14. Rochet, N.M., Kottschade, L.A. & Markovic, S.N. 
Vemurafenib for melanoma metastases to the brain. J Exp 
Med 365, 2439-2441 (2011) 
15. Mackensen, A., et al. Phase I study in melanoma patients 
of a vaccine with peptide-pulsed dendritic cells generated 
in vitro from CD34(+) hematopoietic progenitor cells. Int J 
Cancer  86, 385-392 (2000) 
16. Banchereau, J., et al. Immune and clinical responses in 
patients with metastatic melanoma to CD34(+) 
progenitor-derived dendritic cell vaccine. Cancer Res 61, 
6451-6458 (2001) 
17. Jonuleit, H., et al. A comparison of two types of dendritic 
cell as adjuvants for the induction of melanoma-specific T-
cell responses in humans following intranodal injection. 
Int J Cancer 93, 243-251 (2001) 
18. Schuler-Thurner, B., et al. Rapid Induction of Tumor-
specific Type 1 T Helper Cells in Metastatic Melanoma 
Patients by Vaccination with Mature, Cryopreserved, 
Peptide-loaded Monocyte-derived Dendritic Cells. J Exp 
Med 195, 1279-1288 (2002) 
19. Gilboa, E., Nair, S.K. & Lyerly, H.K. Immunotherapy of 
cancer with dendritic-cell-based vaccines. Cancer 
Immunol Immunother 46, 82-87 (1998) 
20. Leonhartsberger, N., et al. Quality of life during dendritic 
cell vaccination against metastatic renal cell carcinoma. 
Cancer Immunol Immunother (2012) 
21. de Vries, I.J., et al. Maturation of dendritic cells is a 
prerequisite for inducing immune responses in advanced 
melanoma patients. Clin Cancer Res 9, 5091-5100 (2003) 
22. Brichard, V., et al. The tyrosinase gene codes for an 
antigen recognized by autologous cytolytic T lymphocytes 
on HLA-A2 melanomas. J Exp Med 178, 489-495 (1993) 
23. Alexander B. H. Bakker, et al. Identification of a novel 
peptide derived from the melanocyte-specific gp100 
antigen as the dominant epitope recognized by an HLA-
A2.1-restricted anti-melanoma CTL line. Int J Cancer 62, 
97-102 (1995) 
24. Figdor, C.G., de Vries, I.J., Lesterhuis, W.J. & Melief, C.J. 
Dendritic cell immunotherapy: mapping the way. Nat Med 
10, 475-480 (2004) 
25. Lesterhuis, W.J., et al. Wild-type and modified gp100 
peptide-pulsed dendritic cell vaccination of advanced 
melanoma patients can lead to long-term clinical 
responses independent of the peptide used. Cancer 
Immunol Immunother 60, 249-260 (2011) 
26. Lesterhuis, W.J., et al. Route of administration modulates 
the induction of dendritic cell vaccine-induced antigen-
specific T cells in advanced melanoma patients. Clin 
Cancer Res 17, 5725-5735 (2011) 
27. Nestle, F.O., et al. Vaccination of melanoma patients with 
peptide- or tumor lysate-pulsed dendritic cells. Nat Med 
4, 328-332 (1998) 
28. Dhodapkar, M.V., Krasovsky, J., Steinman, R.M. & 
Bhardwaj, N. Mature dendritic cells boost functionally 
superior CD8(+) T-cell in humans without foreign helper 
epitopes. J Clin Invest 105, R9-R14 (2000) 
29. Zitvogel, L. & Kroemer, G. Anticancer 
immunochemotherapy using adjuvants with direct 
cytotoxic effects. J Clin Invest 119, 2127-2130 (2009) 
30. Lake, R.A. & Robinson, B.W. Immunotherapy and 
chemotherapy--a practical partnership. Nature rev 5, 397-
405 (2005) 
31. Nowak, A.K., et al. Induction of tumor cell apoptosis in 
vivo increases tumor antigen cross-presentation, cross-
priming rather than cross-tolerizing host tumor-specific 
CD8 T cells. J Immunol 170, 4905-4913 (2003) 
32. Shurin, G.V., Tourkova, I.L., Kaneno, R. & Shurin, M.R. 
Chemotherapeutic agents in noncytotoxic concentrations 
increase antigen presentation by dendritic cells via an IL-
12-dependent mechanism. J Immunol 183, 137-144 
(2009) 
33. Lesterhuis, W.J., et al. Platinum-based drugs disrupt 
STAT6-mediated suppression of immune responses 
against cancer in humans and mice. J Clin Invest 121, 
3100-3108 (2011) 
34. Manegold, C., et al. Randomized phase II trial of a toll-like 
receptor 9 agonist oligodeoxynucleotide, PF-3512676, in 
combination with first-line taxane plus platinum 
chemotherapy for advanced-stage non-small-cell lung 
cancer. J Clin Oncol 26, 3979-3986 (2008) 
35. Boni, A., et al. Selective BRAFV600E inhibition enhances T-
cell recognition of melanoma without affecting 
lymphocyte function. Cancer Res 70, 5213-5219 (2010) 
36. Blasius, A.L., et al. Bone marrow stromal cell antigen 2 is a 
specific marker of type I IFN-producing cells in the naive 
mouse, but a promiscuous cell surface antigen following 
IFN stimulation. J Immunol 177, 3260-3265 (2006) 
37. Zhang, J., et al. Characterization of Siglec-H as a novel 
endocytic receptor expressed on murine plasmacytoid 
dendritic cell precursors. Blood 107, 3600-3608 (2006) 
Discussion & Summary
162
 38. Loschko, J., et al. Antigen delivery to plasmacytoid 
dendritic cells via BST2 induces protective T cell-mediated 
immunity. J Immunol 186, 6718-6725 (2011) 
39. Fitzgerald-Bocarsly, P. & Jacobs, E.S. Plasmacytoid 
dendritic cells in HIV infection: striking a delicate balance. 
J Leukoc Biol 87, 609-620. 
40. Cao, W., et al. Regulation of TLR7/9 responses in 
plasmacytoid dendritic cells by BST2 and ILT7 receptor 
interaction. J Exp Med 206, 1603-1614 (2009) 
41. Fanger, N.A., Wardwell, K., Shen, L., Tedder, T.F. & Guyre, 
P.M. Type I (CD64) and type II (CD32) Fc gamma receptor-
mediated phagocytosis by human blood dendritic cells. J 
Immunol 157, 541-548 (1996) 
42. Kato, M., et al. Expression of human DEC-205 (CD205) 
multilectin receptor on leukocytes. Int Immunol 18, 857-
869 (2006) 
43. Kuwajima, S., et al. Interleukin 15-dependent crosstalk 
between conventional and plasmacytoid dendritic cells is 
essential for CpG-induced immune activation. Nat 
Immunol 7, 740-746 (2006) 
44. Nierkens, S., et al. Immune adjuvant efficacy of CpG 
oligonucleotide in cancer treatment is founded 
specifically upon TLR9 function in plasmacytoid dendritic 
cells. Cancer Res (2012) 
45. Kramer, M., et al. Cross-Talk between Human Dendritic 
Cell Subsets Influences Expression of RNA Sensors and 
Inhibits Picornavirus Infection. J Innate Immun 2, 360-370 
(2010) 
46. Piccioli, D., et al. Human plasmacytoid dendritic cells are 
unresponsive to bacterial stimulation and require a novel 
type of cooperation with myeloid dendritic cells for 
maturation. Blood 113, 4232-4239 (2009) 
47. Lou, Y., et al. Plasmacytoid dendritic cells synergize with 
myeloid dendritic cells in the induction of antigen-specific 
antitumor immune responses. J Immunol 178, 1534-1541 
(2007) 
48. Montoya, C.J., et al. Activation of plasmacytoid dendritic 
cells with TLR9 agonists initiates invariant NKT cell-
mediated cross-talk with myeloid dendritic cells. J 
Immunol 177, 1028-1039 (2006) 
49. Li, Z., Menoret, A. & Srivastava, P. Roles of heat-shock 
proteins in antigen presentation and cross-presentation. 
Curr Opin Immunol 14, 45-51 (2002) 
50. Tacken, P.J., Torensma, R. & Figdor, C.G. Targeting 
antigens to dendritic cells in vivo. Immunobiol 211, 599-
608 (2006) 
51. Binder, R.J. & Srivastava, P.K. Peptides chaperoned by 
heat-shock proteins are a necessary and sufficient source 
of antigen in the cross-priming of CD8+ T cells. Nat 
Immunol 6, 593-599 (2005) 
52. Tacken, P.J., et al. Targeted delivery of Toll-like receptor 
ligands to human and mouse dendritic cells strongly 
enhances adjuvanticity. Blood 118, 6836-6844 (2011) 
53. Schlosser, E., et al. TLR ligands and antigen need to be 
coencapsulated into the same biodegradable microsphere 
for the generation of potent cytotoxic T lymphocyte 
responses. Vaccine 26, 1626-1637 (2008) 
54. Heit, A., et al. Protective CD8 T cell immunity triggered by 
CpG-protein conjugates competes with the efficacy of live 
vaccines. J Immunol 174, 4373-4380 (2005) 
55. Schirmbeck, R., Riedl, P., Zurbriggen, R., Akira, S. & 
Reimann, J. Antigenic epitopes fused to cationic peptide 
bound to oligonucleotides facilitate Toll-like receptor 9-
dependent, but CD4+ T cell help-independent, priming of 
CD8+ T cells. J Immunol 171, 5198-5207 (2003) 
56. Cruz, L.J., et al. Targeted PLGA nano- but not 
microparticles specifically deliver antigen to human 
dendritic cells via DC-SIGN in vitro. J Control Release 144, 
118-126 
57. Solbrig, C.M., Saucier-Sawyer, J.K., Cody, V., Saltzman, 
W.M. & Hanlon, D.J. Polymer nanoparticles for 
immunotherapy from encapsulated tumor-associated 
antigens and whole tumor cells. Mol Pharm 4, 47-57 
(2007) 
58. Prasad, S., et al. Polymer nanoparticles containing tumor 
lysates as antigen delivery vehicles for dendritic cell-based 
antitumor immunotherapy. Nanomedicine 7, 1-10 (2011) 
 
 
11 
163
 164
 Chapter 12 
 
 
Nederlandse Samenvatting 
 
 Nederlandse samenvatting  
 
Kanker 
Kanker is na hart –en vaatziekten de 
belangrijkste doodoorzaak in Nederland. Per 
jaar wordt er in Nederland bij ongeveer 
70.000 mensen kanker vastgesteld en 
overlijden er 37.000 aan deze ziekte. Kanker 
ontstaat doordat lichaamscellen genetische 
verandering ondergaan, waardoor ze 
ongecontroleerd kunnen gaan groeien. 
Melanoom is een vorm van huidkanker die 
uitgaat van melanine bevattende pigment-
cellen of melanoctyen. Een melanoom kan 
ontstaan uit goedaardige moedervlekken, al is 
de kans hierop per moedervlek erg klein. 
Verder kan het ontstaan uit onrustige 
moedervlekken of "spontaan" uit normale 
huid waar tevoren geen moedervlek was 
opgemerkt. Er is sprake van een melanoom als 
een groep pigmentcellen is veranderd in 
kankercellen (melanoom betekent letterlijk: 
zwart gezwel). De laatste jaren is in de 
westerse wereld de incidentie van melanoom 
erg gestegen; op dit moment is het de 8e 
gediagnosticeerde vorm van kanker in 
Europese vrouwen en 17e in mannen. 
Melanoom is de dodelijkste vorm van 
huidkanker, hoewel het maar 4% van alle 
gevallen representeert, vertegenwoordigt het 
meer dan 75% van alle huidkanker ge-
relateerde sterfgevallen. De overleving van 
melanoom patiënten is sterk afhankelijk van 
de fase van de ziekte op het moment van 
diagnose. Het  chirurgisch verwijdering van de 
tumor is een succesvolle behandeling, maar 
alleen in de vroege stadia van de ziekte. Zodra 
er sprake is van uitzaaiingen (metastases) is 
melanoom over het algemeen gesproken 
ongeneeslijk met een gemiddelde overleving 
tussen de 6 tot 10 maanden. De 5-jaar 
overleving (het aantal patiënten dat 5 jaar na 
diagnose van de uitzaaiingen leeft) is minder 
dan 10%. Chemotherapie wordt vaak gebruikt 
om gemetastaseerde melanoom te be-
handelen, ondanks de relatief lage respons 
(minder dan 15%). We mogen dus rustig 
zeggen dat er voor patiënten met een 
gemetastaseerde ziekte weinig goede 
vooruitzichten zijn op basis van huidige 
therapieën, met een zeer beperkt aantal 
goedgekeurde alternatieve behandeling 
opties. Daarom wordt er wereldwijd door 
verschillende centra gezocht naar betere en 
innovatieve behandeling strategieën om de 
strijd tegen kanker aan te gaan. Een vorm van 
zo’n innovatieve strategie is immuuntherapie. 
In dit proefschrift worden resultaten en 
argumenten naar voren gebracht dat 
immuuntherapie op basis van de toediening 
van geactiveerde en peptide-beladen 
plasmacytoide dendritsche cellen een veel-
belovende strategie is om gemetastaseerde 
melanoom patiënten te behandelen. Verder is 
een wegenkaart weergegeven hoe we denken 
dat plasmacytoide dendritsche cellen gebruikt 
kunnen worden voor het opwekken van 
immuunresponsen door hen direct in het 
lichaam van een patiënt te manipuleren. 
 
 
Het immuunsysteem 
Het menselijk lichaam is opgebouwd uit 
miljarden bouwstenen (cellen) die we met het 
blote oog niet kunnen zien (Figuur 1). 
Verschillende soorten en combinaties van 
cellen zijn betrokken bij een grote diversiteit 
aan processen in ons lichaam. Een zeer 
belangrijk systeem dat ons dagelijks 
beschermd tegen allerlei ziekteverwekkers 
zoals virussen, bacteriën en parasieten, is het 
immuunsysteem. Daarnaast beschermd het 
immuunsysteem ons in de meeste gevallen 
ook tegen veranderde lichaamseigen cellen, 
zoals kankercellen. Om al deze taken zo goed 
Figuur 1 Ons lichaam is opgebouwd uit 
miljarden bouwstenen. 
Discussion & Summary
166
 mogelijk uit te voeren kan ons immuun-
systeem onderverdeeld worden in twee 
verschillende systemen; het aangeboren deel 
en de verworven (adaptieve) deel. Het 
aangeboren immuunsysteem wordt ook wel 
het niet-specifieke immuunsysteem genoemd, 
omdat het minder specifiek de ziekte-
verwekker herkent, maar het is wel snel 
werkzaam. Het adaptieve deel daarentegen 
past zich aan de ziekteverwekkers aan, dit kost 
tijd, maar zal uiteindelijk leiden tot een sterke 
afweer. Bovendien is het lichaam daarna vaak 
langdurig beschermd tegen deze ziekte-
verwekker door een zogenoemd ontstaan van 
immunologisch geheugen. 
Het aangeboren immuunsysteem bestaat uit 2 
verdedigingslinies. De 1e linie bevat barrières 
zoals de huid en de slijmlaag van de darmen 
en de luchtwegen die ervoor zorgen dat er 
geen besmetting kan plaatsvinden. Wanneer 
ziekteverwekkers toch door deze barrière 
breken komen ze in aanraking met de 2e 
verdedigingslinie bestaande uit antimicrobiële 
moleculen (bijvoorbeeld histaminen) en witte 
bloedcellen (bijvoorbeeld granulocyten, 
macrofagen of dendritische cellen) (Figuur 2). 
De adaptieve afweer is de afweer die door de 
niet-specifieke afweer wordt geactiveerd voor 
het bestrijden van specifieke ziekteverwekkers 
en bestaat uit B- en T-cellen. Het zijn de 
antigeen presenterende cellen van het niet-
specifieke immuunsysteem die zorgen dat T-
cellen worden geactiveerd. Wanneer deze 
antigeen presenterende cellen ziekte-
verwekkers tegen komen zullen zij deze 
‘opeten’ en gedurende hun reis naar het 
opleidingsinstituut voor T cellen (in de 
lymfeklieren) verwerken en kleine stukjes 
(antigenen) van deze ziekteverwekker 
presenteren. Wanneer een T cel in opleiding 
zo’n antigen gepresenteerd krijgt zal hij zich 
vermeerderen en zich door het lichaam 
verspreiden om deze ziekteverwekker op te 
sporen en op te ruimen (Figuur 2).    
 
Dendritische cellen 
Eén familie van antigeen presenterende cellen 
die we in ons lichaam hebben zijn de 
dendritische cellen. Deze cellen zijn het meest 
gespecialiseerd om T cellen te instrueren en te 
activeren, daarom noemen we ze ook wel 
professionele antigeen presenterende cellen. 
In Hoofdstuk 1 & 2 introduceren we dat er 
verschillende dendritische cellen zijn die 
allemaal uitgerust zijn met een specifiek 
arsenaal aan moleculen/receptoren die 
betrokken zijn bij de herkenning en opname 
van onder andere ziekteverwekkers. Eén van 
deze verschillende soorten is de 
plasmacytoide dendritische cel. De 
plasmacytoide dendritische cel verschilt van 
andere dendritische cel subsets in één 
specifieke eigenschap, namelijk de secretie 
van grote hoeveelheden type I interferonen in 
reactie op bacteriële of virale stimuli. Via deze 
type I interferonen zijn zij in staat om met 
andere immuuncellen te ‘praten’ en de 
aangeboren en de adaptieve arm van het 
immuunsysteem met elkaar te verbinden.  
In de Hoofdstukken 3, 4 en 5 wordt 
beschreven hoe we opname receptoren en 
mechanismen die gebruikt worden door 
plasmacytoide dendritische cellen kunnen 
gebruiken om antigenen in de plasmacytoide 
cel te krijgen. Op deze manier zijn we instaat 
om specifiek plasmacytoide dendritische 
cellen in het lichaam van antigenen te 
voorzien. Vervolgens zal de plasmacytoide 
dendritische cel dit antigen niet alleen gaan 
verwerken en presenteren, maar ook stofjes 
uitscheiden die er voor zorgen dat het 
immuunsysteem optimaal geprikkeld word. 
Deze strategie zorgt ervoor dat we van 
buitenaf het immuunsysteem kunnen sturen 
om een immuunrespons op te wekken tegen 
allerlei vormen van antigenen die afkomstig 
kunnen zijn van virussen, bacteriën of zelfs 
tumoren.  
 
Immuuntherapie  
Er is in de laatste jaren veel vooruitgang 
geboekt in de behandeling van kanker met 
behulp van onder andere chemotherapie en 
bestraling. Bij deze vormen van therapie 
ontstaan echter veel bijwerkingen omdat niet 
alleen kankercellen worden gedood, maar ook 
normale gezonde cellen. Een andere 
veelbelovende therapie is immuuntherapie. 
Het doel van immuuntherapie is het induceren 
en/of activeren van afweercellen van het 
eigen immunsysteem zodat zij tumorcellen 
kunnen doden. De zogenaamde killer T-cellen 
kunnen antigenen die alleen, of in sterk 
verhoogde hoeveelheden in tumorcellen voor- 12 
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 komen en niet, of slechts in lage 
hoeveelheden aanwezig zijn in gezonde cellen 
herkennen en vervolgens de tumor cel doden. 
Door dendritische cellen uit de patiënt te 
halen, deze antigenen van de tumor te voeren 
en ze vervolgens terug in de patiënt te spuiten 
kunnen we er voor zorgen dat killer T-cellen 
de tumor gaan herkennen. Plasmacytoide 
dendritische cellen, verantwoordelijk voor de 
productie van grote hoeveelheden type I 
interferonen, zijn erg belangrijk in het 
verbinden van de aangeboren met de 
adaptieve afweer. Door deze eigenschap 
hebben wij gepostuleerd dat de  
plasmacytoide dendritische cel een 
veelbelovende cel kan zijn om te gebruiken 
Figuur 2 Activatie van T cellen (1) Op de plaats van infectie komt de dendritische cel ziekteverwekkers tegen. 
Als de dendritische cel ze herkent zal hij de ziekteverwekker opeten (2) en vervolgens afreizen naar de 
lymfklier (3). Gedurende deze reis zal de dendritische cel zijn activatie proces doorlopen en de 
ziekteverwekker gaan verwerken tot kleine stukjes en deze op zijn buitenkant gaan presenteren (groene 
stukjes). Eenmaal aangekomen in lymfklier reist hij naar het T-cel training centrum om daar de T-cellen te 
instrueren hoe ze de ziekteverwekker kunnen herkennen (4). Na deze instructie verlaten de killer T-cellen het 
training centrum en gaan ze in het lichaam op zoek naar de ziekteverwekker (5). Als ze eenmaal op de plaats 
van infectie aankomen zullen ze de ziekteverwekker herkennen en doodmaken (5,6).  
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 voor op dendritische cellen gebaseerde 
immuuntherapie. In Deel 3 behandelen we 
zowel het preklinische als het klinische 
onderzoek. Een belangrijke voorwaarde om 
plasmacytoide dendritische cellen te 
gebruiken in klinische trials is dat ze goed 
geactiveerd moeten zijn. Het gebruik van 
plasmacytoide dendritische cellen in klinische 
trial was lang gehinderd door de gelimiteerde 
hoeveelheid van klinisch goedgekeurde 
chemische stoffen die instaat zijn om 
plasmacytoide dendritische cellen te 
activeren. In Hoofdstuk 6 beschrijven we dat 
bepaalde vaccins, normaal gebruikt voor 
inentingen tegen ziekten, goed instaat zijn om 
plasmacytoide dendritische cellen te activeren 
en dat deze activatie in een soort gelijke mate 
gereguleerd lijkt te zijn als de bekende CpG 
subvormen. In Hoofdstuk 7 laten we zien dat 
in het bijzonder het vaccin tegen teken 
geïnduceerde encefalitis (FSME) erg goed 
instaat is om plasmacytoide dendritische 
cellen te activeren. Het FSME vaccin zorgt er 
niet alleen voor dat plasmacytoide 
dendritische cellen goed geactiveerd zijn en T-
cellen mobiliseren, maar ook dat ze instaat 
zijn om zelf ook tumor cellen dood te maken.  
Aangezien dit FSME vaccin goedgekeurd is 
voor klinische toepassing zijn we instaat om 
voor de eerste keer ter wereld een klinische 
trial te starten met deze relatief zeldzame 
dendritische cel subset. In Hoofdstuk 8 
beschrijven we een fase I klinische studie 
waarin we laten zien dat het gebruik van 
geactiveerde en tumor-peptide beladen 
plasmacytoide dendritische cellen om 
eindstadium melanoom te behandelen veilig is 
en weinig bijwerkingen heeft. Verder 
beschrijven wij dat we door deze patiënten 
met plasmacytoide dendritische cellen te 
vaccineren instaat zijn om tumor-specifieke 
killer T-cellen te mobiliseren en te activeren. 
Maar nog veel belangrijker ook de overleving 
van melanoom patiënten hebben we door 
vaccinatie met plasmacytoide dendritische 
cellen kunnen verlengen. Recente 
ontwikkelingen op het gebied van 
behandelingsmethoden voor melanoom 
patiënten suggereren dat therapieën beter 
gecombineerd kunnen worden in plaats van 
aangeboden te worden als monotherapie. In 
Hoofdstuk 9 onderzoeken we deze 
mogelijkheid door het effect van chemostatica 
op het functioneren van plasmacytoide 
dendritische cellen te bestuderen. Wij hebben 
beschreven dat plasmacytoide dendritische 
cellen die geactiveerd zijn in de aanwezigheid 
van bepaalde chemostatica minder goed 
instaat zijn om T-cellen te activeren. Daardoor 
zijn wij van mening dat een 
combinatietherapie op basis van 
plasmacytoide dendritische cellen en 
bepaalde chemostatica niet een goede 
aanvulling of alternatief is op bestaande 
therapieën.  
In Deel 4  beschrijven en bediscussiëren we de 
resultaten die in dit proefschrift zijn 
beschreven. In Hoofdstuk 10 geven we een 
overzicht over de capaciteit van de 
verschillende soorten dendritische cellen om 
antigenen te kunnen cross-presenteren, en 
concluderen we dat ze het allemaal kunnen. 
Gebaseerd op die conclusie beschrijven we in 
Hoofdstuk 11 welke receptor we het beste 
kunnen ‘targeten’ wanneer we plasmacytoide 
dendritische cellen direct willen manipuleren 
zonder ze eerst uit het lichaam van een 
patiënt te moeten halen.  
 
Conclusie 
Het is algemeen aanvaard dat plasmacytoide 
dendritische cellen door hun productie van 
type I interferonen een belangrijke rol bij het 
induceren van immuun responsen. Echter, 
hun rol als professionele antigeen 
presenterende cel wordt vaak inferieur 
beschouwd in vergelijking met andere soorten 
dendritische cellen. In dit proefschrift wordt 
aangetoond dat plasmacytoide dendritische 
cellen de mogelijkheid hebben om antigeen 
opname receptoren te benutten om daarmee 
antigenen op te nemen, te verwerken en 
vervolgens te zorgen voor de inductie van 
antigeen specifieke T cel responsen. Verder 
hebben we de eerste klinische studie 
beschreven waarin melanoom patiënten 
werden gevaccineerd met tumor-peptide 
beladen geactiveerde plasmacytoide 
dendritische cellen. Hierin werd aangetoond 
dat vaccinatie met tumor-peptide beladen 
plasmacytoide dendritische cellen de 
frequentie van tumor-specifieke T-cellen 
verhoogd en zorgt voor interferon 
geïnduceerde responsen in vivo. Nog 
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 belangrijker, we zagen een duidelijke 
verbetering in de algehele overleving na 
behandeling met deze vorm van therapie. 
Deze bevindingen maken de weg vrij voor het 
gebruiken van deze zeldzame cellen voor cel 
therapeutische toepassingen. Naar mijn 
mening zijn er nog vele wegen die onderzocht 
kunnen worden om te begrijpen wat de 
exacte rol is die plasmacytoide dendritische 
cellen spelen in de initiatie en de continuatie 
van immuun response bij gezondheid en 
ziekte. 
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I'd rather regret the things I've done  
than regret the things I haven't done  
Lucille Ball 
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Stellingen behorende bij dit proefschrift 
 
Plasmacytoid Dendritic Cells & Immunotherapy of Cancer 
 
 
1. We can re-evaluate the status of human plasmacytoid dendritic cells as professional 
antigen presenting cell (this thesis). 
 
2. The targeted delivery of antigens and TLR ligands towards human plasmacytoid dendritic 
cells can be facilitated by exploiting antigen uptake receptors (this thesis). 
 
3. Prophylactic vaccines are safe, good and cheap substitutes for synthetic GMP TLR ligands 
(this thesis). 
 
4. It is feasible to exploit clinical grade plasmacytoid dendritic cells for immunotherapeutic 
purposes in melanoma patients (this thesis). 
 
5. Vaccination of melanoma patients with autologous activated plasmacytoid dendritic cells 
induces vaccine specific immune responses and enhances overall survival (this thesis). 
 
6. Wat gemakkelijk wegleest, kan moeilijk tot stand zijn gekomen 
 
7. Do not go where the path may lead, go instead where there is no path and leave a trail.  
Ralph Waldo Emerson  
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Albert Einstein  
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